U.S. patent application number 12/658612 was filed with the patent office on 2012-04-05 for neutral amino acid transporter and gene thereof.
This patent application is currently assigned to J-Pharma Co., Ltd.. Invention is credited to Hitoshi Endou, Yoshikatsu Kanai.
Application Number | 20120083588 12/658612 |
Document ID | / |
Family ID | 26538829 |
Filed Date | 2012-04-05 |
United States Patent
Application |
20120083588 |
Kind Code |
A1 |
Endou; Hitoshi ; et
al. |
April 5, 2012 |
Neutral amino acid transporter and gene thereof
Abstract
The present invention relates to an amino acid transporter
protein having the ability to mediate the transport of amino acids
into a cell, a gene encoding the protein, an antibody having a
reactivity with the protein, a cell which produces the antibody,
related kits and methods.
Inventors: |
Endou; Hitoshi; (Kanagawa,
JP) ; Kanai; Yoshikatsu; (Osaka, JP) |
Assignee: |
J-Pharma Co., Ltd.
Tokyo
JP
|
Family ID: |
26538829 |
Appl. No.: |
12/658612 |
Filed: |
February 8, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10913191 |
Aug 5, 2004 |
7666999 |
|
|
12658612 |
|
|
|
|
09786389 |
Jul 18, 2001 |
7332572 |
|
|
PCT/JP99/04789 |
Sep 3, 1999 |
|
|
|
10913191 |
|
|
|
|
Current U.S.
Class: |
530/387.3 |
Current CPC
Class: |
A01K 2217/05 20130101;
C07K 14/705 20130101; A61P 35/00 20180101; A61K 38/00 20130101 |
Class at
Publication: |
530/387.3 |
International
Class: |
C07K 16/46 20060101
C07K016/46 |
Foreign Application Data
Date |
Code |
Application Number |
Sep 3, 1998 |
JP |
10-249993/1998 |
Sep 2, 1999 |
JP |
11-248546/1999 |
Claims
1. Protein which is a cell surface protein having an ability of
mediating the transport of amino acid into cell and having an
ability of mediating the incorporation of at least one amino acid
selected from a group consisting of leucine (Leu), isoleucine
(Ile), phenylalanine (Phe), methionine (Met), tyrosine (Tyr),
tryptophan (Trp), valine (Val) and histidine (His) into the cell in
an Na.sup.+-independent manner.
2. The protein according to claim 1, wherein, when it coexists with
a 4F2hc protein classified under a type II membrane glycoprotein or
a part thereof, it has an ability of transportation of neutral
amino acid and substances similar thereto.
3. The protein according to claim 2, wherein the 4F2hc protein
classified under a type II membrane glycoprotein is a protein
having an amino acid sequence mentioned in SEQ ID NO:6 or NO:8 or
an amino acid sequence where a part of amino acids thereof is
deleted, substituted or added.
4. The protein according to any of claims 1 to 3, wherein it is a
protein derived from human being or rat.
5. The protein according to any of claims 1 to 4, wherein it has an
amino acid sequence of any of the following (1) and (2). (1): an
amino acid sequence mentioned in SEQ ID NO: 2 or NO:4 (2): an amino
acid sequence mentioned in SEQ ID NO:2 or NO:4 where one or more
amino acid(s) is/are deleted, substituted or added.
6. A polypeptide containing a partial amino acid sequence in the
amino acid sequence mentioned in SEQ ID NO:2 or NO:4 and having an
antigenicity.
7. DNA coding for any of the protein mentioned in any of claims 1
to 5.
8. The DNA according to claim 7, wherein it is a DNA derived from
human being or rat.
9. DNA coding for a cell surface protein which hybridizes under a
stringent condition to the DNA having a base sequence of from 66th
to 1586th bases mentioned in SEQ ID NO:1 or having a base sequence
of from 64th to 1599th bases mentioned in SEQ ID NO:3 and has an
ability of mediating the incorporation of at least one kind of
amino acid into cell.
10. The DNA according to claim 9, wherein it codes for a cell
surface protein where incorporation of amino acid into the cell is
mediated by the coexistence of a 4F2hc protein classified under the
type II membrane glycoprotein or a part thereof.
11. The DNA according to claim 10, wherein the 4F2hc protein
classified under the type II membrane glycoprotein has an amino
acid sequence mentioned in SEQ ID NO:6 or NO:8 or an amino acid
sequence where a part of amino acids is deleted, substituted or
added.
12. RNA which is able to be derived from the DNA mentioned in
claims 7 to 11.
13. The RNA according to claim 12, wherein it is an RNA having a
base sequence mentioned in SEQ ID NO:26 or NO:27.
14. An expression vector containing the DNA mentioned in any of
claims 7 to 11.
15. A transformant cell which is transformed by the expression
vector mentioned in claim 14.
16. The transformant cell according to claim 14 or 15, wherein the
transformant cell is further transformed by a DNA containing a base
sequence comprising a base sequence of from 110th to 1696th bases
in the base sequence mentioned in SEQ ID NO:5 and any one of
nonsense base sequence represented by TAG, TGA or TAA adjacent to
the 1696th base.
17. The transformant cell according to any of claims 14 to 16,
wherein the transformant cell is further transformed by a DNA
coding for a reporter protein.
18. A cell which is derived from human being into which the RNA
mentioned in claim 12 or 13 is introduced.
19. The cell according to claim 18, wherein the cell is an oocyte
of Xenopus laevis.
20. An antiserum or a polyclonal antibody having a reactivity with
the protein mentioned in any of claims 1 to 5 or to the polypeptide
mentioned in claim 6.
21. A monoclonal antibody having a reactivity with the protein
mentioned in any of claims 1 to 5 or to the polypeptide mentioned
in claim 6 or a part of the monoclonal antibody.
22. The monoclonal antibody or a part of the monoclonal antibody
according to claim 21, wherein the monoclonal antibody is a
recombined chimera monoclonal antibody comprising a variable region
of immunoglobulin derived from mammals except human being and a
constant region of immunoglobulin derived from human being.
23. The monoclonal antibody or a part of the monoclonal antibody
according to claim 21, wherein the monoclonal antibody is a
recombined human type monoclonal antibody comprising all or a part
of a complementarity-determining region of a hypervariable region
of immunoglobulin derived from mammals except human being, a frame
region of a hypervariable region of immunoglobulin derived from
human being and a constant region of immunoglobulin derived from
human being.
24. The monoclonal antibody or a part of the monoclonal antibody
mentioned in any of claims 21 to 23, wherein the monoclonal
antibody is a human monoclonal antibody.
25. A cell which produces the monoclonal antibody mentioned in any
of claims 21 to 24.
26. The cell according to claim 25, wherein the cell is a fused
cell prepared by a fusion of a B cell derived from non-human
mammals having an ability of producing the monoclonal antibody with
a myeloma cell derived from mammals.
27. The cell according to claim 25, wherein the cell is a
genetically recombined cell transformed by introduction of DNA
coding for heavy chain of the monoclonal antibody, DNA coding for
light chain thereof or both of the DNA into the cell.
28. A pharmaceutical composition containing the DNA mentioned in
any of claims 7 to 11 and a pharmaceutically acceptable
carrier.
29. The pharmaceutical composition according to claim 28, wherein
the pharmaceutical composition is used for suppressing the growth
of the tumor cells.
30. A pharmaceutical composition containing the RNA mentioned in
claim 12 or 13 and a pharmaceutically acceptable carrier.
31. The pharmaceutical composition according to claim 30, wherein
the pharmaceutical composition is used for suppressing the growth
of the tumor cells.
32. A pharmaceutical composition containing the antiserum or the
polyclonal antibody mentioned in claim 20 and a pharmaceutically
acceptable carrier.
33. The pharmaceutical composition according to claim 32, wherein
the pharmaceutical composition is used for suppressing the growth
of the tumor cells.
34. A pharmaceutical composition containing the monoclonal antibody
mentioned in any of claims 21 to 24 or a part of the monoclonal
antibody and a pharmaceutically acceptable carrier.
35. The pharmaceutical composition according to claim 34, wherein
the pharmaceutical composition is used for suppressing the growth
of the tumor cells.
36. A labeled monoclonal antibody in which the monoclonal antibody
mentioned in any of claims 21 to 24 is labeled with a labeling
substance which is able to give a detectable signal either solely
or by the reaction with other substance.
37. The labeled monoclonal antibody according to claim 36, wherein
the labeling substance is enzyme, fluorescent substance,
chemiluminescent substance, biotin, avidin or radioisotope.
38. A kit which is to detect the protein having the amino acid
sequence mentioned in SEQ ID NO:2 or a fragment where the kit
comprises the labeled monoclonal antibody mentioned in claim 36 or
37.
39. A method for the examination whether protein is expressed in a
sample or for the examination of the expressed amount,
characterized in that, the method comprises: (1) a step where the
sample is contacted to the labeled monoclonal antibody mentioned in
claims 36 or 37 and (2) a step where the amount of the labeled
monoclonal antibody bonded to the sample is measured by detecting
fluorescence, chemiluminescence or radioactivity depending upon the
type of the labeling substance bonded to the labeled monoclonal
antibody.
40. The method according to claim 39, wherein the sample is tumor
cell, tumor tissue, tumor-having organ or a part thereof.
41. A labeled DNA in which the DNA mentioned in any of claims 7 to
11 or a fragment thereof is labeled with enzyme, fluorescent
substance, chemiluminescent substance, biotin, avidin or
radioisotope.
42. A radiolabeled RNA in which the RNA mentioned in claim 12 or 13
or a fragment thereof is labeled with a radioisotope.
43. A kit for detecting the gene coding for the protein mentioned
in any of claims 1 to 5, characterized in that, the kit comprises
the labeled DNA mentioned in claim 41 or the radioactive RNA
mentioned in claim 42.
44. A method for detecting the action as a substrate of a test
substance to the ability for transporting the neutral amino acids
of the protein using the protein mentioned in any of claims 1 to
5.
45. The method according to claim 44, wherein the cell transformed
by the DNA mentioned in any of claims 7 to 11 is used.
46. The method according to claim 44, wherein an oocyte of Xenopus
laevis is used.
47. The method according to any of claims 44 to 46, wherein the
test substance is a substance other than an amino acid.
48. A method for screening the test substance having an action of
suppressing the ability for transport of neutral amino acid and
similar substance thereto of the protein using the protein
mentioned in any of claims 1 to 5.
49. The method according to claim 48, wherein the cell which is
transformed by the DNA mentioned in any of claims 7 to 11 is
used.
50. The method according to claim 49, wherein an oocyte of Xenopus
laevis is used.
51. A method for the identification of a substance having an
ability of inhibiting the transcription of the DNA mentioned in any
of claims 7 to 11 to mRNA or the expression of the protein
mentioned in any of claims 1 to 5.
52. A substance which is detected, screened or identified by a
method mentioned in any of claims 44 to 51.
53. The substance according to claim 52, wherein the substance is a
substance having an ability of inhibiting the growth of tumor
cell.
54. A transgenic mouse having an extrinsic gene, characterized in
that, a DNA coding for a protein having an amino acid sequence
mentioned in SEQ ID NO:2 or NO:4 is incorporated on an intrinsic
gene of the mouse whereupon the mouse has a cell expressing the
protein in its body.
55. The transgenic mouse according to claim 54, wherein the DNA is
a DNA which contains a base sequence comprising a base sequence of
from 66th to 1586th bases in the base sequence mentioned in SEQ ID
NO:1 and any one nonsense base sequence represented by TAG, TGA or
TAA adjacent to the 1586th base or a base sequence comprising a
base sequence of from 64th to 1599th bases in the base sequence
mentioned in SEQ ID NO:3 and any one nonsense base sequence
represented by TAG, TGA or TAA adjacent to the 1599th base.
Description
FIELD OF THE INVENTION
[0001] The present invention relates to an amino acid transporter
protein or a part thereof, DNA coding for the protein or a part
thereof, RNA coding for the protein or a part thereof, DNA
hybridizing to the DNA, an expression vector containing the DNA, a
transformed cell transformed by the DNA or by the vector, a cell in
which the RNA is introduced, an antibody or a part thereof having a
reactivity with the protein or a part thereof, a cell which
produces the antibody, a labeled DNA in which a part of the DNA is
radiolabeled, a labeled RNA in which a part of the RNA is
radiolabeled, a labeled antibody in which the antibody or a part of
the antibody is labeled, a kit comprising the labeled DNA, a kit
comprising the labeled RNA, a kit comprising the labeled antibody,
a pharmaceutical composition containing a part of the DNA, a
pharmaceutical composition containing a part of the RNA, a
pharmaceutical composition containing the antibody or a part of the
antibody, a method for determining whether the protein is expressed
or for measuring the expressed amount thereof, a method for
identifying a substance having an ability of inhibiting the
biological activity of the protein, a method for identifying the
substance having an ability of inhibiting the transcription of DNA
coding for the protein into mRNA, a method for identifying the
substance having an ability of inhibiting the expression of the
protein, a substance which is identified by the identifying method
and a transgenic mouse into which the DNA coding for the protein of
the present invention is introduced.
BACKGROUND ART
[0002] Amino acids play a very important role not only as a
substrate for protein synthesis but also as a precursor in
gluconeogenesis and in biosynthesis of many biomolecules such as
porphyrin, purine and pyrimidine.
[0003] Most of such a biosynthesis reaction is carried out in cells
and, therefore, in the cells, various proteins which are generally
called amino acid transporters for incorporating amino acid into
the cells from outside of the cells are contained in cell
membrane.
[0004] The amino acid transporter not only functions for supplying
amino acids to each cell but also is incorporated into tissues
playing a role of an epithelial transport of amino acids in small
intestine and renal tubule and a resorption of neurotransmitter in
nervous tissue whereby it is oriented at an important position for
the expression of a specific function of tissues.
[0005] With regard to an amino acid transport mechanism (an amino
acid transport system mediated by amino acid transporter), its
identification and classification have been carried out using
cultured cells and cell membrane samples since about 1960's and,
reflecting the diversity of amino acid molecules, there have been
identified amino acid transport systems mediated by various amino
acid transporters having different substrate specificity (Physiol.
Rev. Vol. 70, p. 43-77, 1990).
[0006] However, such a transport system does not independently
function to each amino acid but each amino acid bears an
intracellular transport for more than one amino acids using the
more than one amino acids as substrates.
[0007] Amino acids are classified into basic amino acids
(diamino/monocarboxylic acids) having positive charge, acidic amino
acids (monoamino/dicarboxylic acids) having negative charge and
neutral amino acids (monoamino/monocarboxylic acids; or those
excluding basic amino acids or acidic amino acids). Because of such
a charge of amino acid, when a neutral amino acid or an acidic
amino acid having negative charge, for example, is transported into
cells having negative electric potential against the concentration
gradient, it is necessary to carry out an active transport
associated with some energy consumption.
[0008] From such a viewpoint, in amino acid transporters, that
which shows a dependency on sodium (Na.sup.+) and that which shows
an independency on Na.sup.+ are present like in the case of a sugar
transport system. The Na.sup.+-dependent transporter has a big
concentrating ability since it is able to transport the amino acid
against the concentration gradient by coupling amino acid transport
with Na.sup.+ transport and, therefore, it plays an important role
in the site in a living body where formation of a big concentration
difference mediated by cell membrane is requested (Annual Rev.
Kidney "Structure and Function of Kidney-Specific Organic Solute
Transporters", p. 91-100, 1995, published by Chugai Igakusha). Such
a Na.sup.+-dependent transporter can be further classified into two
families, i.e. an Na.sup.+/Cl.sup.--dependent transporter family
and an Na.sup.+/K.sup.--dependent transporter family (Annual Rev
Neurosci., Vol. 16, p. 73-93, 1993 and FASEB J., Vol. 7, p.
1450-1459, 1993).
[0009] Further, in combination of such a charge property, amino
acid transporters can be classified, in view of the substrate
specificity, into molecule where basic amino acid
(diamino/monocarboxylic acid) is a substrate, molecule where acidic
amino acid (monoamino/dicarboxylic acid) is a substrate and
molecule where neutral amino acid (monoamino/monocarboxylic acid;
or that excluding basic amino acid or acidic amino acid) is a
substrate.
[0010] It has been known that, for example, a basic amino acid
having amino group or imidazole group on the side chain such as
arginine, lysine and histidine (basic amino acid which is nearly
neutral) is transported mostly by an Na.sup.+-independent amino
acid transporter y.sup.+ (J. Membrane Biol., Vol. 66, p. 213-225,
1982). It has been known that an acidic amino acid having carboxyl
group on the side chain such as glutamic acid and aspartic acid is
transported by an Na.sup.+-dependent amino acid transporter
X.sup.-.sub.A,G (Biochim. Biophys. Acta, Vol. 732, p. 24-31, 1983).
In the case of transport of a neutral amino acid to which many
amino acids belong, it has been known that an Na.sup.+-independent
amino acid transporter L (Ann. Rev. Physiol., Vol. 46, p. 417-433,
1984) and Na.sup.+-dependent amino acid transporters A and ASC
(Ann. Rev. Physiol., Vol. 46, p. 417-433, 1984 and J. Membrane
Biol., Vol. 52, p. 83-92, 1980) play an important role (Physiol.
Rev., Vol. 70, p. 43-77, 1990 and Saishin Igaku, Vol. 50, p.
1997-2004, 1995).
[0011] As mentioned already, amino acids play a very important role
as materials in biosynthesis of various biocomponents taking place
in cells and, therefore, it is presumed that abnormal transport of
the amino acid into cell participates in various symptoms.
[0012] It has been known from the studies up to now that the
symptoms in which abnormal transport mechanism of the amino acid
into cells are participated are aminoaciduia where disorder of
amino acid resorption from renal tubule occurs and amyotrophic
lateral sclerosis, etc. in which disorder of glutamic acid
incorporation and nerve cell death are participated (Annual Rev
Kidney "Structure and Function of Kidney-Specific Organic Solute
Transporters", p. 91-100, 1995, published by Chugai Igakusha;
Saishin Igaku, Vol. 50, p. 1997-2004, 1995; and Saishin Igaku, Vol.
51, p. 64-70, 1996).
[0013] Amino acid transporters play an essential and very important
role in incorporation of amino acids necessary for generation,
differentiation, proliferation and maintenance of all cells and,
therefore, they are believed to participate not only in the
above-mentioned symptoms but also in onset of many other symptoms.
In addition, when the indispensability of amino acid transporter in
living body is taken into consideration, it is hardly concluded
that incorporation of various amino acids is not mediated by
several already-identified transporters only but it is believed
that many other unknown amino acid transporters will be
present.
[0014] Identification of such unknown amino acid transporters which
play a role essential for existence and maintenance of cells,
tissues, organs and living body has a possibility of clarification
of causes for onset of various diseases for which the causes have
not been clarified yet. In addition, if the relation between such
amino acid transporters and various diseases is made clear, an
effective treatment of such diseases will become possible by
regulation of biological function or expression of the amino acid
transporters. Accordingly, it is a pressing need to identify new
amino acid transporter and to clarify the relation between the
transporter molecule and a symptom.
[0015] However, in spite of medical and social needs as such, it is
a current state that there has been little progress in
identification of an amino acid transporter and clarification of an
amino acid transport mechanism.
[0016] Thus, in order to identify an amino acid transporter
molecule, it is necessary to purify the molecule and, in order to
analyze the activity of the purified substance, it is necessary to
reconstitute the purified substance to cell membrane so that an
amino acid transport activity is regenerated. However, an amino
acid transporter molecule has a relatively little expression amount
as a membrane protein and has a relatively small regenerating
efficiency and, therefore, there is a difficulty in the technique
in the identification of new molecules.
[0017] In addition, identification of an amino acid transporter
which is specifically expressed in abnormal cells directly
participating in the symptom such as cancer cells (tumor cells) and
plays a role of supplying an amino acid to the abnormal cells has a
very important significance in the clarification of existence and
proliferation of such symptom-related cells and also in the
development of therapeutic methods for cancer, etc. However, an
amino acid transporter is inherently a molecule essential for the
existence of normal cells and is believed to be present in a wide
range of cell species and, accordingly, it is not easy to identify
an amino acid transporter molecule which is expressed specifically
in such abnormal cells.
[0018] As a neutral amino acid transporter, ASCT1 and ASCT2 have
been cloned as sodium-dependent transporters (Kanai, Curr. Opin.
Cell Biol., 9, 565 (1997)). However, the main substrates thereof
are alanine, serine, cysteine, threonine and glutamine and their
substrate specificity is different from a neutral amino acid
transporting system L. Further, glycine transporter and proline
transporter have been cloned but their substrate specificity is
different from neutral amino acid transport system L (Amara and
Kuhar, Annu. Rev. Neurosci., 16, 73 (1993)).
[0019] Although not a transporter per se, cDNAs of rBAT and 4F2hc
which are a type II membrane glycoprotein having only one
transmembrane structure believed to be an activating factor for an
amino acid transporter have been cloned and it has been known that,
when they are expressed in oocytes of Xenopus laevis, uptake of a
basic amino acid is activated together with that of a neutral amino
acid (Palacin, J. Exp. Biol., 196, 123 (1994)).
[0020] Accordingly, it is an effective key for providing a
therapeutic method for the symptom and disease that an amino acid
transporter molecule which has not been identified yet and is
specifically expressed in abnormal cells deeply associated with
such a symptom is identified and that the relation between the
molecule and existence/proliferation of the abnormal cells is
clarified.
[0021] Thus, when the biological activity of the amino acid
transporter molecule or the expression of the molecule is
controlled, it is now possible to treat the diseases.
[0022] The present inventors have paid their attention to the
already-known cell membrane surface molecule 4F2 (CD98) which is
believed to be essential for the proliferation of tumor cells in
order to investigate a novel amino acid transporter which is
specifically expressed in such symptom-related abnormal cells or,
particularly, tumor cells and have succeeded in identifying a novel
amino acid transporter molecule named LAT1 (L-type amino acid
transporter-1) which is particularly significantly expressed in
tumor cells as compared with the expression in normal cells.
[0023] Thus, for a quick cell division and continuous growth and
proliferation, the tumor cells are to be provided with nutrients
such as amino acids and saccharides thereinto and it is believed
that such a providing is carried out by means of an up-regulation
of an amino acid transporter which is specific to the nutrients
(Physiol. Rev., Vol. 70, p. 43-77, 1990). For growth, proliferation
and maintenance of the tumor cells, a protein biosynthesis is to be
carried out in the cells and, therefore, incorporation of the
essential amino acids into the cells (transport from outside of the
cells to inside of the cells) is particularly important.
[0024] From the studies up to now, it has been believed that, for
the proliferation of tumor cells, a known cell membrane surface
antigen named 4F2 (CD98) classified into a type II membrane
glycoprotein believed to have a function of activating the amino
acid transporter which has not been identified yet will play an
important role (J. Immunol., Vol. 126, p. 1409-1414, 1981; J.
Immunol., Vol. 129, p. 623-628, 1982; Proc. Natl. Acad. Sci. USA.,
Vol. 84, p. 6526-6530, 1987; Cancer Res., Vol. 46, p. 1478-1484,
1986; J. Biol. Chem., Vol. 267, p. 15285-15288, 1992; Proc. Natl.
Acad. Sci. USA, Vol. 89, p. 5606-5610, 1992; Biochem. J., Vol. 324,
p. 535-541, 1997; and J. Exp. Biol., Vol. 196, p. 123-137,
1994).
[0025] Under such circumstances, the present inventors have carried
out an intensive investigation for identification of human tumor
cell membrane surface molecule which conjugates or interacts with a
4F2 molecule and found a gene coding for a novel amino acid
transporter LAT1 having the following characteristics whereupon the
present invention has been accomplished.
DISCLOSURE OF THE INVENTION
[0026] The amino acid transporter LAT1 or, particularly, the amino
acid transporter LAT1 derived from human being in accordance with
the present invention has the following characteristics.
[0027] (1) As a result of a northern blotting using tumor cells
derived from human being and mRNA derived from human normal
tissues, its expression is noted as a band of about 4.8 kb in tumor
cells derived from human being of a wide range including stomach
signet ring cell carcinoma (KATO III), malignant melanoma (G-361)
and lung small cell carcinoma (RERF-LC-MA). In the human normal
tissues, its expression is similarly confirmed as a band of about
4.8 kb only in specific and limited tissues where neogenesis and
proliferation of cells are vigorous (placenta, liver of fetus, bone
marrow, testicle, brain and peripheral leukocytes).
[0028] (2) Open reading frame (ORF; including termination codon)
has a base sequence comprising 1,524 bases (a base sequence from
66th to 1589th bases in the base sequence mentioned in SEQ ID NO:1)
and the ORF codes for an amino acid sequence comprising 507 amino
acids as a whole and has a molecular weight of about 55 kDa
(calculated value) (SEQ ID NO:2).
[0029] (3) As a result of a hydrophobic plot analysis, human LAT1
has 12 transmembrane regions and is identified as a membrane
surface molecule having a phosphorylated site by tyrosine protein
kinase (119th Tyr in an amino acid sequence of SEQ ID NO:2) and a
phosphorylated site by protein kinase C (189th Ser and 346th Ser in
an amino acid sequence of SEQ ID NO:2) in an intracellular
region.
[0030] (4) In a cell in which human LAT1 and human 4F2hc (4F2 heavy
chain) are co-expressed, a very strong incorporation of leucine
(Leu), isoleucine (Ile), phenylalanine (Phe), methionine (Met),
tyrosine (Tyr), tryptophan (Trp) and valine (Val) which are neutral
amino acids and histidine (His) which is a nearly neutral basic
amino acid is confirmed. In addition, significant incorporation of
threonine, cysteine, asparagine and glutamine which are other
neutral amino acids is confirmed as well.
[0031] (5) In a cell in which human LAT1 and human 4F2hc are
co-expressed, not only the incorporation of the above-mentioned
amino acids but also known incorporation of pharmaceuticals such as
L-DOPA which is a remedy for Parkinson's disease and
physiologically active substance such as triiodothyronine (thyroid
hormone) are confirmed. In addition, incorporation of BCH
(2-amino-2-norbornane-carboxylic acid) known as an inhibitor for
incorporation of neutral amino acids is confirmed as well.
[0032] (6) In a Michaelis-Menten kinetic test, a Km value showing
the affinity of the human LAT1 with the above-mentioned various
substrates is about 21 .mu.M.
[0033] (7) The above-mentioned incorporation of various amino
acids, pharmaceuticals and physiologically active substances
mediated by LAT1 into the cells is not dependent upon Na.sup.+ ion
and Cl.sup.- ion.
[0034] Thus, the present invention discloses, for the first time in
the world, an amino acid transporter in which a specific expression
is noted in tumor cells of a wide range as compared with normal
cells and which is believed to be essential for existence and
proliferation of various tumor cells having a wide substrate
specificity.
[0035] From the above-mentioned characteristics of the amino acid
transporter molecule of the present invention, the molecule is
quite hopeful as a target in the development of an antitumor agent
(anticancer agent) for example. Thus, when a pharmaceutical agent
having an activity of suppressing the biological activity of the
molecule or the expression of the molecule (such as antisense DNA
pharmaceuticals, antisense RNA pharmaceuticals, antibody
pharmaceuticals, antibody fragment pharmaceuticals, peptide
antagonist pharmaceuticals and non-peptide antagonist
pharmaceuticals including low-molecular compounds) is used so as to
suppress the incorporation of nutrients (various amino acids and
physiologically active substance) into tumor cells mediated by the
molecule, it is now possible that the tumor cells are made in a
hungry state and that existence and proliferation of the tumor
cells are suppressed.
[0036] Accordingly, the protein of the present invention or a part
thereof, DNA coding for the protein or a part thereof, RNA coding
for the protein or a part thereof, DNA hybridizing to the DNA,
expression vector containing the DNA, transformed cell transformed
by the DNA or by the vector, a cell in which the RNA is introduced,
antibody or a part thereof having a reactivity with the protein or
a part thereof, a cell which produces the antibody, a labeled DNA
in which a part of the DNA is radiolabeled, a labeled RNA in which
a part of the RNA is radiolabeled, a labeled antibody in which the
antibody or a part of the antibody is labeled, a kit comprising the
labeled DNA, a kit comprising the labeled RNA and a kit comprising
the labeled antibody are quite useful as a pharmaceutical agent
having such an antitumor effect and/or as a reagent in the
development of such pharmaceuticals.
[0037] In addition, when the above-mentioned DNA, RNA or various
substances of the present invention such as transformed cell are
used, it is also possible to provide various identifying methods
(or assay methods) for such various pharmaceuticals.
BRIEF DESCRIPTION OF THE DRAWINGS
[0038] FIG. 1 shows a homology in amino acid sequence of a human
amino acid transporter LAT1 with that of a rat amino acid
transporter LAT1.
[0039] FIG. 2 shows hydrophilic and hydrophobic regions of a human
amino acid transporter LAT1 by a hydrophobic plot analysis.
[0040] FIG. 3 shows an expressed state of mRNA of a human amino
acid transporter LAT1 in various human tissues by a northern
blotting.
[0041] FIG. 4 shows an incorporation activity of leucine into the
cells of Xenopus laevis oocytes wherein a human amino acid
transporter LAT1 and a human cell membrane surface molecule 4F2hc
are co-expressed.
[0042] FIG. 5 shows the amount of leucine incorporated into the
cells when Xenopus laevis oocytes wherein a human amino acid
transporter LAT1 and a human cell membrane surface molecule 4F2hc
are co-expressed are incubated in the presence of various
salts.
[0043] FIG. 6 shows an affinity of a human amino acid transporter
LAT1 to the substrate in a Michaelis-Menten kinetic test.
[0044] FIG. 7 shows the amount of radiolabeled leucine as a
substrate incorporated into the cells when Xenopus laevis oocytes
wherein a human amino acid transporter LAT1 and a human cell
membrane surface molecule 4F2hc are co-expressed are incubated in
the presence of various amino acids.
[0045] FIG. 8 shows the amount of radiolabeled phenylalanine as a
substrate incorporated into the cells when Xenopus laevis oocytes
wherein a human amino acid transporter LAT1 and a human cell
membrane surface molecule 4F2hc are co-expressed are incubated in
the presence of amino acid or a pharmaceutical agent.
[0046] FIG. 9 shows the amount of radiolabeled leucine as a
substrate incorporated into the cells when Xenopus laevis oocytes
wherein a human amino acid transporter LAT1 and a human cell
membrane surface molecule 4F2hc are co-expressed are incubated in
the presence of amino acid or physiologically active substance.
[0047] FIG. 10 shows the amount of various radiolabeled amino acids
as substrates incorporated into the cells of Xenopus laevis oocytes
wherein a human amino acid transporter LAT1 and a human cell
membrane surface molecule 4F2hc are co-expressed.
[0048] FIG. 11 shows the result of the experiment of leucine
incorporation by oocytes into which mRNA derived from rat C6 glioma
and/or cRNA of rat 4F2hc gene are/is injected.
[0049] FIG. 12 shows hydrophobic plots of a rat neutral amino acid
transporter LAT1.
[0050] FIG. 13 is a photograph as a substitute for a drawing which
shows the result of analysis of expression of LAT1 gene mRNA in
various organ tissues of rat by a northern blotting.
[0051] FIG. 14 is a photograph as a substitute for a drawing which
shows the result of comparison of expression of LAT1 gene mRNA in
each culture cell line of rat with expression of LAT1 gene mRNA in
the liver of rat by a northern blotting.
[0052] FIG. 15 is a photograph as a substitute for a drawing which
shows the result of analysis of expression of LAT1 gene mRNA in
each culture cell line of human being by northern blotting.
[0053] FIG. 16 shows the result where an experiment of
incorporation of leucine using oocytes into which rat LAT1 gene
cRNA and/or rat 4F2hc gene cRNA are/is injected is carried out
after 2 or 5 days after injection of cRNA.
[0054] FIG. 17 shows the result of testing the influence of added
salt in an experiment of incorporation of leucine using oocytes
into which rat LAT1 gene cRNA and rat 4F2hc gene cRNA are
injected.
[0055] FIG. 18 shows the result of testing the influence of
concentration of the substrate leucine in an experiment of
incorporation of leucine using oocytes into which rat LAT1 gene
cRNA and rat 4F2hc gene cRNA are injected.
[0056] FIG. 19 shows the result of testing the influence of
addition of various amino acids or similar compounds thereto on the
system in an experiment of incorporation of leucine using oocytes
into which rat LAT1 gene cRNA and rat 4F2hc gene cRNA are
injected.
[0057] FIG. 20 shows the result of testing the influence of
addition of D-leucine or BCH to a medium on cell proliferation in
an cultured rat liver cell line.
[0058] FIG. 21 is a photograph as a substitute for a drawing which
shows the result of analysis of expression of LAT1 gene mRNA and
4F2hc gene mRNA in cultured human tumor cell line by a northern
blotting.
[0059] FIG. 22 is a photograph as a substitute for a drawing which
shows the result of analysis of expression of LAT1 gene mRNA and
4F2hc gene mRNA in cultured human tumor cell line (leukemia cells)
by a northern blotting.
[0060] FIG. 23 shows the result of Na.sup.+ dependency of leucine
incorporation of T24 cells.
[0061] FIG. 24. Upper graph shows the concentration dependency of
T24 cells for a leucine incorporation (Michaelis-Menten kinetic
test); lower graph shows the result of analysis of concentration
dependency of T24 cells for a leucine incorporation by
Eadie-Hoffstee plots.
[0062] FIG. 25 shows the result of influence of addition of various
amino acids or similar compounds to the system in the leucine
incorporation experiment by T24 cells.
[0063] FIG. 26 shows the result of analysis of the effect of BCH
using double reciprocal plots in a leucine incorporation experiment
by T24 cells.
[0064] FIG. 27 shows the effect of BCH on the growth of T24 cells
(A) and Daudi cells (B).
[0065] FIG. 28 shows the result of investigation of survival effect
by BCH, D-Leu and D-Ala after intraperitoneal transplantation of
mouse sarcoma 180 cells to ICR mouse.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0066] Each of the various inventions in the present application
specifically has the following usefulness.
[0067] DNA, RNA and transformed cell of the present invention are
useful not only in the manufacture of the protein of the present
invention as a recombined protein using a gene recombination
technique but also as a reagent (tool) for drug design, screening
and identification such as for a pharmaceutical agent for
controlling (activating, suppressing and inhibiting) the biological
activity of the protein of the present invention, a pharmaceutical
agent for inhibiting the transcription of the protein of the
present invention into mRNA, a pharmaceutical agent for inhibiting
the translation of the mRNA into the protein of the present
invention, a pharmaceutical agent for inhibiting the interaction of
the protein with other molecule, etc.
[0068] To be more specific, DNA of the present invention can be
used not only in an assay for the identification of a
pharmaceutical agent controlling the biological activity of the
protein of the present invention but also in an assay for the
identification of a pharmaceutical agent controlling the expression
of the protein of the present invention.
[0069] In the former assay, cells of mammals, etc. are transformed
by DNA coding for the amino acid transporter molecule of the
present invention to express the molecule in the cells, the
transformed cells are incubated in the coexistence of the test
substance and the substrate (such as amino acid) for the molecule,
the numbers of the substrate incorporated into the cells thereby
are compared with the incorporation in the control cells and the
activity of the test substance to the control of the biological
activity of the amino acid transporter of the present invention is
evaluated.
[0070] The latter assay is represented by the so-called reporter
gene assay which is commonly used in the assay, screening and the
identification of such a pharmaceutical agent and by the so-called
high through put screening where the reporter gene assay is a
principle and the screening is carried out by a machine (robot)
(Soshiki Baiyo Kogaku, Vol. 23, No. 13, p. 521-524; and U.S. Pat.
No. 5,670,113).
[0071] In the present invention, DNA coding for the amino acid
transporter molecule of the present invention, DNA coding for the
expression regulation control region of the DNA and DNA coding for
a reporter protein molecule emitting the fluorescence such as
luciferase are inserted in such a manner that, depending upon the
expression of the transporter molecule, the reporter protein
molecule is able to be expressed, the resulting expression vector
is used for transformation of the cells which are commonly used in
the manufacture of gene recombinant protein, the resulting
transformed cells are contacted to the test compound, and the
amount of the transporter molecule which is expressed depending
upon the action of the compound is indirectly measured by measuring
the amount of the fluorescence emitted from the reporter protein
which is expressed together with the expression of the molecule
whereupon it is analyzed whether the compound affects the
expression of the transporter molecule (U.S. Pat. No. 5,436,128 and
U.S. Pat. No. 5,401,629).
[0072] Moreover, the RNA of the present invention is able to be
used for an assay for the identification of a pharmaceutical agent
which controls the biological activity of the amino acid
transporter protein molecule of the present invention.
[0073] Thus, the present assay is that the RNA coding for the amino
acid transporter molecule of the present invention is injected into
oocytes of Xenopus laevis for example to express the transporter
molecule in the cells, an incubation is carried out in the
coexistence of the test substance and the substrate (amino acid,
etc.) of the molecule and the amount of the substrate incorporated
into the cells is compared with the incorporation into the control
cells whereupon the activity of the test substance to the control
of the biological activity of the amino acid transporter of the
present invention is evaluated.
[0074] A part of the DNA of the present invention and a part of the
RNA thereof may be used as a probe in the case of identification of
DNA or RNA which is hybridized in a colony hybridization method or
a plaque hybridization method. In addition, a part of the DNA of
the present invention may be used as a primer for the amplification
of the gene coding for the DNA of the present invention or the
transporter molecule of the present invention using a PCR
(polymerase chain reaction).
[0075] Further, a part of the DNA of the present invention, the DNA
which is complementary to the DNA and a part of the RNA of the
present invention are not only useful as the reagent as mentioned
above but also useful as the so-called antisense DNA pharmaceutical
agent or antisense RNA pharmaceutical agent.
[0076] Thus, antisense pharmaceutical agent is an agent according
to a mechanism of inhibiting the transcription from DNA to mRNA or
the translation from the mRNA to protein utilizing the nature of
bonding a part of base sequence of DNA, a part of base sequence
complementary to the base sequence of the DNA or a part of base
sequence of RNA to DNA or RNA having a sequence complementary to
the base sequence thereof. When a part of the antisense sequence in
the antisense pharmaceutical agent is subjected to a chemical
modification, it is possible to modify the properties such as
increase in a half life in blood, permeability into cells,
targeting efficiency to disease target site, etc.
[0077] In the protein of the present invention, the state where the
protein molecule is expressed on the cell surface is utilized
whereby it is possible as mentioned above to identify the
pharmaceutical agent which controls the biological activity of the
protein of the present invention or the expression of the protein.
In addition, based upon the amino acid sequence of the protein, it
is also possible to design a peptide antagonist having an ability
of inhibiting the biological activity of the protein. The peptide
antagonist designed as such is useful as a pharmaceutical agent
where binding of the amino acid transporter which is a protein of
the present invention to a substrate or binding of a protein of the
present invention to other molecule is competitively inhibited so
that the biological function of the protein of the present
invention is not achieved.
[0078] The protein of the present invention or a part thereof and
the cells such as transformed cell expressing the protein are
useful as an immunosensitized antigen in the preparation of
antibody (antiserum, monoclonal antibody) to the protein of the
present invention.
[0079] Antiserum (polyclonal antibody) having a reactivity with the
amino acid transporter molecule which is a protein of the present
invention and a monoclonal antibody are useful as antibody
pharmaceutical agents by inhibiting (neutralizing) the achievement
of biological activity of the molecule by binding to the
molecule.
[0080] In addition, the antibody is useful as a reagent in the
analysis (immunohistological staining, western blotting, ELISA,
etc.) of expressed state of the protein of the present invention in
various biosamples (cells, tissues, organs or body fluids) by
labeling with various substances which are able to achieve a
detectable signal.
[0081] Like in such a labeled antibody, the labeled DNA where the
DNA of the present invention or a part thereof is labeled with
various substances which are able to achieve a detectable signal is
useful as a reagent in a test (such as southern blotting, FISH,
etc.) in the identification of the gene coding for the protein of
the present invention.
[0082] In addition, a radiolabeled RNA where the RNA of the present
invention or a part thereof is similarly labeled with radioisotope
is useful as a reagent in an analysis (such as northern blotting)
of expressed state of mRNA coding for the protein of the present
invention in cells, tissues or organs.
[0083] Further, with regard to the DNA of the present invention,
when the DNA of an amino acid transporter derived from human being
which is an embodiment of the present invention is introduced into
mammals other than human being such as mouse, it is possible to
prepare a transgenic animal as a model animal.
[0084] It is furthermore possible that a gene coding for the amino
acid transporter of the present invention derived from human being
is used as a probe to clone a gene coding for a homologue protein
derived from rabbit or mouse and, based upon the resulting genetic
information, the intrinsic gene coding for the homologue protein of
mouse or rabbit is destroyed (inactivated) to prepare a model
animal (knockout animal). When physical, biological, pathological
and genetic characteristics of such a model animal are analyzed,
functions of the amino acid transporter according to the present
invention can be clarified in more detail.
[0085] In addition, when the model animal where the intrinsic gene
is destroyed as such is crossed with the transgenic animal, it is
possible to prepare a model animal having only the gene (DNA) which
codes for the amino acid transporter of the present invention
derived from human being. When the above-mentioned pharmaceutical
agent (antisense pharmaceutical agent, peptide antagonist,
low-molecular non-peptide compound, antibody, etc.) which controls
the biological activity of the amino acid transporter molecule of
the present invention or the expression of the molecule is
administered to this model animal, it is possible to evaluate the
therapeutic effect of the pharmaceutical agent.
[0086] Thus, the present invention is to provide the substance, the
drug, the reagent and the method having a very high utility in
industry as mentioned above which is described in each of the
following <1> to <55>.
[0087] <1> Protein which is a cell surface protein having an
ability of mediating the transport of amino acid into cell and
having an ability of mediating the incorporation of at least one
amino acid selected from a group consisting of leucine (Leu),
isoleucine (Ile), phenylalanine (Phe), methionine (Met), tyrosine
(Tyr), tryptophan (Trp), valine (Val) and histidine (His) into the
cell in an Na.sup.+-independent manner.
[0088] <2> The protein according to <1>, wherein, when
it coexists with a 4F2hc protein classified under a type II
membrane glycoprotein or a part thereof, it has an ability of
transportation of neutral amino acid and substances similar
thereto.
[0089] <3> The protein according to <2>, wherein the
4F2hc protein classified under a type II membrane glycoprotein is a
protein having an amino acid sequence mentioned in SEQ ID NO:6 or
NO:8 or an amino acid sequence where a part of amino acids thereof
is deleted, substituted or added.
[0090] <4> The protein according to any of <1> to
<3>, wherein it is a protein derived from human being or
rat.
[0091] <5> The protein according to any of <1> to
<4>, wherein it has an amino acid sequence of any of the
following (1) and (2).
[0092] (1): an amino acid sequence mentioned in SEQ ID NO: 2 or
NO:4
[0093] (2): an amino acid sequence mentioned in SEQ ID NO:2 or NO:4
where one or more amino acid(s) is/are deleted, substituted or
added.
[0094] <6> A polypeptide containing a partial amino acid
sequence in the amino acid sequence mentioned in SEQ ID NO:2 or
NO:4 and having an antigenicity.
[0095] <7> DNA coding for any of the protein mentioned in
<1> to <5>.
[0096] <8> The DNA according to <7>, wherein it is a
DNA derived from human being or rat.
[0097] <9> DNA coding for a cell surface protein which
hybridizes under a stringent condition to the DNA having a base
sequence of from 66th to 1586th bases mentioned in SEQ ID NO:1 or
having a base sequence of from 64th to 1599th bases mentioned in
SEQ ID NO:3 and has an ability of mediating the incorporation of at
least one kind of amino acid into cell.
[0098] <10> The DNA according to <9>, wherein it codes
for a cell surface protein where incorporation of amino acid into
the cell is mediated by the coexistence of a 4F2hc protein
classified under the type II membrane glycoprotein or a part
thereof.
[0099] <11> The DNA according to <10>, wherein the
4F2hc protein classified under the type II membrane glycoprotein
has an amino acid sequence mentioned in SEQ ID NO:6 or NO:8 or an
amino acid sequence where a part of amino acids is deleted,
substituted or added.
[0100] <12> RNA which is able to be derived from the DNA
mentioned in <7> to <11>.
[0101] <13> The RNA according to <12>, wherein it is an
RNA having a base sequence mentioned in SEQ ID NO:26 or NO:27.
[0102] <14> An expression vector containing the DNA mentioned
in any of the above <7> to <11>.
[0103] <15> A transformant cell which is transformed by the
expression vector mentioned in the above <14>.
[0104] <16> The transformant cell according to <14> or
<15>, wherein the transformant cell is further transformed by
a DNA containing a base sequence comprising a base sequence of from
110th to 1696th bases in the base sequence mentioned in SEQ ID NO:5
and any one of nonsense base sequence represented by TAG, TGA or
TAA adjacent to the 1696th base.
[0105] <17> The transformant cell according to any of the
above <14> to <16>, wherein the transformant cell is
further transformed by a DNA coding for a reporter protein.
[0106] <18> A cell which is not derived from human being into
which the RNA mentioned in the above <12> or <13> is
introduced.
[0107] <19> The cell according to <18>, wherein the
cell is an oocyte of Xenopus laevis.
[0108] <20> An antiserum or a polyclonal antibody having a
reactivity with the protein mentioned in any of the above <1>
to <5> or to the polypeptide mentioned in the above
<6>.
[0109] <21> A monoclonal antibody having a reactivity with
the protein mentioned in any of the above <1> to <5> or
to the polypeptide mentioned in the above <6> or a part of
the monoclonal antibody.
[0110] <22> The monoclonal antibody or a part of the
monoclonal antibody according to <21>, wherein the monoclonal
antibody is a recombined chimera monoclonal antibody comprising a
variable region of immunoglobulin derived from mammals except human
being and a constant region of immunoglobulin derived from human
being.
[0111] <23> The monoclonal antibody or a part of the
monoclonal antibody according to <21>, wherein the monoclonal
antibody is a recombined human type monoclonal antibody comprising
all or a part of a complementarity-determining region of a
hypervariable region of immunoglobulin derived from mammals except
human being, a frame region of a hypervariable region of
immunoglobulin derived from human being and a constant region of
immunoglobulin derived from human being.
[0112] <24> The monoclonal antibody or a part of the
monoclonal antibody according to any of the above <21> to
<23>, wherein the monoclonal antibody is a human monoclonal
antibody.
[0113] <25> A cell which produces the monoclonal antibody
mentioned in any of the above <21> to <24>.
[0114] <26> The cell according to the above <25>,
wherein the cell is a fused cell prepared by a fusion of a B cell
derived from non-human mammals having an ability of producing the
monoclonal antibody with a myeloma cell derived from mammals.
[0115] <27> The cell according to the above <25>,
wherein the cell is a genetically recombined cell transformed by
introduction of DNA coding for heavy chain of the monoclonal
antibody, DNA coding for light chain thereof or both of the DNA
into the cell.
[0116] <28> A pharmaceutical composition containing the DNA
mentioned in any of the above <7> to <11> and a
pharmaceutically acceptable carrier.
[0117] <29> The pharmaceutical composition according to
<28>, wherein the pharmaceutical composition is used for
suppressing the growth of the tumor cells.
[0118] <30> A pharmaceutical composition containing the RNA
mentioned in the above <12> or <13> and a
pharmaceutically acceptable carrier.
[0119] <31> The pharmaceutical composition according to
<30>, wherein the pharmaceutical composition is used for
suppressing the growth of the tumor cells.
[0120] <32> A pharmaceutical composition containing the
antiserum or the polyclonal antibody mentioned in the above
<20> and a pharmaceutically acceptable carrier.
[0121] <33> The pharmaceutical composition according to
<32>, wherein the pharmaceutical composition is used for
suppressing the growth of the tumor cells.
[0122] <34> A pharmaceutical composition containing the
monoclonal antibody mentioned in any of the above claims <21>
to <24> or a part of the monoclonal antibody and a
pharmaceutically acceptable carrier.
[0123] <35> The pharmaceutical composition according to
<34>, wherein the pharmaceutical composition is used for
suppressing the growth of the tumor cells.
[0124] <36> A labeled monoclonal antibody in which the
monoclonal antibody mentioned in any of the above <21> to
<24> is labeled with a labeling substance which is able to
give a detectable signal either solely or by the reaction with
other substance.
[0125] <37> The labeled monoclonal antibody according to the
above <36>, wherein the labeling substance is enzyme,
fluorescent substance, chemiluminescent substance, biotin, avidin
or radioisotope.
[0126] <38> A kit which is to detect the protein having the
amino acid sequence mentioned in SEQ ID NO:2 or a fragment where
the kit comprises the labeled monoclonal antibody mentioned in the
above <36> or <37>.
[0127] <39> A method for the examination whether protein is
expressed in a sample or for the examination of the expressed
amount, characterized in that, the method comprises:
[0128] (1) a step where the sample is contacted to the labeled
monoclonal antibody mentioned in the above <36> and
<37> and
[0129] (2) a step where the amount of the labeled monoclonal
antibody bonded to the sample is measured by detecting
fluorescence, chemiluminescence or radioactivity depending upon the
type of the labeling substance bonded to the labeled monoclonal
antibody.
[0130] <40> The method according to the above <39>,
wherein the sample is tumor cell, tumor tissue, tumor-having organ
or a part thereof.
[0131] <41> A labeled DNA in which the DNA mentioned in any
of the above <7> to <11> or a fragment thereof is
labeled with enzyme, fluorescent substance, chemiluminescent
substance, biotin, avidin or radioisotope.
[0132] <42> A radiolabeled RNA in which the RNA mentioned in
the above <12> or <13> is labeled with a
radioisotope.
[0133] <43> A kit for detecting the gene coding for the
protein mentioned in any of the above <1> to <5>,
characterized in that, the kit comprises the labeled DNA mentioned
in the above <41> or the radioactive RNA mentioned in the
above <42>. To be more precise, a kit for detecting the gene
coding for the protein having an amino acid sequence mentioned in
SEQ ID NO:2, characterized in that, the kit comprise the labeled
DNA mentioned in the above <41> or the radioactive RNA
mentioned in the above <42>.
[0134] <44> A method for detecting the action as a substrate
of a test substance to the ability for transporting the neutral
amino acids of the protein using the protein mentioned in any of
<1> to <5>.
[0135] <45> The method according to the above <44>,
wherein the cell transformed by the DNA mentioned in any of the
above <7> to <11> is used.
[0136] <46> The method according to the above <44>,
wherein an oocyte of Xenopus laevis is used.
[0137] <47> The method according to any of the above
<44> to <46>, wherein the test substance is a substance
other than an amino acid.
[0138] <48> A method for screening the test substance having
an action of suppressing the ability for transport of neutral amino
acid and similar substance thereto of the protein using the protein
mentioned in any of the above <1> to <5>. To be more
precise, a method for identification of a substance having an
ability of inhibiting the ability of mediating the incorporation of
any one amino acid selected from a group consisting of leucine
(Leu), isoleucine (Ile), phenylalanine (Phe), methionine (Met),
tyrosine (Tyr), histidine (His), tryptophan (Trp) and valine (Val)
into cells which is a biological function of the protein having an
amino acid sequence mentioned in SEQ ID NO:2, characterized in
that, the method comprises the steps of the following (1) and
(2).
[0139] (1) a step in which any of the cells mentioned in the
following (a) to (d) is incubated in the coexistence of the
substance and a radiolabeled amino acid where any one amino acid
selected from a group consisting of leucine (Leu), isoleucine
(Ile), phenylalanine (Phe), methionine (Met), tyrosine (Tyr),
histidine (His), tryptophan (Trp) and valine (Val) is labeled with
a radioisotope or in the presence of the radiolabeled amino acid
only:
[0140] (a) a naturally-occurring cell in which a protein having an
amino acid sequence mentioned in SEQ ID NO:2 and a protein having
an amino acid sequence mentioned in SEQ ID NO:6 are
co-expressed;
[0141] (b) a recombinant cell in which a protein having an amino
acid sequence mentioned in SEQ ID NO:2 and a protein having an
amino acid sequence mentioned in SEQ ID NO:6 are co-expressed by a
co-transformation using a DNA containing a base sequence of 66th to
1586th bases in the base sequence mentioned in SEQ ID NO:1 and a
base sequence comprising any one nonsense base sequence represented
by TAG, TGA or TAA adjacent to the 1586th base and a DNA containing
a base sequence of 110th to 1696th bases in the base sequence
mentioned in SEQ ID NO:5 and a base sequence comprising any one
nonsense base sequence represented by TAG, TGA or TAA adjacent to
the 1696th base;
[0142] (c) a non-human-derived recombinant cell in which a protein
having an amino acid sequence mentioned in SEQ ID NO:2 and a
protein having an amino acid sequence mentioned in SEQ ID NO:6 are
co-expressed by a co-introduction of an RNA containing a base
sequence of 1st to 1521st bases in the base sequence mentioned in
SEQ ID NO:26 and a base sequence comprising any one nonsense base
sequence represented by UAG, UGA or UAA adjacent to the 1521st base
and an RNA containing a base sequence of 1st to 1587th bases in the
base sequence mentioned in SEQ ID NO:27 and a base sequence
comprising any one nonsense base sequence represented by UAG, UGA
or UAA adjacent to the 1587th base; or
[0143] (d) a tumor cell derived from human being; and
[0144] (2) a step in which the radioactivity of the cell incubated
in the coexistence of the substance and the radiolabeled amino acid
and the radioactivity of the cell incubated in the presence of the
radiolabeled amino acid only are measured and the difference
between them is compared.
[0145] <49> The method according to <48>, wherein the
cell which is transformed by the DNA mentioned in any of the above
<7> to <11> is used.
[0146] <50> The method according to <48>, wherein an
oocyte of Xenopus laevis is used.
[0147] <51> A method for the identification of a substance
having an ability of inhibiting the transcription of the DNA
mentioned in any of the above <7> to <11> to mRNA or
the expression of the protein mentioned in any of the above
<1> to <5>.
[0148] <52> A substance which is detected, screened or
identified by a method mentioned in any of the above <44> to
<51>.
[0149] <53> The substance according to <52>, wherein
the substance is a substance having an ability of inhibiting the
growth of tumor cell.
[0150] <54> A transgenic mouse having an extrinsic gene,
characterized in that, a DNA coding for a protein having an amino
acid sequence mentioned in SEQ ID NO:2 or NO:4 is incorporated on
an intrinsic gene of the mouse whereupon the mouse has a cell
expressing the protein in its body.
[0151] <55> The transgenic mouse according to <54>,
wherein the DNA is a DNA which contains a base sequence comprising
a base sequence of from 66th to 1586th bases in the base sequence
mentioned in SEQ ID NO:1 and any one nonsense base sequence
represented by TAG, TGA or TAA adjacent to the 1586th base or a
base sequence comprising a base sequence of from 64th to 1599th
bases in the base sequence mentioned in SEQ ID NO:3 and any one
nonsense base sequence represented by TAG, TGA or TAA adjacent to
the 1599th base.
[0152] The present invention will now be illustrated in detail as
hereunder by clarifying the meanings of the terms used in the
present invention and also the general method for the manufacture
of DNA, proteins, antibodies, cells produced by the antibody,
transformants, labeled DNA, labeled RNA, labeled antibodies,
pharmaceutical compositions, transgenic mice, etc. of the present
invention.
[0153] The term "mammals" used in the present invention means all
mammals such as human being, cattle, horse, pig, goat, sheep, dog,
cat, chicken, rabbit, rat, hamster, guinea pig and mouse;
preferably, human being, cattle, horse, pig, goat, sheep, dog, cat,
chicken, rabbit, rat, hamster, guinea pig and mouse; and,
particularly preferably, human being, rat, hamster, guinea pig and
mouse.
[0154] The terms "mammals except human being" and "non-human
mammals" used in the present invention have the same meaning and
stand for all mammals except human being in the above-defined
mammals.
[0155] "Amino acid" used in the present invention means all amino
acids present in nature and, preferably, it is the amino acid
represented as follows in accordance with the three-letter notation
or one-letter notation by alphabets used for representing the amino
acid.
[0156] Thus, glycine (Gly/G), alanine (Ala/A), valine (Val/V),
leucine (Leu/L), isoleucine (Ile/I), serine (Ser/S), threonine
(Thr/T), aspartic acid (Asp/D), glutamic acid (Glu/E), asparagine
(Asn/N), glutamine (Gln/Q), lysine (Lys/K), arginine (Arg/R),
cysteine (Cys/C), methionine (Met/M), phenylalanine (Phe/F),
tyrosine (Tyr/Y), tryptophan (Trp/W), histidine (H is/H) and
proline (Pro/P).
[0157] Amino acids are classified into acidic, basic and neutral
amino acids according to the state of polarity and charge of the
amino acid. When the above-mentioned amino acids are classified
according to such a classification, they are classified as follows
and, when the degree of polarity and charge are more finely
classified or a classification is carried out by taking other
parameters into consideration, there are amino acids which are not
always suitable for the following classification.
[0158] (Acidic Amino Acids)
[0159] Aspartic acid (Asp/D) and glutamic acid (Glu/E).
[0160] (Basic Amino Acids)
[0161] Lysine (Lys/K), arginine (Arg/R) and histidine (His/H).
[0162] (Neutral Amino Acids)
[0163] Leucine (Leu/L), isoleucine (Ilea), phenylalanine (Phe/F),
methionine (Met/M), tyrosine (Tyr/Y), tryptophan (Trp/W), valine
(Val/V), histidine (His/H), threonine (Thr/T), cysteine (Cys/C),
asparagine (Asn/N), glutamine (Gln/Q), glycine (Gly/G), alanine
(Ala/A), serine (Ser/S) and proline (Pro/P).
[0164] The term "protein" used in the present invention means a
molecule being derived from the above-mentioned mammals and having
a specific amino acid sequence comprising the above-mentioned amino
acids.
[0165] The "protein" of the present invention is a protein which is
mentioned in any of the above-mentioned <1> to <5>. To
be more specific, it is
[0166] "a cell surface protein having an ability of mediating the
transport of an amino acid into cell and the protein has an ability
of mediating an incorporation of any one amino acid selected from a
group consisting of leucine (Leu), isoleucine (Ile), phenylalanine
(Phe), methionine (Met), tyrosine (Tyr), histidine (His),
tryptophan (Trp) and valine (Val) in the cell in which the protein
of the following (1) or (2) is expressed:
[0167] (1) a protein having an amino acid sequence mentioned in SEQ
ID NO:6 or NO:8; or
[0168] (2) a homologous protein to the protein having an amino acid
sequence mentioned in SEQ ID NO:6 or NO:8 and being coded by DNA
which hybridizes to DNA containing a base sequence mentioned in SEQ
ID NO:5 or NO:7 under a stringent condition"
[0169] The above-mentioned protein of the present invention
therefore means a protein which, when the protein of the present
invention is co-expressed on a cell membrane where a human-derived
cell membrane surface molecule 4F2hc having an amino acid sequence
mentioned in SEQ ID NO:6 or a homologous protein thereto derived
from non-human animal is expressed, is able to give a property of
inducing the incorporation of any one of the above-mentioned amino
acids into the cell.
[0170] Here, the "homologous protein" means a protein derived from
animal species except human being having a sequence homology to the
amino acid sequence (SEQ ID NO:6) of human-derived cell membrane
surface molecule 4F2hc, being believed to be derived from the
common ancestor protein in terms of evolution and having the same
physiological function as that of the human-derived 4F2hc.
[0171] Preferably, the protein of the present invention is any of
the proteins of the following (1) and (2).
[0172] (1) a protein having an amino acid sequence mentioned in SEQ
ID NO:2; or
[0173] (2) a protein having an amino acid sequence where one or
more amino acid(s) in the amino acid sequence mentioned in SEQ ID
NO:2 is/are deleted, substituted or added and the protein is
characterized in having an ability of mediating the incorporation
of any one of amino acids selected from a group consisting of
leucine (Leu), isoleucine (Ile), phenylalanine (Phe), methionine
(Met), tyrosine (Tyr), histidine (His), tryptophan (Trp) and valine
(Val) in the cell in which the protein having the amino acid
sequence mentioned in SEQ ID NO:6 is expressed.
[0174] Here "more amino acids" means plural amino acids. To be more
specific, that is 1 to 40 amino acid(s), preferably 1 to 30 amino
acid(s), more preferably 1 to 20 amino acid(s) and, particularly
preferably, 1 to 10 amino acid(s).
[0175] A partial modification (deletion, substitution, insertion
and addition) of the amino acid in the amino acid sequence of the
protein of the present invention as mentioned above can be
introduced by a partial modification of the base sequence coding
for the protein. The partial modification of the base sequence can
be introduced by a common method using a known site-specific
mutagenesis (Proc. Natl. Acad. Sci., USA, Vol. 81, p. 5662-5666,
1984).
[0176] The "partial amino acid sequence" in the present invention
is an embodiment of the protein of the present invention as
mentioned above and it means any partial amino acid sequence
(protein fragment) in the amino acid sequence. Preferably, it is a
partial sequence containing a site which is necessary for the
protein of the present invention to achieve its biological function
or a site where the protein of the present invention bonds to or
interact with other protein molecule (receptor or ligand).
[0177] In addition, "polypeptide containing a partial amino acid
sequence and having an antigenicity" in the present invention means
a polypeptide containing the above-mentioned partial amino acid
sequence and being recognized as a not-one's-own substance or a
foreign substance due to the immune response mechanism of the
mammal when the polypeptide is administered into the body of the
above-mentioned mammal whereby production of an antibody to the
polypeptide in the body of the mammal is possible.
[0178] The polypeptide containing the protein of the present
invention or the partial amino acids in the amino acid sequence of
the protein of the present invention can be expressed by an
appropriate use of a method known in the technical field such as a
chemical synthesis or a cell incubation method or a modified method
thereof in addition to the genetic recombination technique which
will be mentioned later.
[0179] It is also possible that the protein of the present
invention is expressed by an injection of the RNA of the present
invention which will be mentioned later into various cells such as
oocytes of Xenopus laevis whereupon a direct translation of the RNA
infused into the cells to the protein takes place without the
transcription from DNA to mRNA (Special Issue of Jikken Igaku,
"Method of Experiments of Biosignals", Vol. 11, No. 3, p. 30-38,
1993).
[0180] "DNA" of the present invention is that which is mentioned
any of the above <7> to <11>. A preferred embodiment is
the DNA which codes for the protein or the polypeptide of the
present invention. DNA having any base sequence such as cDNA, DNA
which is complementary to the cDNA and genomic DNA is covered as
well so far as it is a DNA being able to code for the protein of
the present invention. The DNA of the present invention further
covers any DNA composed of any codon so far as the codon codes for
the same amino acid. Further, one preferred embodiment of the DNA
of the present invention is a DNA coding for the human-derived
protein of the present invention.
[0181] More particularly, the DNA of the present invention is a DNA
which is mentioned in any of the following (1) to (3).
[0182] (1) DNA which codes for the protein mentioned in any of the
above <1> to <5>. Here, the DNA covers a DNA having any
base sequence such as cDNA, DNA which is complementary to the cDNA
and genomic DNA so far as it is a DNA coding for the protein such
as a protein comprising the amino acid sequence mentioned in SEQ ID
NO:2 or No:4.
[0183] (2) DNA which contains a base sequence comprising the base
sequence which comprises a base sequence of 66th to 1586th bases in
the base sequence mentioned in SEQ ID NO:1 and any one nonsense
base sequence represented by TAG, TGA or TAA adjacent to the 1586th
base or the base sequence of 64th to 1599th bases in the base
sequence mentioned in SEQ ID NO:3 and any one nonsense base
sequence represented by TAG, TGA or TAA adjacent to the 1599th
base.
[0184] Here, "nonsense base sequence" is any of the base sequence
of TAG, TGA or TAA which is also called termination codon, stop
codon, nonsense codon, termination codon or termination signal and
is a base sequence which codes for the termination point of the
synthesis of protein.
[0185] (3) DNA which codes for the cell surface protein having an
ability of mediating the incorporation of at least one amino acid
into cell by hybridizing, under a stringent condition, to a DNA
having a base sequence which comprises a base sequence of 66th to
1586th bases of the base sequence of SEQ ID NO:1 or a base sequence
of 64th to 1599th bases of the base sequence of SEQ ID NO:3 and at
least any one nonsense base sequence represented by TAG, TGA or TAA
adjacent to the 1599th base where incorporation of the amino acid
into cell is mediated without dependent upon the coexistence of any
of the proteins of the following (a) and (b).
[0186] (a) protein having an amino acid sequence mentioned in SEQ
ID NO:6 or NO:8; and
[0187] (b) protein having an amino acid sequence mentioned in SEQ
ID NO:6 or NO:8 where one or more amino acid(s) is/are deleted,
substituted or added.
[0188] The term "more amino acids" used here has the same meaning
as defined already.
[0189] The term "under a stringent condition" used here means a
condition for carrying out the hybridization and, to be more
specific, it means temperature and salt concentration. The
temperature is usually about 36.degree. C. to about 42.degree. C.
and, depending upon the length and the degree of complementarily of
the probe used, it may be also set as follows.
[0190] For example, when a probe having 50 or more bases is used
and a hybridization is carried out under 0.9% NaCl, the aim of the
temperature (Tm) giving a dissociation of 50% is calculated from
the following formula and the temperature of hybridization can be
set as shown in the following formula.
Tm=82.3.degree. C.+0.41.times.(G+C)%-500/n-0.61.times.(formamide)
%
[0191] (n is a base number of the probe)
Temperature=Tm-25.degree. C.
[0192] When a probe having 100 or more bases (G+C=40 to 50%) is
used, the aim is that Tm changes according to the following (1) and
(2).
[0193] (1) Tm lowers about 1.degree. C. per 1% mismatch.
[0194] (2) Tm lowers at the rate of 0.6 to 0.7.degree. C. per 1%
formamide.
[0195] Accordingly, the temperature condition in the case of a
combination of a completely complemented chains may be made as
follows.
[0196] (A) 65 to 75.degree. C. (when no formamide added)
[0197] (B) 35 to 45.degree. C. (in the presence of 50%
formamide)
[0198] The temperature condition in the case of a combination of
incompletely complemented chains may be made as follows.
[0199] (A) 45 to 55.degree. C. (when no formamide added)
[0200] (B) 35 to 42.degree. C. (in the presence of 30%
formamide)
[0201] The temperature condition when a probe having 23 or less
bases may be made 37.degree. C. or the following formula may be an
aim.
Temperature=2.degree. C..times.(numbers of T+A)+4.degree.
C..times.(numbers of G+C)-5.degree. C.
[0202] With regard to a salt concentration, 5.times.SSC or
equivalent thereto may be usually set.
[0203] Accordingly, the temperature in a hybridization in the
present invention may, for example, be set at about 37.degree. C.
while the salt concentration may be set at 5.times.SSC or
equivalent thereto.
[0204] The above-mentioned DNA of the present invention may be that
which is prepared by any method. For example, complementary DNA
(cDNA) prepared from mRNA, DNA prepared from genomic DNA, DNA
obtained by chemical synthesis, DNA obtained by amplification by
means of a PCR using RNA or DNA as a template and DNA which is
constituted by an appropriate combination of those methods are
included in the DNA of the present invention.
[0205] DNA which codes for the protein of the present invention may
be prepared by a method where cDNA is cloned from mRNA of the
protein of the present invention by a conventional method, a method
where genomic DNA is isolated and subjected to splicing treatment,
a chemical synthetic method, etc.
[0206] (1) For example, with regard to a method of cloning of cDNA
from mRNA of the protein of the present invention, the following
method is exemplified.
[0207] First, from the above-mentioned tissue or cell wherefrom the
protein of the present invention is generated/produced, mRNA which
codes for the protein of the present invention is prepared.
Preparation of mRNA is carried out, for example, by a method where
a whole RNA prepared by a known method such as a guanidine
thiocyanate method (Chirgwin, et al., Biochemistry, Vol. 18, p.
5294, 1979), a hot phenol method or an AGPC method is subjected to
an affinity chromatography using oligo(dT)cellulose or
poly-U-Sepharose.
[0208] Then cDNA chain is synthesized by, for example, a known
method such as that using a reverse transcriptase, e.g. a method by
Okayama (Mol. Cell. Biol., Vol. 2, p. 161, 1982; and ibid., Vol. 3,
p. 280, 1983), a method by Hoffman, et al. (Gene, Vol. 25, p. 263,
1983), etc. using the above-prepared mRNA as a template whereupon
the cDNA is converted to a double-stranded cDNA. The resulting cDNA
is integrated into a plasmid vector or a phage vector and, after
Escherichia coli is transformed or subjected to an in vitro
packaging, it is transfected into E. coli whereupon a cDNA library
is prepared.
[0209] With regard to the plasmid vector used here, there is no
particular limitation so far as it is duplicated and held in a host
and, with regard to the phage vector used, anything which is able
to proliferate in the host may be used. Examples of the vector for
cloning which is usually applied are .lamda.ZipLox, pUC19,
.lamda.gt10 and .lamda.gt11. However, when subjecting to an
immunological screening which will be mentioned later, a vector
having a promoter which is able to express a gene coding for the
protein of the present invention in a host is preferred.
[0210] With regard to a method for integration of cDNA into
plasmid, an example is a method by Maniatis, et al. which is
mentioned in Molecular Cloning, A Laboratory Manual, second
edition, Cold Spring Harbor Laboratory, No. 1, p. 53, 1989. With
regard to a method for integration of cDNA into phage vector, an
example is a method by Hyunh, et al., DNA Cloning, a Practical
Approach, Vol. 1, p. 49, 1985. To be more simple, a commercially
available cloning kit (such as that manufactured by Gibco or Takara
Shuzo) may be used as well. The recombined plasmid or phage vector
prepared as such is introduced into an appropriate host in
prokaryotic cells (such as E. coli:HB101, DH5.alpha. or MC1061/P3,
etc.).
[0211] With regard to a method for the introduction of plasmid into
a host, a calcium chloride method or a calcium chloride/rubidium
chloride method mentioned in Molecular Cloning, a Laboratory
Manual, second edition, Cold Spring Harbor Laboratory, No. 1, p.
74, 1989), an electroporation method, etc. may be exemplified. With
regard to a method for the introduction of phage vector into a
host, a method where phage DNA is subjected to an in vitro
packaging and then introduced into a proliferated host may be
exemplified. The in vitro packaging method may be easily carried
out using a commercially available in vitro packaging kit (such as
that manufactured by Stratagene, Amersham, etc.).
[0212] A method for the isolation of cDNA coding for the protein of
the present invention from the cDNA library prepared by the
above-mentioned method is carried out by a combination of common
cDNA screening methods.
[0213] For example, a method where DNA which contains a part of or
all of the base sequence coding for the amino acid sequence of the
protein of the present invention or DNA which has a homology to the
base sequence is prepared separately, this is labeled with .sup.32P
or [.alpha.-.sup.32P]CTP to prepare a probe and then a clone which
contains the desired cDNA is screened by a known colony
hybridization method (Crunstein, et al., Proc. Natl. Acad. Sci.
USA, Vol. 72, p. 3961, 1975) or a plaque hybridization method
(Molecular Cloning, A Laboratory Manual, second edition, Cold
Spring Harbor Laboratory, No. 2, p. 108, 1989) and a method where a
PCR primer is prepared, the specific region of the protein of the
present invention is amplified by a PCR and the clone which has a
DNA fragment coding for the region is selected, etc. may be
exemplified.
[0214] When a cDNA library prepared by the vector which is able to
express the cDNA (such as .lamda.ZipLox or .lamda.gt11 phage
vector) is used, a desired clone can be selected utilizing an
antigen-antibody reaction using an antibody which has a reactivity
with the protein of the present invention. When clone is treated in
a large scale, it is preferred to use a screening method utilizing
a PCR.
[0215] The base sequence of the DNA prepared as such can be
determined by a method by Maxam-Gilbert (Maxam, et al., Proc. Natl.
Acad. Sci. USA, Vol. 74, p. 560, 1977), a method where
dideoxynucleotide synthetic chain is stopped using phage M13
(Sanger, et al., Proc. Natl. Acad. Sci. USA, Vol. 74, p. 5463-5467,
1977) or a diterminator cycle sequencing method (manufactured by
Applied Biosystems). The gene coding for the protein of the present
invention can be prepared by a method where all or a part thereof
is excised from the above-prepared clone using a restriction
enzyme, etc.
[0216] (2) With regard to a method of preparation by isolating the
DNA coding for the protein of the present invention from the
genomic DNA derived from the cell expressing the protein of the
present invention as mentioned above, the following method will be
exemplified. Thus, the cell is dissolved preferably using SDS or
protenase K, etc. and extraction with phenol is repeated whereby
protein is removed from DNA. RNA is digested preferably by
ribonuclease. The resulting DNA is partially digested by an
appropriate restriction enzyme and the resulting DNA fragment is
amplified by an appropriate phage or cosmid to prepare a library. A
clone having a desired sequence is detected, for example, by a
method where a radiolabeled DNA probe is used and all or a part of
the gene coding for the protein of the present invention is excised
from the clone by a restriction enzyme or the like and is
collected.
[0217] (3) Manufacture of the cDNA coding for the protein having
the amino acid sequence mentioned in SEQ ID NO:2 which is an
embodiment of the DNA of the present invention can be carried out
by a conventional method based upon a base sequence mentioned in
SEQ ID NO:1.
[0218] For example, a rat C6 glioma cell is used as a gene source
and mRNA (poly(A) RNA) is prepared therefrom. This is fractionated
and each fraction is introduced into oocytes of Xenopus laevis
together with the cRNA of 4F2hc.
[0219] Since cDNA of gene of 4F2hc has been reported already
[Broer, et. al, Biochem. J., Vol. 312, p. 863, 1995], it is
possible to easily prepare the gene of 4F2hc from this sequence
information using a PCR, etc. From the resulting cDNA of 4F2hc, it
is possible to synthesize an RNA which is complementary thereto
(cRNA) (capped one) using T3 or T7 RNA polymerase, etc.
[0220] With regard to the oocyte into which cRNA of 4F2hc and mRNA
are introduced, transport (incorporation) of the substrate into the
cell is measured using leucine or the like as a substrate and an
mRNA fraction showing a high incorporation activity is selected
whereby the mRNA of LAT1 can be concentrated. A cDNA library is
prepared using this concentrated mRNA as a base. From the cDNA of
the library, cRNA (capped one) is prepared where one group consists
of about 500 clones and each group is introduced into oocytes
together with cRNA of 4F2hc and, using the incorporation activity
of the substrate as an index, a positive group is selected. When a
positive group is found, it is further classified into subgroups
and the same operation is repeated whereupon clones containing cDNA
of LAT1 gene can be obtained.
[0221] With regard to the resulting cDNA, its base sequence is
determined by a common method and a translation region is analyzed
whereby the protein coded thereby or, in other words, the amino
acid sequence of LAT1 can be determined.
[0222] The fact that the resulting cDNA is a cDNA of a neutral
amino acid transporter gene or, in the other words, that the
genetic product coded by the cDNA is a neutral amino acid
transporter can, for example, be ascertained as follows. Thus, the
cRNA prepared from the resulting cDNA of LAT1 gene is expressed by
introducing into oocytes together with the cRNA of 4F2hc and the
ability of transport (incorporation) of the neutral amino acid into
the oocytes can be confirmed in the same manner as mentioned above
by measuring the incorporation of the substrate into the oocytes
according to a conventional incorporation test (Kanai and Hediger,
Nature, 360, 467-471 (1992)) using an appropriate neutral amino
acid as a substrate.
[0223] The same incorporation experiment is applied to the
expressed cell whereby it is possible to investigate the
characteristic of LAT1 such as the characteristic that LAT1 carries
out an exchange of amino acids, a substrate specificity of LAT1,
etc.
[0224] When the resulting cDNA of LAT1 gene is used and an
appropriate cDNA library or genomic DNA library prepared from
different gene sources is screened, it is possible to isolate the
homologous gene, chromosomal gene, etc. derived from different
tissues and different organisms.
[0225] Further, when a common PCR (polymerase chain reaction) is
carried out using a synthetic primer designed based upon the
information of the disclosed base sequence of the gene of the
present invention (a base sequence shown in SEQ ID NO:1 or a part
thereof), it is possible to isolate a gene from a cDNA library or a
genomic DNA library.
[0226] SEQ ID NO:3 of the Sequence Listing which will be mentioned
later shows a full-length cDNA base sequence (about 3.5 kbp) of
gene of a neutral amino acid transporter (rat LAT1) derived from a
rat C6 glioma cell line and an amino acid sequence (512 amino
acids) of the protein coded to the translation region thereof. SEQ
ID NO:4 of the Sequence Listing shows an amino acid sequence (512
amino acids) of a neutral amino acid transporter (rat LAT1) derived
from a rat C6 glioma cell line.
[0227] A DNA library such as a cDNA library or a genomic DNA
library can be prepared by a method mentioned, for example, in
Molecular Cloning (by Sambrook, J., Fritsh, E. F. and Maniatis, T.,
published by Cold Spring Harbor Press in 1989). Alternatively, a
commercially available library may be used if available.
[0228] In the preparation of a cDNA coding for the protein derived
from human being, it can be also prepared by the following manner
that a cosmid library into which human genomic DNA (chromosomal
DNA, genomic DNA) is further introduced (Laboratory Manual Human
Genome Mapping, edited by Masaaki Hori and Yusuke Nakamura,
published by Maruzen) is prepared, then the cosmid library is
screened to give a positive clone containing the DNA of the coding
region of the desired protein and a coding DNA excised from the
positive clone is used as a probe for carrying out a screening of
the above-mentioned cDNA library.
[0229] SEQ ID NO:1 of the Sequence Listing which will be mentioned
later shows a full-length cDNA base sequence (about 4.5 kbp) of the
gene of a neutral amino acid transporter (human LAT1) derived from
human being and an amino acid sequence (507 amino acids) of the
protein coded to the translation region thereof. SEQ ID NO:2 of the
Sequence Listing shows an amino acid sequence (507 amino acids) of
a neutral amino acid transporter (human LAT1) derived from human
being.
[0230] SEQ ID NO:5 of the Sequence Listing shows a full-length cDNA
base sequence (about 1.8 kbp) of the gene of 4F2hc protein derived
from human being and an amino acid sequence (529 amino acids) of
the protein coded to the translation region thereof and SEQ ID NO:6
of the Sequence Listing shows an amino acid sequence (529 amino
acids) of the 4F2hc protein derived from human being. SEQ ID NO:7
of the Sequence Listing shows a full-length cDNA base sequence
(about 1.8 kbp) of the gene of 4F2hc protein derived from rat and
an amino acid sequence (527 amino acids) of the protein coded to
the translation region thereof and SEQ ID NO:8 of the Sequence
Listing shows an amino acid sequence (527 amino acids) of the 4F2hc
protein derived from rat.
[0231] "Expression vector" of the present invention means a
recombinant vector containing the DNA of the present invention.
There is no particular limitation for the recombinant vector of the
present invention so far as it is able to conduct a
self-multiplication in various hosts such as prokaryotic cells
and/or eukaryotic cell including plasmid vector and phage
vector.
[0232] In a simple manner, the recombinant vector can be prepared
by linking the DNA of the present invention by a common method to a
vector for recombination available in the art (plasmid DNA and
bacteriophage DNA). Specific examples of the applicable vector for
recombination in the case of plasmid derived from Escherichia coli
are pBR322, pBR325, pUC12, pUC13 and pUC19; in the case of plasmid
derived from yeast are pSH19 and pSH15; and in the case of plasmid
derived from Bacillus subtilis are pUB110, pTP5 and pC194. Examples
of the phage are bacteriophage such as .lamda. phage and also
animal and insect virus such as retrovirus, vaccinia virus and
nuclear polyhedrosis virus (pVL 1393 manufactured by Invitrogen).
Further example is pZL1.
[0233] For an object of expression of the protein of the present
invention, expression vector is useful. With regard to an
expression vector, there is no particular limitation therefor so
far as it has an ability of expressing the protein of the present
invention in various host cells of prokaryotic cells and/or
eukaryotic cells. For example, pMAL C2, pEF-BOS (Nucleic Acid
Research, Vol. 18, p. 5322, 1990; etc.) or pME18S (Handbook of
Genetic Engineering, Supplementary Issue of Jikken Igaku, 1992;
etc.) may be exemplified.
[0234] When bacteria, particularly Escherichia coli, are used as a
host cell, an expression vector is usually constituted at least
from promoter-operator region, initiation codon, DNA coding for the
protein of the present invention, termination codon, terminator
region and replicable unit.
[0235] When yeast, animal cell or insect cell is used as a host, it
is preferred that an expression vector contains at least promoter,
initiation codon, DNA coding for the protein of the present
invention and termination codon. It may further contain DNA coding
for a signal peptide, enhancer sequence, non-translated region on
5'- and 3'-sides of the gene coding for the protein of the present
invention, splicing conjugated part, polyadenylation site,
selective marker region or duplicable unit. Depending upon an
object, it may also contain gene for gene amplification (marker)
which is commonly used.
[0236] Promoter-operator region for expressing the protein of the
present invention in bacteria contains promoter, operator and
Shine-Dalgarno (SD) sequence (such as AAGG). When the host is a
bacterium of genus Escherichia, appropriate examples are those
which contain Trp promoter, lac promoter, rec A promoter, .lamda.PL
promoter, lpp promoter and tac promoter. Examples of the promoter
for expressing the protein of the present invention in yeast are
PHO5 promoter, PGK promoter, GAP promoter and ADH promoter and,
when the host belongs to genus Bacillus, the examples are SL01
promoter, SP02 promoter and penP promoter. When the host is a
eukaryotic cell such as a mammalian cell, its examples are promoter
derived from SV40, promoter for retrovirus and heat shock promoter.
Preferred examples are SV-40 and retrovirus. However, there is no
particular limitation to the above. Utilization of enhancer is an
effective method for the expression as well.
[0237] With regard to the suitable initiation codon, methionine
codon (ATG) is exemplified.
[0238] With regard to the termination codon, commonly used
termination codons (such as TAG, TGA and TAA) are exemplified.
[0239] With regard to the terminator region, commonly used natural
or synthetic terminator may be used.
[0240] Duplicable unit means the DNA having an ability of being
able to duplicate its total DNA sequence in host cells and includes
natural plasmid, artificially modified plasmid (DNA fragment
prepared from natural plasmid) and synthetic plasmid. With regard
to a suitable plasmid, plasmid pBR322 or artificially modified
product thereof (DNA fragment obtained by treating pBR322 with an
appropriate restriction enzyme) in the case of E. coli; yeast 2.mu.
plasmid or yeast chromosomal DNA in the case of yeast; and plasmid
pRSVneo (ATCC 37198), plasmid pSV2dhfr (ATCC 37145), plasmid
pdBPV-MMTneo (ATCC 37224), plasmid pSV2neo (ATCC 37149), etc. in
the case of mammalian cells.
[0241] With regard to the enhancer sequence, polyadenylation site
and splicing combination site, those which are commonly used by the
persons skilled in the art such as each of those derived from SV40
may be used.
[0242] With regard to the selective marker, those which are
commonly used may be used by a conventional method. For example,
gene which is resistant to antibiotics such as tetracycline,
ampicillin, neomycin or kanamycin is exemplified.
[0243] With regard to the gene for a gene amplification,
dihydrofolic acid reductase (DHFR) gene, thymidinekinase gene,
neomycin-resistant gene, glutamic acid-synthetic enzyme gene,
adenosinedeaminase gene, ornithinedecarboxylase gene, hygromycin B
phosphotransferase gene, aspartate transcarbamylase, etc. are
exemplified.
[0244] The expression vector of the present invention can be
prepared by continuously and cyclically linking at least the
above-mentioned promoter, initiation codon, DNA coding for the
protein of the present invention, termination codon and terminator
region to an appropriately duplicable unit. If necessary in that
case, it is also possible to use an appropriate DNA fragment (such
as linker, other restriction site, etc.) by a common method such as
digestion with a restriction enzyme or ligation using a T4 DNA
ligase.
[0245] The "transformed cell" of the present invention is a cell
which is transformed by the above-mentioned expression vector or
DNA of the present invention and can be prepared by introducing the
DNA or expression vector into prokaryotic cell or eukaryotic cell
as a host cell.
[0246] With regard to the host cell used in the present invention,
there is no particular limitation so far as it is adapted to the
above-mentioned expression vector and is able to be transformed and
its examples are various cells such as natural cell or artificially
established recombinant cell which are commonly used in the
technical field of the present invention such as bacteria
(belonging to genus Escherichia and genus Bacillus), yeast
(belonging to genus Saccharomyces, genus Pichia, etc.), animal
cells and insect cells.
[0247] Preferably, it is Escherichia coli or animal cells and, to
be more specific, E. coli (DH5.alpha., TB1, HB101, etc.),
mouse-derived cells (COP, L, C127, Sp2/0, NS-1 and NIH3T3, etc.),
rat-derived cells (PC12, PC12h, etc.), hamster-derived cells (BHK
and CHO, etc.), monkey-derived cells (COS1, COS3, COS7, CV1 and
Velo, etc.) and human-derived cells (HeLa, cells derived from
diploid fibroblast, HEK293 cells, myeloma cells and Namalwa, etc.)
may be exemplified.
[0248] Introduction of expression vector into host cells
(transformation (character transfer)) may be carried out by a
method which has been known already.
[0249] Thus, the transformation can be carried out, for example, by
a method of Cohen, et al. (Proc. Natl. Acad. Sci. USA, Vol. 69, p.
2110, 1972), a protoplast method (Mol. Gen. Genet., Vol. 168, p.
111, 1979) and a competent method (J. Mol. Biol., Vol. 56, p. 209,
1971) in the case of bacteria (Escherichia coli, Bacillus subtilis,
etc.); for example, by a method of Hinnen, et al. (Proc. Natl.
Acad. Sci. USA, Vol. 75, p. 1927, 1978) and a lithium method (J.
Bacteriol., Vol. 153, p. 163, 1983) in the case of Saccharomyces
cerevisiae; for example, by a method of Graham (Virology, Vol. 52,
p. 456, 1973) in the case of animal cells; and, for example, by a
method of Summers, et al. (Mol. Cell. Biol., Vol. 3, p. 2156-2165,
1983) in the case of insect cell; respectively.
[0250] The "protein" of the present invention can be expressed by
incubation of the above-prepared transformant cell (hereinafter,
this will be used in a sense of covering the substance into which
the character is transferred) containing the expression vector in a
nutritive medium.
[0251] It is preferred that the nutritive medium contains carbon
source, inorganic nitrogen source or organic nitrogen source
necessary for the growth of the host cell (transformant). With
regard to the carbon source, glucose, dextran, soluble starch,
sucrose, etc. may be exemplified; and with regard to the inorganic
nitrogen source or an organic nitrogen source, ammonium salts,
nitrates, amino acid, corn steep liquor, peptone, casein, meat
extract, soybean cake, potato extract, etc. may be exemplified. If
desired, other nutrients (such as inorganic salt [e.g., calcium
chloride, sodium dihydrogen phosphate and magnesium chloride],
vitamins, antibiotic substances [e.g., tetracycline, neomycin,
ampicillin and kanamycin], etc.) may be contained therein.
[0252] The incubation may be carried out by a method which has been
known in the art. The incubating conditions such as temperature, pH
of the medium and incubating time may be appropriately selected so
as to abundantly express the protein of the present invention.
[0253] As hereunder, the specific media and incubating conditions
which are used depending upon the host cell will be exemplified
although the present invention is not limited thereto at all.
[0254] When the host is bacteria, Actinomyces, yeast or filamentous
fungi, a liquid medium containing the above-mentioned nutrients is
appropriate for example. Preferably, it is a medium where the pH is
5-8.
[0255] When the host is E. coli, examples of the preferred medium
are LB medium, M9 medium (Miller, et al., Exp. Mal Genet., Cold
Spring Harbor Laboratory, p. 431, 1972), etc. In that case, the
incubation may be carried out usually at 14-43.degree. C. for about
3-24 hours together, if necessary, with aeration and stirring.
[0256] When the host is genus Bacillus, the incubation may be
carried out usually at 30.sup.-40.degree. C. for about 16-96 hours,
if necessary, with aeration and stirring.
[0257] When the host is yeast, it is preferred that the medium is,
for example, a Burkholder minimum medium (Bostian, Proc. Natl.
Acad. Sci. USA, Vol. 77, p. 4505, 1980) and the pH is preferably
5-8. Incubation is carried out usually at about 20-35.degree. C.
for about 14-144 hours and, if necessary, aeration and stirring may
be conducted.
[0258] When the host is animal cells, MEM medium containing about
5-20% of bovine fetus serum (Science, Vol. 122, p. 501, 1952), DMEM
medium (Virology, Vol. 8, p. 396, 1959), RPMI 1640 medium (J. Am.
Med. Assoc., Vol. 199, p. 519, 1967), 199 medium (Proc. Soc. Exp.
Biol. Med., Vol. 73, p. 1, 1950), etc. may be used as a medium. The
pH of the medium is preferably about 6-8 and the incubation is
carried out usually at about 30-40.degree. C. for about 15-72
hours. If necessary, aeration and stirring may be conducted as
well.
[0259] When the host is insect cells, Grace's medium containing
bovine fetus serum (Proc. Natl. Acad. Sci. USA, Vol. 82, p. 8404,
1985), etc. may be used for example and its pH is preferably about
5-8. The incubation is carried out usually at about 20-40.degree.
C. for about 15-100 hours and, if necessary, aeration and stirring
may be conducted as well.
[0260] The protein of the present invention can be expressed by
such a manner that the transformant which is prepared as above
using the expression vector or the DNA of the present invention as
mentioned above is incubated under the above-mentioned incubating
condition.
[0261] When the protein of the present invention is prepared as a
soluble protein, the cells are collected after the cell incubation
and suspended in an appropriate buffer solution and, after the cell
walls and/or cell membranes of the cell, etc. are destroyed by, for
example, means of ultrasonic wave, lysozyme, freeze-thaw, etc., a
method such as centrifugation, filtration, etc. is carried out
whereupon the membrane fraction containing the protein of the
present invention is obtained. The membrane fraction is solubilized
using a surface-active agent such as Triton-X 100 to give a crude
solution. The crude solution is subjected to a commonly used
purifying method so as to purify and isolate the protein whereupon
the protein of the present invention can be isolated as a soluble
protein.
[0262] With regard to a method for isolation and for purification,
there may be exemplified a method where the solubility is utilized
such as salting-out and solvent precipitation methods; a method
where the difference in molecular weights is utilized such as
dialysis, ultrafiltration, gel filtration and a sodium
dodecylsulfate-polyacrylamide gel electrophoresis method; a method
where the charge is utilized such as ion exchange chromatography
and hydroxylapatite chromatography; a method where the specific
affinity is utilized such as affinity chromatography; a method
where the difference in hydrophobicity is utilized such as a
reversed phase high-performance chromatography; and a method where
the difference in isoelectric points is utilized such as
isoelectric focusing.
[0263] The "RNA" of the present invention is an RNA which is
mentioned in the above <5> and will be mentioned later.
[0264] "an RNA which contains a base sequence of base numbers of
from 1st to 1521st of the base sequence mentioned in SEQ ID NO:26
and a base sequence comprising any of one nonsense base sequence
represented by UAG, UGA or UAA adjacent to the base of the base
number of 1521st"
[0265] Here, the term "nonsense base sequence" means any of the
base sequences of UAG, UGA and UAA which is also called termination
codon, stop codon, nonsense codon, termination codon or termination
signal and is a base sequence coding for the termination point of
the translation to the protein.
[0266] The RNA of the present invention can be prepared by a common
method using a commercially available RNA polymerase (such as T7
RNA polymerase) using a DNA sequence complementary to the DNA
mentioned in the above <1>, i.e. "DNA which contains a base
sequence of from 66th to 1586th bases of the base sequence
mentioned in SEQ ID NO:1 and any one of the nonsense base sequences
of TAG, TGA and TAA adjacent to the 1586th base" as a template.
[0267] The RNA of the present invention can be used for expressing
the protein of the present invention in various cells. Thus, when
the RNA of the present invention is injected into oocytes of
Xenopus laevis, it is possible to directly express the protein of
the present invention in the cells from the injected RNA without a
transcription from DNA to mRNA (Special Issue of Jikken Igaku,
"Method of Experiments of Biosignals", Vol. 11, No. 3, p. 30-38,
1993).
[0268] Another feature of the present invention is the DNA as
mentioned in the above <4> which will be given as
follows.
[0269] "DNA which contains a partial base sequence in the base
sequence mentioned in SEQ ID NO:1 or DNA where a part of the DNA is
chemically modified, or DNA which contains a base sequence which is
complementary to the partial base sequence or DNA where a part of
the DNA is chemically modified and has the following
characteristics (1) and (2).
[0270] (1) the partial base sequence is a base sequence which is
not so completely identical with the partial base sequence of the
base sequence mentioned in SEQ ID NO:3; and
[0271] (2) the DNA or the chemically modified DNA hybridizes to the
gene coding for the protein having an amino acid sequence mentioned
in SEQ ID NO:2.
[0272] Here, "a partial base sequence in the base sequence
mentioned in SEQ ID NO:1" means a partial base sequence comprising
optional numbers of base in any site contained in the base sequence
mentioned in SEQ ID NO:1''.
[0273] The DNA is useful as a probe in an operation of a DNA
hybridization or an RNA hybridization. In an object of using the
DNA as a probe, there may be exemplified a partial base sequence of
continuous 20 or more bases, preferably a partial base sequence of
continuous 50 or more bases, more preferably a partial base
sequence of continuous 100 or more bases, still more preferably a
partial base sequence of continuous 200 or more bases and,
particularly preferably, a partial base sequence of continuous 300
or more bases as the partial base sequence.
[0274] The above-mentioned DNA is also useful as a primer in a PCR.
In an object of using the DNA as a primer in a PCR, there may be
exemplified a partial base sequence of continuous 5 to 100 bases,
preferably a partial base sequence of continuous 5 to 70 bases,
more preferably a partial base sequence of continuous 5 to 50 bases
and, still more preferably, a partial base sequence of continuous 5
to 30 bases as the partial base sequence.
[0275] Further, the above-mentioned DNA is useful as an antisense
pharmaceutical agent as well. Thus, the DNA hybridizes to the RNA
or the DNA coding for the protein having an amino acid sequence
mentioned in SEQ ID NO:2 whereby transcription of the DNA to mRNA
or translation of the mRNA to protein can be inhibited as well.
[0276] In an object of using the above DNA as an antisense
pharmaceutical agent, there may be exemplified a partial base
sequence of continuous 5 to 100 bases, preferably a partial base
sequence of continuous 5 to 70 bases, more preferably a partial
base sequence of continuous 5 to 50 bases and, still more
preferably, a partial base sequence of continuous 5 to 30 bases as
the partial base sequence.
[0277] When the DNA is used as an antisense pharmaceutical, it is
possible to subject a part of the base sequence of the DNA to a
chemical modification so as to increase its half life (stability)
in blood when the DNA is administered into the body of a patient,
to increase a permeability in the intracellular membrane, to
increase the resistance to decomposition in or the absorption with
a digestive organs in the case of an oral administration, etc. With
regard to the chemical modification, that of a phosphoric acid bond
in the oligonucleotide structure, ribose, nucleic acid base,
saccharide site, 3'- and/or 5'-terminal(s), etc. may be
exemplified.
[0278] With regard to a modification of the phosphoric acid bond, a
change of one or more the bond(s) to any of phosphodiester bond
(D-oligo), phosphorothioate bond, phosphorodithioate bond
(S-oligo), methyl phosphate bond (MP-oligo), phosphoroamidate bond,
non-phosphoric acid bond and methyl phosphonothioate or to a
combination thereof may be given. With regard to a modification of
ribose, a change to 2'-fluororibose, to 2'-O-methylribose, etc. may
be given. With regard to a modification of nucleic acid base, a
change to 5-propynyluracil, to 2-aminoadenine, etc. may be
given.
[0279] Another feature of the present invention is the RNA
mentioned in the above <6> which will be as follows.
[0280] "an RNA containing a partial base sequence in the base
sequence of RNA having a base sequence complementary to the base
sequence mentioned in SEQ ID NO:26 or an RNA in which a part of the
RNA is chemically modified, wherein the RNA or the chemically
modified RNA is characterized in hybridizing to an RNA which codes
for the protein having an amino acid sequence mentioned in SEQ ID
NO:2"
[0281] Here, "partial base sequence" means a partial base sequence
comprising any numbers of bases at any site.
[0282] The above-mentioned RNA is useful as an antisense
pharmaceutical agent as well. Thus, the RNA hybridizes to the RNA
or the DNA coding for the protein having an amino acid sequence
mentioned in SEQ ID NO:2 whereby transcription of the DNA to mRNA
or translation of the mRNA to protein can be inhibited.
[0283] In an object of using the above RNA as an antisense
pharmaceutical agent, there may be exemplified a partial base
sequence of continuous 5 to 100 bases, preferably a partial base
sequence of continuous 5 to 70 bases, more preferably a partial
base sequence of continuous 5 to 50 bases and, still more
preferably, a partial base sequence of continuous 5 to 30 bases as
the partial base sequence.
[0284] When the RNA is used as an antisense pharmaceutical agent,
it is possible to subject a part of the base sequence of the RNA to
a chemical modification so as to increase its half life in blood
when the RNA is administered into the body of a patient, to
increase a permeability in the intracellular membrane, to increase
the resistance to decomposition in or the absorption with a
digestive organs in the case of an oral administration, etc. With
regard to the chemical modification, that which is applied to the
above-mentioned antisense DNA may be exemplified.
[0285] The "antibody" of the present invention is a polyclonal
antibody (antiserum) or a monoclonal antibody and, preferably, a
monoclonal antibody.
[0286] To be more specific, it is an antibody having a reactivity
with the protein of the present invention or a part thereof.
[0287] The "antibody" of the present invention covers an antibody
of a natural type which is prepared by immunizing non-human mammal
such as mouse, rat, hamster, guinea pig, chicken, rabbit, goat,
sheep, etc. by a conventional method using the protein of the
present invention or a part thereof (including natural substance,
recombinant and chemically synthesized substance) or the cells in
which the protein is expressed (regardless of natural cell,
transformant cell, normal cell, tumor cell, etc.) as immunogen
(antigen); a recombinant chimera monoclonal antibody and
recombinant human-type monoclonal antibody (CDR-grafted antibody)
which can be manufactured by means of genetic recombination
technique; and a human antibody which can be manufactured using
human antibody-producible transgenic animal, etc.
[0288] In the case of a monoclonal antibody, there is covered a
monoclonal antibody having any isotype such as IgG, IgM, IgA, IgD
and IgE. Preferably, it is IgG or IgM.
[0289] The polyclonal antibody (antiserum) and the monoclonal
antibody of the present invention can be manufactured by the
already-known general manufacturing methods.
[0290] Thus, for example, the above-mentioned immunogen (antigen)
is immunized to mammal, preferably to mouse, rat, hamster, guinea
pig, rabbit, chicken, cat, dog, pig, goat, horse or cattle or, more
preferably, to mouse, rat, hamster, guinea pig or rabbit together,
if necessary, with a Freund's adjuvant.
[0291] The polyclonal antibody (antiserum) can be prepared from the
serum obtained from the immunologically sensitized animal.
[0292] The monoclonal antibody can be manufactured in such a manner
that a hybridoma is prepared from the antibody-producing cell
(spleen, lymph node, bone marrow or tonsil; preferably, B cell of
spleen) obtained from the immunologically sensitized animal with a
cell of a bone marrow type (myeloma cell) having no ability of
autoantibody production, the hybridoma is cloned and a clone which
produces a monoclonal antibody showing a specific affinity to the
antigen used for immunization of mammal is selected by an
immunological measuring method (such as ELISA).
[0293] To be more specific, the monoclonal antibody can be
manufactured as follows. Thus, the protein of the present invention
or a part thereof (including natural substance, recombinant and
chemically synthesized substance) or cell wherein the protein is
expressed (regardless of natural cell, transformant cell, normal
cell or tumor cell) is used as an immunogen and the immunogen is
injected, once or several times, or transplanted to mouse, rat,
hamster, guinea pig, chicken or rabbit or, preferably, to mouse,
rat or hamster (including a transgenic animal which is prepared so
as to produce an antibody derived from other animal such as human
antibody-producing transgenic mouse) subcutaneously,
intramuscularly, intravenously, into hood pad or intraperitoneally
whereupon an immunological sensitization is carried out together,
if necessary, with a Freund's adjuvant. Usually, one to four
immunization(s) is/are carried out every 1 to 14 day(s) from the
initial immunization and antibody-producing cells can be obtained
from the mammal which is immunologically sensitized for about 1 to
5 day(s) from the final immunization.
[0294] Preparation of a hybridoma secreting a monoclonal antibody
can be carried out by a modifying method of Kohler and Milstein
(Nature, Vol. 256, p. 495-497, 1975) or by a method similar
thereto.
[0295] Thus, it can be prepared by a cell fusion of
antibody-producing cells contained in spleen, lymph node, bone
marrow or tonsil or, preferably, in spleen obtained from
immunologically sensitized mammal as above with myeloma cells
having no ability of autoantibody production derived from mammal
such as, preferably, mouse, rat, guinea pig, hamster, rabbit or
human being or, more preferably, mouse, rat or human being.
[0296] With regard to the myeloma cells used for the cell fusion,
it is possible to use, for example, mouse-derived myeloma
P3/X63-AG8.653 (653; ATCC No. CRL 1580), P3/NSI/1-Ag4-1 (NS-I),
P3/X63-Ag8.U1 (P3U1), SP2/0-Ag14 (Sp2/0, Sp2), PAI, F0 or BW5147;
rat-derived myeloma 210RCY3-Ag.2.3.; and human-derived myeloma
U-266AR1, GM1500-6TG-.alpha.1-2, UC729-6, CEM-AGR, D1R11 or
CEM-T15.
[0297] Screening of hybridoma clone producing the monoclonal
antibody is carried out by incubating the hybridoma in, for
example, a microtiter plate and by measuring the reactivity of the
incubated supernatant liquid of the well where the growth is noted
to immunized antigen used in the above immunological sensitization
of mouse by means of an enzyme immunoassay such as RIA or
ELISA.
[0298] Manufacture of a monoclonal antibody from a hybridoma can be
carried out either in vitro or in vivo in the peritoneal effusion
of mouse, rat, guinea pig, hamster or rabbit, preferably in mouse
or rat or, more preferably, in mouse followed by isolating from the
resulting incubated supernatant liquid or peritoneal effusion of
the mammal.
[0299] When an incubation in vitro is carried out, it is possible
to carry out in such a manner that the hybridoma is proliferated,
maintained and stored depending upon the various conditions such as
characteristic of the cell species to be incubated, object of the
test study, method of incubation, etc. and the known nutrient
medium to be used for the production of a monoclonal antibody in
the supernatant fluid of the culture liquid or every nutrient
medium induced and prepared from a known basal medium is used.
[0300] With regard to a basal medium, a low-calcium medium such as
Ham F12 medium, MCDB153 medium or low-calcium MEM medium; a
high-calcium medium such as MCDB104 medium, MEM medium, D-MEM
medium, RPMI 1640 medium, ASF104 medium or RD medium; etc. may be
exemplified. Depending upon the object, the basal medium may
contain serum, hormone, cytokine and/or various inorganic or
organic substances.
[0301] Isolation and purification of the monoclonal antibody can be
carried out, for example, by subjecting the above-mentioned
incubated supernatant liquid or peritoneal effusion to saturated
ammonium sulfate euglobulin precipitating method, caproic acid
method, caprylic acid method, ion-exchange chromatography (DEAE,
DE52, etc.), affinity column chromatography using
anti-immunoglobulin column, protein A column, etc. and the
like.
[0302] It is also possible that the gene coding for the monoclonal
antibody is cloned from the hybridoma, transgenic cow, goat, sheep
or pig where the antibody coding gene is integrated in an intrinsic
gene is prepared by means of a transgenic animal preparing
technique and, from the milk of the transgenic animal, the
monoclonal antibody derived from the antibody gene is obtained in a
large amount (Nikkei Science, issue of April 1997, p. 78-84).
[0303] The "recombinant chimera monoclonal antibody" of the present
invention is a monoclonal antibody which is prepared by a genetic
engineering means and, to be more specific, it means a chimera
monoclonal antibody such as mouse/human chimera monoclonal
antibody, characterized in that for example, its variable region is
that which is derived from mouse immunoglobulin while its constant
region is that which is derived from human immunoglobulin.
[0304] The constant region derived from human immunoglobulin has
its own amino acid sequence depending upon the isotypes of IgG,
IgM, IgA, IgD and IgE and the constant region of the recombinant
chimera monoclonal antibody in the present invention may be a
constant region of human immunoglobulin belonging to any isotype.
Preferably, it is a constant region of human IgG.
[0305] The chimera monoclonal antibody of the present invention
may, for example, be manufactured as follows. It goes without
saying however that the manufacture is not limited to such a method
only.
[0306] For example, a mouse/human chimera monoclonal antibody can
be prepared by referring to Jikken Igaku (Special Issue), Vol. 16,
No. 10, 1988 and Japanese Patent Publication No. 73280/1991.
[0307] Thus, C.sub.H gene (C gene coding for H chain constant
region) obtained from DNA coding for human immunoglobulin is
arranged in an expressible manner to the downstream of active
V.sub.H gene (rearranged VDJ gene coding for H chain variable
region) obtained from DNA coding for a mouse monoclonal antibody
isolated from a hybridoma which produces the mouse monoclonal
antibody or C.sub.L gene (C gene coding for L chain constant
region) obtained from DNA coding for human immunoglobulin is
arranged in an expressible manner to downstream of active V.sub.L
gene (rearranged VJ gene coding for L chain variable region)
obtained from DNA coding for a mouse monoclonal antibody isolated
from the hybridoma whereby it is inserted into one or separate
expression vector(s), host cell is transformed by the expression
vector and the transformed cell is incubated to prepare an aimed
one.
[0308] To be more specific, DNA is extracted from a mouse
monoclonal antibody-producing hybridoma by a common method and the
DNA is digested by an appropriate restriction enzyme (such as
EcoRI, Hind III, etc.), subjected to an electrophoresis (using a
0.7% agarose gel for example) and subjected to a southern blotting.
The migrated gel is stained by ethidium bromide for example and
photographed, position of the marker is marked and the gel is
washed with water twice and dipped in a 0.25M HCl solution for 15
minutes. Then, it is dipped in a 0.4N NaOH solution for 10 minutes
and, during that period, it is gently shaken. It is transferred to
a filter by a common method and, after 4 hours, the filter is
recovered and washed with 2.times.SSC twice. After the filter is
well dried, it is subjected to a baking (75.degree. C. for 3
hours). After completion of the baking, the filter is placed in a
0.1.times.SSC/0.1% SDS solution and treated at 65.degree. C. for 30
minutes. Then it is dipped in a 3.times.SSC/0.1% SDS solution. The
resulting filter is placed in a vinyl bag together with a
prehybridization solution and treated at 65.degree. C. for 3-4
hours.
[0309] Then a probe DNA labeled with .sup.32P and a hybridization
solution are placed therein and made to react at 65.degree. C. for
around 12 hours. After completion of the hybridization, the filter
is washed under appropriate salt concentration, reaction
temperature and time (e.g., 2.times.SSC-0.1% SDS solution at room
temperature for 10 minutes). The filter is placed in a vinyl bag
and a small amount of 2.times.SSC is added, tightly sealed and
subjected to an autoradiography.
[0310] Rearranged VDJ gene and VJ gene coding for H chain and L
chain of the mouse monoclonal antibody, respectively, are
identified by the above-mentioned southern blotting. The region
containing the identified DNA fragments is fractionated by a
sucrose density gradient centrifugation, integrated into a phage
vector (such as Charon 4A, Charon 28, .lamda.EMBL3, .lamda.EMBL4,
etc.) and Escherichia coli (such as LE392, NM539, etc.) is
transformed by the phage vector to prepare a genome library. The
genome library is subjected to a plaque hybridization using an
appropriate probe (H chain J gene, L chain (.kappa.) J gene, etc.)
according to, for example, a Benton-Davis method (Science, Vol.
196, p. 180-182, 1977) to prepare a positive clone containing each
rearranged VDJ gene and VJ gene. A restriction enzyme map of the
resulting clone is prepared and a base sequence is determined
whereupon it is confirmed that a gene containing the aimed
rearranged V.sub.H (VDI) gene or V.sub.L (VI) gene is obtained.
[0311] In the meanwhile, human C.sub.H gene and human C.sub.L gene
each for the preparation of chimera is isolated separately. For
example, in the manufacture of a chimeric antibody with human IgG1,
C.gamma..sub.1 gene which is a C.sub.H gene and C.kappa. gene which
is a C.sub.L gene are isolated. Utilizing the high homology in base
sequence of mouse immunoglobulin gene with human immunoglobulin
gene, those genes can be obtained by isolating from human genome
library using mouse C.gamma..sub.1 gene and mouse C.kappa. gene
corresponding to human C.gamma..sub.1 gene and human C.kappa. gene
as probes.
[0312] To be more specific for example, DNA fragment containing
human C.kappa. gene and holding an enhancer region is isolated from
human lambda Charon 4A HaeIII-AluI genome library (Cell, Vol. 15,
p. 1157-1174, 1978) using Hind III-BamHI fragment of 3 kb from
clone Ig 146 (Proc. Natl. Acad. Sci. USA, Vol. 75, p. 4709-4713,
1978) and EcoRI fragment of 6.8 kb from clone MEP 10 (Proc. Natl.
Acad. Sci. USA, Vol. 78, p. 474-478, 1981) as probes. In addition,
for example, human fetal hepatic cell DNA is cleaved by Hind III
and fractionated by an agarose gel electrophoresis, a band of 5.9
kb is inserted into .lamda.788 and the above-mentioned probe is
used whereupon human C.gamma. gene is isolated.
[0313] Using the mouse V.sub.H gene and the mouse V.sub.L gene and
also the human C.sub.H gene and the human C.sub.L gene isolated as
such, the human C.sub.H gene to the downstream of the mouse V.sub.H
gene or the human C.sub.L gene to the downstream of the mouse
V.sub.L gene is integrated to an expression vector such as pSV2gpt
or pSV2neo using an appropriate restriction enzyme and DNA ligase
according to a conventional method taking the promoter region and
the enhancer region, etc. into consideration. At that time, chimera
genes of mouse V.sub.H gene/human C.sub.H gene and mouse V.sub.L
gene/human C.sub.L gene may be arranged in one expression vector at
the same time or may be arranged in each separate expression
vector.
[0314] The expression vector into which chimera gene is inserted
prepared as such is introduced into a bone marrow cell which does
not produce antibody by itself such as P3.times.63.Ag8.653 cell or
SP210 cell by means of a protoplast fusion method, a DEAE-dextran
method, a calcium phosphate method or an electroporation method.
The transformed cell is selected by incubation in a medium
containing a pharmaceutical agent corresponding to the
pharmaceutical-resistant gene introduced into the expression vector
whereupon the aimed chimera monoclonal antibody-producing cell is
obtained.
[0315] A desired chimera monoclonal antibody is prepared from the
supernatant fluid of the incubated antibody-producing cell selected
as such.
[0316] The "human type antibody (CDR-grafted antibody) of the
present invention is a monoclonal antibody which is prepared by a
genetic engineering means and, to be more specific, it means a
human type monoclonal antibody which is characterized in that a
part of or all of the complementarity-determining region of its
hypervariable region is a complementarity-determining region of the
hypervariable region derived from the mouse monoclonal antibody,
that a frame region of its variable region is a frame region of the
variable region derived from human immunoglobulin and that its
constant region is a constant region derived from human
immunoglobulin.
[0317] Here, the complementarity-determining region of the
hypervariable region means three regions
(complementarity-determining residues: CDR1, CDR2 and CDR3) which
are present in the hypervariable region of the variable region in
the antibody and are the sites directly bonding to the antigen
complementarily while a frame region of the variable region means
the relatively conserved four regions (frameworks: FR1, FR2, FR3
and FR4) intervening before and after the three
complementarity-determining regions.
[0318] In other words, all regions which are other than a part of
or all of the complementarity-determining region of hypervariable
region of mouse monoclonal antibody for example mean a monoclonal
antibody which is substituted for the corresponding region of human
immunoglobulin.
[0319] A constant region derived from human immunoglobulin has each
specific amino acid sequence by an isotype of IgG, IgM, IgA, IgD
and IgE and the constant region of a human-type monoclonal antibody
in the present invention may be a constant region of human
immunoglobulin belonging to any of the isotypes. Preferably, it is
a constant region of human IgG. There is no limitation for the
frame region of the variable region derived from human
immunoglobulin as well.
[0320] The human-type monoclonal antibody of the present invention
can be manufactured, for example, as follows although it goes
without saying that the manufacture is not limited to such a
manufacturing method only.
[0321] For example, a recombinant human-type monoclonal antibody
derived from mouse monoclonal antibody can be prepared by a genetic
engineering means by referring to JP-W-4-506458 and Japanese Patent
Laid-Open No. 296890/1987.
[0322] Thus, at least one mouse H chain CDR gene and at least one
mouse L chain CDR gene corresponding to the mouse H chain CDR gene
are isolated from a hybridoma which produces a mouse monoclonal
antibody while, from human immunoglobulin gene, a human H chain
gene coding for whole regions except the human H chain CDR
corresponding to the above mouse H chain CDR and a human L chain
gene coding for all regions except the human L chain CDR
corresponding to the above mouse L chain CDR are isolated.
[0323] The mouse H chain CDR gene and the human H chain gene
isolated as such are introduced into an appropriate expression
vector in an expressible manner while, in a similar way, the mouse
L chain CDR gene and the human L chain gene are introduced into
another appropriate expression vector in an expressible manner.
Alternatively, it is also possible that the mouse H chain CDR
gene/human H chain gene and mouse L chain CDR gene/human L chain
gene are introduced into the same expression vector in an
expressible manner. When a host cell is transformed by the
expression vector prepared as such, a transformed cell which is
able to produce a human-type monoclonal antibody is obtained and,
when the transformed cell is incubated, an aimed human-type
monoclonal antibody is obtained from the incubated supernatant
liquid.
[0324] The "human antibody" of the present invention is an
immunoglobulin derived from the gene in which all regions including
variable region of H chain and constant region of H chain and
variable region of L chain and constant region of L chain
constituting immunoglobulin code for human immunoglobulin.
[0325] The human antibody can be manufactured in the same manner as
in the above-mentioned method for the manufacture of polyclonal
antibody or monoclonal antibody by a conventional method such as
that a transgenic animal prepared by incorporation of at least
human immunoglobulin gene into locus of mammal except human being
such as mouse is subjected to an immunological sensitization with
antigen.
[0326] For example, a transgenic mouse which produces human
antibody can be prepared by a method mentioned in Nature Genetics,
Vol. 15, p. 146-156, 1997; Nature Genetics, Vol. 7, p. 13-21, 1994;
JP-W-4-504365; International Patent Laid-Open No. WO 94/25585;
Nikkei Science, issue of June, p. 40-50, 1995; Nature, Vol. 368, p.
856-859, 1994; and JP-W-6-500233.
[0327] "A part of the antibody" in the present invention means a
part of the region of the above-mentioned antibody or, preferably,
the monoclonal antibody of the present invention and, to be more
specific, it is F(ab')2, Fab', Fab, Fv (variable fragment of
antibody), sFv, dsFv (disulphide stabilised Fv) or dAb (single
domain antibody) (Exp. Opin. Ther. Patents, Vol. 6, No. 5, p.
441-456, 1996).
[0328] Here, "F(ab').sub.2" and "Fab'" are the antibody fragments
which are manufactured by the treatment of immunoglobulin
(monoclonal antibody) with a protease such as pepsin or papain and
is produced by digestion before and after the disulfide bond
existing between the two H chains in a hinge region. For example,
when IgG is treated with papain, it is cleaved at the upstream of
the disulfide bond existing between the two H chains in the hinge
region to manufacture two homologous antibody fragments where L
chain consisting of V.sub.L (L chain variable region) and C.sub.L
(L chain constant region) and H chain fragment consisting of
V.sub.H (H chain variable region) and CH.gamma.1 (.gamma.1 region
in H chain constant region) are bonded by a disulfide bond at the C
terminal region. Each of those two homologous antibody fragments is
called Fab'.
[0329] When IgG is treated with pepsin, it is cleaved at the
downstream of a disulfide bond existing between two H chains in a
hinge region to manufacture an antibody fragment where the above
two Fab' are bonded in a hinge region and the size is a bit larger
than the above. This antibody fragment is called F(ab').sub.2.
[0330] The "monoclonal antibody-producing cell" of the present
invention means any cell which produces the above-mentioned
monoclonal antibody of the present invention. To be more specific,
it is a cell mentioned in any of the following (1) to (3).
[0331] (1) The monoclonal antibody-producing B cell derived from
non-human mammal which produces the protein of the present
invention as mentioned above, the protein of the present invention
obtained by immunization of non-human mammal by a part thereof or
by cells, etc. which express the protein or monoclonal antibody
having a reactivity with a part thereof.
[0332] (2) The above-mentioned hybridoma (fused cell) obtained by
subjecting the antibody-producing B cell obtained as such to a cell
fusion with a myeloma cell derived from mammal.
[0333] (3) The monoclonal antibody-producing transformed cell
(genetically recombined cell) obtained by transformation of cell
except the monoclonal antibody-producing B cell or monoclonal
antibody-producing hybridoma with a gene (anyone of gene coding for
heavy chain and gene coding for light chain or both of them) coding
for the monoclonal antibody isolated from the monoclonal
antibody-producing B cell or monoclonal antibody-producing
hybridoma.
[0334] Here, the monoclonal antibody-producing transformed cell
(genetically recombined cell) mentioned in the above (3) means the
genetically recombined cell which produces a genetic recombinant of
the monoclonal antibody produced by the above B cell (1) or the
above hybridoma (2). This recombined monoclonal antibody-producing
cell can be manufactured by the same method as used for the
manufacture of the above-mentioned chimera monoclonal antibody and
human-type antibody.
[0335] The "pharmaceutical composition" of the present invention is
a pharmaceutical composition consisting of, for example, any of the
following (a) to (c) with a pharmaceutically acceptable
carrier.
[0336] (a) the above-defined antibody (preferably, monoclonal
antibody; that is not limited to an antibody derived from nature or
a recombined antibody) or a part of the antibody.
[0337] (b) DNA fragment useful as an antisense pharmaceutical agent
such as the following DNA:
[0338] "DNA containing a partial base sequence in the base sequence
mentioned in SEQ ID NO:1 or NO:3 or, preferably, the partial base
sequence having 14 or more bases or DNA where a part of the DNA is
chemically modified; or DNA containing a base sequence
complementary to the partial base sequence or DNA where a part of
the DNA is chemically modified"
[0339] (c) RNA fragment which is useful as an antisense
pharmaceutical agent such as the following RNA:
[0340] "in an RNA containing a partial base sequence of the base
sequence of RNA having a base sequence complementary to the base
sequence mentioned in SEQ ID NO:26 or NO:27 or RNA where a part of
the RNA is chemically modified, the RNA which is characterized in
that the RNA or the chemically modified RNA is hybridized to an RNA
coding for the protein having an amino acid sequence mentioned in
SEQ ID NO:2".
[0341] Here, "pharmaceutically acceptable carrier" is, for example,
excipient, diluent, filler, disintegrating agent, stabilizer,
preservative, buffer, emulsifier, aromatizer, coloring agent,
sweetener, thickener, corrigent, solubilizing aid and other
additives. One or more of such carrier(s) is/are used whereby a
pharmaceutical composition in a form of tablets, pills, diluted
powder, granules, injections, liquids, capsules, troches, elixirs,
suspensions, emulsions, syrups, etc. can be prepared.
[0342] Such a pharmaceutical composition can be administered either
orally or parenterally. Other forms for a parenteral administration
include liquid agent for external use, suppositories for enteric
administration and pessaries containing one or more active
substance(s) and being formulated according to a conventional
method.
[0343] The dose may vary depending upon age, sex, body weight and
symptom of the patient, therapeutic effect, administering method,
treating time, type of the active ingredient (the above-mentioned
protein or antibody) contained in the pharmaceutical composition,
etc. but, usually, it is within a range of from 10 .mu.g to 1,000
mg (or from 10 .mu.g to 500 mg) for one administration to an adult.
However, the dose varies according to various conditions and,
therefore, less amount than the above may be sometimes sufficient
or more than the above range may be sometimes necessary.
[0344] Especially in the case of an injection preparation, it is
prepared, for example, by dissolving or suspending the ingredient
in a non-toxic pharmaceutically acceptable carrier such as a
physiological saline or commercially available distilled water for
injection so as to make the concentration of from 0.1 .mu.g
antibody/ml carrier to 10 mg antibody/ml carrier.
[0345] The injection preparation prepared as such may be
administered to a human patient to be treated from one to several
times a day in a dose of from 1 .mu.g to 100 mg or, preferably,
from 50 .mu.g to 50 mg per kg body weight for each administration.
Examples of the dosage form are medically appropriate dosage forms
such as intravenous injection, subcutaneous injection,
intracutaneous injection, intramuscular injection and
intraperitoneal injection. Intravenous injection is preferred.
[0346] In some cases, an injection preparation may be prepared as a
suspension or an emulsion using a non-aqueous diluent (for example,
propylene glycol, polyethylene glycol, vegetable oil such as olive
oil, alcohol such as ethanol, etc.).
[0347] Aseptization of such an injection preparation can be carried
out by means of a filtration sterilization passing through a
bacteria-retaining filter, compounding of bactericide or
irradiation. Injection preparation can be manufactured in a form of
to-be-prepared-before-use. Thus, an aseptic solid composition is
prepared by means of freeze-drying or the like and may be used by
dissolving in aseptic distilled water for injection or other
solvent before use.
[0348] The pharmaceutical composition of the present invention is
able to inhibit the biological activity of the amino acid
transporter molecule of the present invention or expression of the
molecule and to inhibit the incorporation of the amino acid which
is an essential nutrient for the existence or the proliferation of
tumor cell into cells and can be used for the therapy of
cancer.
[0349] The "transgenic mouse" of the present invention is a
transgenic mouse where DNA (cDNA or genomic DNA) coding for the
protein derived from human being included in the protein of the
present invention is integrated onto the intrinsic locus of the
mouse and the protein of the present invention is expressed in the
body.
[0350] To be more specific, it is a transgenic mouse mentioned in
the above <52> or <53> and is shown in the following
(1) or (2).
[0351] (1) in a transgenic mouse having an extrinsic gene, a
transgenic mouse which is characterized in that, in the mouse, DNA
coding for the protein having an amino acid sequence mentioned in
SEQ ID NO:2 is incorporated onto its intrinsic gene whereby cells
expressing the protein are present in the body.
[0352] (2) the transgenic mouse according to the above (1), wherein
the DNA is a DNA containing a base sequence consisting of the base
sequence of from 66th to 1586th bases of the base sequence
mentioned in SEQ ID NO:1 and any one of the nonsense base sequences
represented by TAG, TGA and TAA adjacent to the 1586th base.
[0353] The transgenic mouse can be prepared by a usual method which
is commonly used in the manufacture of transgenic animals (e.g.,
refer to Newest Manual for Animal Cell Tests, published by LIC,
Chapter 7, p. 361-408, 1990).
[0354] To be more specific, embryonic stem cell (ES cell) obtained
from blastocyst of normal mouse is transformed by an expression
vector into which marker gene (such as neomycin resistant gene) and
gene coding for the protein having an amino acid sequence mentioned
in SEQ ID NO:2 of the present invention are inserted in an
expressible manner. The ES cell where the gene coding for the
protein is integrated onto the intrinsic gene is selected by a
conventional method depending upon the fact whether the marker gene
is expressed. Then, the ES cell selected as such is microinjected
into a fertilized ovum (blastocyst) obtained from another normal
mouse (Proc. Natl. Acad. Sci. USA, Vol. 77, No. 12, pp. 7380-7384,
1980; U.S. Pat. No. 4,873,191). The blastocyst is used as a
preliminary parent and is transplanted to uterus of another normal
mouse. As such, a founder mouse (child mouse) is born from the
preliminary parent mouse. The founder mouse is crossed with a
normal mouse to give a heterogeneic transgenic mouse. The
heterogeneic transgenic mice are crossed to give a homogeneic
transgenic mouse according to Mendel's laws.
[0355] It is also possible to prepare the so-called "knockout
mouse" based upon a base sequence of DNA (particularly, genomic
DNA) coding for protein derived from mouse involved in the present
invention, that is, DNA (particularly, genomic DNA) coding for a
mouse homologue of human-derived amino acid transporter having an
amino acid sequence mentioned in SEQ ID NO:2.
[0356] The knockout mouse is a mouse where the intrinsic gene
coding for the mouse homologue protein is knocked out (inactivated)
and can be prepared, for example, by a positive negative selection
method applying a homologous recombination (U.S. Pat. Nos.
5,464,764, 5,487,992 and 5,627,059; Proc. Natl. Acad. Sci. USA,
Vol. 86, p. 8932-8935, 1989; Nature, Vol. 342, p. 435-438, 1989;
etc.). Such a knockout mouse is an embodiment of the present
invention as well.
[0357] "Labeled DNA" of the present invention is a DNA labeled with
enzyme, fluorescent substance, chemiluminescent substance, biotin,
avidin or radioisotope (such as .sup.3H, .sup.14C, .sup.125I,
.sup.131I, etc.) used for the labeling of "labeled monoclonal
antibody" which will be mentioned later.
[0358] For example, a radiolabeled DNA which is labeled with a
radioisotope can be used as a reagent in various test methods, such
as southern blotting, for identification of gene coding for the
protein of the present invention (Jikken Igaku, Supplementary
Issue, "Handbook of Genetic Engineering", published by Yodosha, p.
133-140, 1992).
[0359] In addition, a labeled DNA which is labeled with a
radioactive substance or with a non-radioactive substance such as
biotin can be used as a reagent in an in situ hybridization for the
analysis of the position of genomic DNA coding for the protein of
the present invention on chromosomes (e.g., FISH (fluorescence in
situ hybridization), Jikken Igaku, Supplementary Issue, "Handbook
of Genetic Engineering", published by Yodosha, 1992, p.
271.sup.-277).
[0360] "Radiolabeled RNA" of the present invention is an RNA where
the RNA of the present invention is labeled with a radioisotope
such as .sup.3H, .sup.14C, .sup.125I, .sup.131I, etc.
[0361] The radiolabeled RNA is useful as a reagent for the analysis
of expressed state of mRNA coding for the protein of the present
invention in cells, tissues or organs such as a northern blotting
(Jikken Igaku, Supplementary Issue, "Handbook of Genetic
Engineering", published by Yodosha, p. 133-140, 1992).
[0362] The "labeled substance which can achieve a detectable signal
by itself or by the reaction with another substance" for labeling
"labeled monoclonal antibody" of the present invention means a
substance which is used for a step where it is bonded to the
above-defined monoclonal antibody by a physicochemical bond, etc.
so that the presence of the monoclonal antibody can be
detected.
[0363] To be more specific, it is enzyme, fluorescent substance,
chemiluminescent substance, biotin, avidin, radioisotope, or the
like.
[0364] To be still more specific, enzyme such as peroxidase (e.g.,
horseradish peroxidase), alkaline phosphatase, 13-D-galactosidase,
glucose oxidase, glucose-6-phosphate dehydrogenase, alcohol
dehydrogenase, malic acid dehydrogenase, penicillinase, catalase,
apoglucose oxidase, urease, luciferase and acetylcholine esterase;
fluorescent substance such as fluorescein isothiocyanate,
phycobiliprotein, rare earth metal chelate, dansyl chloride and
tetramethyl rhodamine isothiocyanate; radioisotope such as 3H,
.sup.14C, .sup.123I and .sup.131I; biotin; avidin; and
chemiluminescent substance may be exemplified.
[0365] Here, each of a radioisotope and a fluorescent substance is
solely able to give a detectable signal. On the contrary, each of
enzyme, chemiluminescent substance, biotin and avidin is solely
unable to give a detectable signal and, therefore, a detectable
signal is resulted upon the reaction with one or more other
substance(s). For example, in the case of enzyme, at least a
substrate is necessary and, depending upon a method for the
measurement of the enzymatic activity (e.g., colorimetric method,
fluorescent method, bioluminescent method, chemiluminescent method,
etc.), various substrates are used. For example, in the case of
peroxidase, hydrogen peroxide is used as a substrate. In the case
of biotin, it is common to conduct a reaction using at least avidin
or an enzyme-modified avidin (such as
streptoavidin-.beta.-galactosidase) as a substrate although that is
not a limitation. If necessary, various coloring substances
depending upon the substrate may be used. For example, when
streptoavidin-.beta.-galactosidase is used as a substrate for
biotin, it is possible to use
4-methyl-umbelliferyl-.beta.-D-galactosidase as a coloring
substance.
[0366] The "labeled monoclonal antibody" of the present invention
and the above-mentioned "labeled DNA" mean a monoclonal antibody
and DNA, respectively, which are labeled with various labeling
substances as mentioned above.
[0367] The labeled monoclonal antibody can be used for the
detection or the quantitative determination of the above-mentioned
protein of the present invention. To be more specific, it can be
used for the detection of the expression or for the measurement of
the expressed amount of the protein of the present invention in
various living body samples such as cells (regardless of normal
cells, abnormal cells such as tumor cell derived from a living body
suffering from disease, natural cells and genetically recombined
cells), tissues (regardless of the source whether they are from
healthy organism or from organism suffering from disease) or organs
(regardless of the source whether they are from healthy organism or
from organism suffering from disease). Such a measurement can be
carried out according to a conventional method using a commonly
used immunohistological technique (Jikken Igaku, Supplementary
Issue, "Handbook of Cell Engineering", Yodosha, p. 207-213,
1992).
[0368] Further, the labeled monoclonal antibody of the present
invention can be used not only for the above-mentioned
immunohistological test but also for a western blotting method
where a soluble membrane protein is prepared from the cell, tissue,
organ or a part thereof as a sample to be tested by a conventional
method and the soluble membrane protein is made to react with the
labeled monoclonal antibody whereby the presence or absence of the
protein of the present invention in the soluble membrane protein
can be confirmed (Jikken Igaku, Supplementary Issue, "Handbook of
Cell Engineering", Yodosha, p. 201-206, 1992).
[0369] In the immunohistological measurement mentioned as above,
any labeled monoclonal antibody which is labeled with any of the
above-mentioned labeling substances may be used but, when high
detection sensitivity or quantitative sensitivity and convenience
in the operation are taken into consideration, it is preferred to
use a monoclonal antibody which is labeled with an enzyme such as
peroxidase or with biotin.
[0370] The present invention also relates to a method for the
detection or for the quantitative determination of the protein of
the present invention by an immunohistological technique using the
above-mentioned labeled monoclonal antibody. To be more specific,
it is a method as mentioned above containing, for example, the
following steps (1) and (2).
[0371] (1) a step where the sample is contacted to the labeled
monoclonal antibody of the present invention; and
[0372] (2) a step where the amount of the labeled monoclonal
antibody bonded to the sample is measured by the detection of
fluorescence, chemiluminescence or radioactivity depending upon the
type of the labeling substance bonded to the labeled monoclonal
antibody.
[0373] Here, "cell" covers a primary culture cell obtained from
human organism, cell line made into subculturable and genetically
recombined cell (transformed cell) where a genetic operation is
carried out and, preferably, it is a primary culture cell. The cell
further covers normal cell and abnormal cell obtained from organism
of a patient suffering from disease. Examples of the abnormal cell
are various tumor cells. The term "tissue" means any tissue derived
from organism of a healthy animal or of a patient suffering from
disease and examples of the tissue derived from organism of the
patient are tumor tissues. The term "organ or a part thereof" means
any organ derived from organism of a healthy animal or of a patient
suffering from disease or a part thereof. Examples of the organ
derived from the patient are organs having tumor.
[0374] To be more specific, the method of the present invention
may, for example, include the following steps although this is not
a limitation.
[0375] (step 1) a step where normal cell, normal tissue or normal
organ which is derived, for example, from a healthy person which is
excised upon surgical operation and discarded or a part thereof or
tumor cell, tumor tissue or tumor-having organ derived from a
patient suffering from cancer or a part thereof (the organ or a
part thereof may, if necessary, be sliced to give a slice) is fixed
with para-formaldehyde or the like to prepare a fixed sample;
[0376] (step 2) a step where the labeled monoclonal antibody of the
present invention which is labeled with biotin or enzyme such as
peroxidase is added to the fixed sample to carry out an
antigen-antibody reaction;
[0377] (step 3) a step where the fixed sample is washed if
necessary and then substrate depending upon the type of the enzyme
used or avidin or enzyme-modified avidin such as
streptoavidin-.beta.-galactosidase is added whereupon the labeled
substance on the labeled antibody is made to react with the
substrate, avidin or enzyme-modified avidin (with regard to the
substrate, it is possible to add hydrogen peroxide together with
diaminobenzidine, 4-chloro-1-naphthol or aminoethylcarbazole in
case a labeled antibody which is labeled with enzyme such as
peroxidase is used in step 2; avidin or enzyme-modified avidin is
used when a labeled antibody which is labeled with biotin is used
in step 2);
[0378] (step 4) a step where, in case an enzyme-modified avidin is
used in step 3, a substrate depending upon the type of the enzyme
used for the modification (such as
4-methyl-umbelliferyl-(3-D-galactoside) is added whereupon the
substrate is made to react with the enzyme bonded to avidin;
[0379] (step 5) a step where the fixed sample is washed if
necessary so that an enzymatic reaction and a coloring reaction are
stopped; and
[0380] (step 6) a step where the fixed sample is observed under a
microscope to measure the color intensity, fluorescence intensity
or luminescence intensity.
[0381] Since the amino acid transporter protein of the present
invention shows a specific expression in a broad range of tumor
cells as compared with the expression in normal cells, there is a
possibility to judge whether the cell or tissue to be tested is
normal or abnormal such as tumor cell when the expression of the
protein is detected in various cells or tissues of organism using
the above-mentioned immunohistological method.
[0382] Another feature of the present invention is to identify a
substance which has an ability of inhibiting the biological
activity of the protein of the present invention. To be specific,
it is a method which was mentioned already for example.
[0383] "A method for identifying a substance having an action of
suppressing the ability for mediating the incorporation of any one
amino acid selected from a group consisting of leucine (Leu),
isoleucine (Ile), phenylalanine (Phe), methionine (Met), tyrosine
(Tyr), histidine (His), tryptophan (Trp) and valine (Val) into
cells where the ability is a biological function of the protein
having an amino acid sequence mentioned in SEQ ID NO:2 or NO:4,
characterized in that, the method comprises the steps of the
following (1) and (2).
[0384] (1) a step in which any of the cells mentioned in the
following (a) to (d) is incubated in the coexistence of the
substance and a radiolabeled amino acid where any one amino acid
selected from a group consisting of leucine (Leu), isoleucine
(Ile), phenylalanine (Phe), methionine (Met), tyrosine (Tyr),
histidine (His), tryptophan (Trp) and valine (Val) is labeled with
a radioisotope or in the presence of the radiolabeled amino acid
only;
[0385] (a) a naturally-occurring cell in which a protein having an
amino acid sequence mentioned in SEQ ID NO:2 or NO:4 and a protein
having an amino acid sequence mentioned in SEQ ID NO:6 are
co-expressed;
[0386] (b) a recombinant cell in which a protein having an amino
acid sequence mentioned in SEQ ID NO:2 and a protein having an
amino acid sequence mentioned in SEQ ID NO:6 or NO:8 are
co-expressed by a co-transformation using a DNA containing a base
sequence of a translation region in the base sequence mentioned in
SEQ ID NO:1 or NO:3;
[0387] (c) a non-human-derived recombinant cell in which a protein
having an amino acid sequence mentioned in SEQ ID NO:2 and a
protein having an amino acid sequence mentioned in SEQ ID NO:6 are
co-expressed by a co-introduction of an RNA containing a base
sequence of 1st to 1521st bases in the base sequence mentioned in
SEQ ID NO:26 and a base sequence comprising any one nonsense base
sequence represented by UAG, UGA or UAA adjacent to the 1521st base
and an RNA containing a base sequence of 1st to 1587th bases in the
base sequence mentioned in SEQ ID NO:27 and a base sequence
comprising any one nonsense base sequence represented by UAG, UGA
or UAA adjacent to the 1587th base; or
[0388] (d) a tumor cell derived from human being; and
[0389] (2) a step in which the radioactivity of the cell incubated
in the coexistence of the substance and the radiolabeled amino acid
and the radioactivity of the cell incubated in the presence of the
radiolabeled amino acid only are measured and the difference
between them is compared.
[0390] Thus, the method of the present invention is a method which
is characterized in that a property of a cell in which the amino
acid transporter protein of the present invention (having an amino
acid sequence mentioned in SEQ ID NO:2) and the human-derived cell
membrane surface molecule 4F2hc (having an amino acid sequence
mentioned in SEQ ID NO:6) are co-expressed has an ability of
incorporating at least any amino acid from leucine (Leu),
isoleucine (Ile), phenylalanine (Phe), methionine (Met), tyrosine
(Tyr), histidine (His), tryptophan (Trp) and valine (Val).
[0391] Thus, the inhibiting activity of the test substance can be
measured by a comparison of the amount of the labeled amino acid
incorporated by the cell in an incubation of the cell in the
presence of any of the above-mentioned amino acids labeled with a
radioisotope (.sup.3H, .sup.14C, .sup.125I or .sup.131I, etc.) and
the test substance with the amount of the labeled amino acid
incorporated by the cell in an incubation of the cell in the
presence of the labeled amino acid only containing no the test
substance.
[0392] With regard to the cell, any cell may be utilized so far as
it is a cell which co-expresses the two protein molecules. For
example, any of the natural cell mentioned in the above (a), the
transformed cell (genetically recombined cell) which is transformed
by two DNA's coding for each of the both protein molecules as
mentioned in (b), the cell into which RNA coding for each of the
both protein molecules as mentioned in (c) is introduced and the
tumor cell derived from human being as mentioned in (d) may be
used.
[0393] With regard to the host cell used for the preparation of the
transformed cell, various cells which are mentioned in the passage
where a method for the expression of the protein of the present
invention using the DNA of the present invention is mentioned in
detail may be used.
[0394] For example, various cells such as natural cell or
artificially established recombinant cell which are commonly used
in the technical field of the present invention (e.g., bacteria
(such as those belonging to genus Escherichia and to genus
Bacillus), yeast (genus Saccharomyces, Pichia, etc.), animal cells
or insect cells) may be exemplified.
[0395] Preferred ones are Escherichia coli and animal cells and, to
be more specific, E. coli (DH5.alpha., TB1, HB101, etc.), cells
derived from mouse (COP, L, C127, Sp2/0, NS-1, NIH3T3, etc.), cells
derived from rat (PC12, PC12h, etc.), cells derived from hamster
(BHK, CHO, etc.), cells derived from monkey (COS1, COS3, COS7, CV1,
Velo, etc.) and cells derived from human being (HeLa, cells derived
from diploid fibroblast, HEK293 cell, myeloma cell, Namalwa, etc.)
may be exemplified.
[0396] With regard to the cell into which the RNA is infused,
oocytes of Xenopus laevis may be exemplified (Special Issue of
Jikken Igaku, "Experimental Methods for Biosignals", Vol. 11, No.
3, p. 30-38, 1993).
[0397] With regard to the tumor cell derived from human being, any
tumor cell may be used although it is preferred to use a tumor cell
where the protein having an amino acid sequence mentioned in SEQ ID
NO:2 and the protein having an amino acid sequence mentioned in SEQ
ID NO:6 are confirmed to be co-expressed.
[0398] Here, "substance" means a natural substance existing in
nature and any substance which is artificially prepared. The
substance may be roughly classified into "peptide substance" and
"non-peptide substance".
[0399] With regard to the "peptide substance", the above fully
mentioned antibody of the present invention (preferably monoclonal
antibody and, particularly preferably, recombined human-type
monoclonal antibody or human monoclonal antibody), oligopeptide and
chemically modified substance of any of them. With regard to the
oligopeptide, a peptide comprising 5 to 30 amino acids or,
preferably, 5 to 20 amino acids may be exemplified. The chemical
modification may be designed depending upon various objects such as
an increase in half life in blood when administered to organism, an
increase in resistance to decomposition or absorption in a
digestive organ when administered orally, etc.
[0400] With regard to the "non-peptide substance", there may be
exemplified "DNA containing a partial base sequence or chemically
modified DNA prepared by a chemical modification thereof" useful as
an antisense pharmaceutical agent fully mentioned in the definition
of the invention in the above-mentioned <4>, "RNA containing
a partial base sequence or chemically modified RNA prepared by a
chemical modification thereof" useful as an antisense
pharmaceutical agent fully mentioned in the definition of the
invention in the above-mentioned <6> and chemically
synthesized any "compound". Here, with regard to the "compound",
there may be exemplified a compound having a molecular weight of
about 100 to about 1,000, preferably from about 100 to about 800
or, more preferably, from about 100 to about 600 except DNA, RNA
and the above-mentioned peptide substance.
[0401] With regard to the substance which can identified by the
method for the identification of the present invention, a substance
having an ability of inhibiting the proliferation of any tumor cell
generated in any tissue of human body is desired. Examples of the
tissue are brain, neck, liver, spleen, kidney, large intestine,
small intestine, duodenum, prostate gland, lung, stomach, heart,
skin, bone marrow, uterus, ovary, testicle, mouth, tongue, bone and
chest.
[0402] Still another feature of the present invention is a method
for the identification of a substance having an ability of
inhibiting the transcription of the gene coding for the protein of
the present invention to mRNA or the expression of protein of the
present invention. To be more specific, it is the following method
which was mentioned already.
[0403] "a method for the identification of a substance having an
ability of inhibiting the transcription of the gene coding for the
protein having an amino acid sequence mentioned in SEQ ID NO:2 or
NO:4 to mRNA or the expression of the protein having an amino acid
sequence mentioned in SEQ ID NO:2 or 4 which is characterized in
containing the following steps:
[0404] (1) a step where a cell which is a cell co-transformed by
the DNA of the following (a), (b) and (c) and the cell is
transformed in such a manner that, depending upon the expression of
the protein having an amino acid sequence of SEQ ID NO:2 coded by
the DNA of the (a), a reporter protein coded by the DNA of the (c)
is expressed at the same time is incubated in the presence or
absence of the substance:
[0405] (a) DNA containing a base sequence of the translation region
of the base sequence mentioned in SEQ ID NO:1 or NO:3;
[0406] (b) DNA containing a base sequence of the translation region
of the base sequence mentioned in SEQ ID NO:5 or NO:7;
[0407] (c) DNA coding for a reporter protein; and
[0408] (2) a step where expressed amounts of the reporter protein
in each of the cells incubated in the presence of the substance and
those incubated in the absence of the substance are measured and
compared".
[0409] The method is the so-called "reporter gene assay" and, to be
more specific, it is a method where DNA coding for the amino acid
transporter molecule of the present invention, DNA coding for the
expression adjustment controlling region of the DNA and DNA coding
for reporter protein generating fluorescence (luciferase derived
from firefly, umishiitake [a kind of marine plants], etc.; GFP
(green fluorescence protein) derived from jellyfish; etc,) are
inserted in such a manner that the reporter protein molecular can
be expressed depending upon the expression of the transporter
molecule, cell which is commonly used for the manufacture of
genetically recombined protein is transformed by the above-prepared
expression vector, the resulting one is contacted to the test
compound and the amount of transporter molecule expressed depending
upon the action of the compound is indirectly measured by measuring
the amount of fluorescence generated by the reporter protein which
is expressed together with the expression of the molecule whereupon
it is analyzed whether the compound affects the expression of the
transporter molecule (U.S. Pat. Nos. 5,436,128 and 5,401,629 may be
referred to for example).
[0410] Incidentally, although the identification of the compound
using the present assay is possible by means of a manual operation,
that can be carried out quickly and easily using the so-called high
through-put screening where the assay is carried out automatically
using a machine (robot) (Soshiki Baiyo Kogaku, Vol. 23, No. 13, p.
521-524; U.S. Pat. No. 5,670,113).
[0411] The terms "cell" and "substance" used in the above-mentioned
method are the same as those defined already.
EXAMPLES
[0412] The present invention will now be illustrated in more detail
by way of Examples although it goes without saying that the present
invention is not limited to the embodiments mentioned in those
Examples only.
[0413] Incidentally, in the following Examples, each operation was
carried out according to the method mentioned in Molecular Cloning
(by Sambrook, J., Fritsh, E. F. and Maniatis, T.; published by Cold
Spring Harbor Press in 1989) unless otherwise mentioned or, when a
commercially available reagent or kit was used, it was used
according to the directions for use thereof.
Example 1
Isolation of cDNA of Human Cell Membrane Surface Molecule 4F2hc and
Preparation of cRNA
[0414] (1) Preparation of cDNA Fragment Coding for Rat 4F2hc by
Means of an RT-PCR.
[0415] According to the conventional method, pure poly(A).sup.+RNA
was prepared from liver of rat. 5'-Primer (SEQ ID NO:9) and
3'-primer (SEQ ID NO:10) were also synthesized based upon a cDNA
sequence (Biochem. J., Vol. 312, p. 863, 1995) coding for rat
4F2hc.
[0416] An RT-PCR (reverse transcription-polymerase chain reaction;
Jikken Igaku, Supplementary Issue, "PCR and Its Applications", Vol.
8, No. 9, 1990; and "Gene Amplification PCR--Its Basis and New
Developments", published by Kyoritsu Shuppan, 1992) was carried out
using the two primers and Taq polymerase (manufactured by Takara)
where the poly(A).sup.+RNA was used as a template. The reaction was
carried out according to the protocol attached the polymerase using
a DNA Thermal Cycler (manufactured by Perkin Elmer Cetus).
[0417] The amplified cDNA was subjected to an agarose
electrophoresis and purified using a DNA extraction kit
(manufactured by Qiagen) to prepare a fragment of rat 4F2hc gene
(from 34th to 479th bases of the base sequence mentioned in SEQ ID
NO:7).
[0418] Incidentally, the cDNA sequence coding for the rat 4F2hc and
the corresponding amino acid sequence were mentioned in SEQ ID NO:7
and NO:8, respectively.
[0419] (2) Manufacture of cDNA Coding for Human 4F2hc and
Preparation of cRNA.
[0420] A kit for the synthesis of cDNA (trade name; Superscript
Choice System; manufacture by Gibco) is used and, according to the
experimental operation method attached to the kit, human cDNA was
prepared from poly(A).sup.-RNA (manufactured by Clontech) derived
from human placenta and the cDNA was integrated into a cleaved site
of a phage vector .lamda.ZipLox (manufactured by Gibco) with a
restriction enzyme EcoRI using a DNA ligase (manufactured by Gibco)
to prepare a human cDNA library.
[0421] The gene fragment of rat 4F2hc prepared in the above (1) was
labeled with .sup.32P-dCTP to manufacture a probe and that was used
as a probe for a plaque hybridization.
[0422] The above-prepared human cDNA library was screened as
follows using the probe.
[0423] The cDNA library was sown on an agar plate and a replica was
prepared using a commercially available filter membrane. A
hybridization was carried out at 37.degree. C. for one night in a
hybridization solution using the replica and the radioactive probe.
With regard to the solution for the hybridization, a buffer of pH
6.5 containing 5.times.SSC, 3.times.Denhard's solution, 0.2% of
SDS, 10% of dextran sulfate, 50% of formamide, 0.01% of Antifoam B
(an antifoaming agent manufactured by Sigma), 0.2 mg/ml of salmon
sperm-modified DNA, 2.5 mM of sodium pyrophosphate and 25 mM of MES
was used. The filter membrane was washed with 0.1.times.SSC/0.1%
SDS at 37.degree. C.
[0424] The positive clone selected by the hybridization was
isolated by a single plaque, subjected to an in vivo excision,
recombined to a plasmid pZL1 (manufactured by Gibco) and recovered
as a plasmid DNA. The plasmid DNA was further subcloned to a
pBlueScriptII SK (-) (manufactured by Stratagene).
[0425] In order to determine the base sequence of cDNA of human
4F2hc contained in the resulting clone, seven kinds of primers were
synthesized (SEQ ID NO:11 to SEQ ID NO:17). The base sequence of
cDNA was determined by a dye terminator cycle sequencing method (by
Applied Biosystems) using the seven kinds of synthetic primers and
T7 primers and SP6 primers which were the commercially available
universal primers (manufactured by Stratagene). As a result, it was
confirmed that the cloned cDNA was that of the gene of human
4F2hc.
[0426] Incidentally, the cDNA sequence coding for the human 4F2hc
and the corresponding amino acid sequence were mentioned in SEQ ID
NO:5 and SEQ ID NO:6, respectively.
[0427] From the plasmid containing the cDNA of human 4F2hc prepared
as above, cRNA (an RNA complementary to cDNA; SEQ ID NO:27) was
prepared according to a conventional method using a T7 RNA
polymerase (manufactured by Stratagene) (Special Issue of Jikken
Igaku, "Method of Experiments of Biosignals", Vol. 11, No. 3, p.
33-34, 1993).
Example 2
Isolation of cDNA of Human Amino Acid Transporter LAT1 and
Preparation of cRNA
[0428] Human cDNA was prepared from poly(A).sup.+RNA (purchased
from Clontech) derived from human teratocarcinoma cell line PA-1
using a kit for the synthesis of cDNA (trade name: Superscript
Choice System; manufactured by Gibco) according to an experimental
operation method attached to the kit and then the cDNA was
integrated into a site of a phage vector .lamda.ZipLox
(manufactured by Gibco) cleaved by a restriction enzyme EcoRI using
a DNA ligase (manufactured by Gibco) to prepare a human cDNA
library.
[0429] cDNA (DDBJ/EMBL/Gen Bank registration No: AB015432; a
segment corresponding to 1135th to 1529th bases of SEQ ID NO:3)
coding for a rat amino acid transporter LAT1 was excised by a
restriction enzyme BamHI. Incidentally, an amino acid sequence of
the rat amino acid transporter LAT1 was mentioned in SEQ ID
NO:4.
[0430] This DNA segment was labeled with .sup.32P-dCTP to prepare a
probe and it was used as a probe for a plaque hybridization.
[0431] The above-prepared human cDNA library was screened as
follows using the probe.
[0432] The cDNA library was sown on an agar plate and a replica was
prepared using a commercially available filter membrane. A
hybridization was carried out for one night at 37.degree. C. in a
hybridization solution using the replica and the radioactive probe.
With regard to the solution for the hybridization, a buffer of pH
6.5 containing 5.times.SSC, 3.times.Denhard's solution, 0.2% of
SDS, 10% of dextran sulfate, 50% of formamide, 0.01% of Antifoam B
(an antifoaming agent manufactured by Sigma), 0.2 mg/ml of salmon
sperm-modified DNA, 2.5 mM of sodium pyrophosphate and 25 mM of MES
was used. The filter membrane was washed with 0.1.times.SSC/0.1%
SDS at 37.degree. C.
[0433] The positive clone selected by the hybridization was
isolated by a single plaque, subjected to an in vivo excision,
recombined to a plasmid pZL1 (manufactured by Stratagene) and
recovered as a plasmid DNA. The plasmid DNA was excised by a
restriction enzyme PstI to give three cDNA fragments having the
sizes of 1.8 kb, 2.5 kb and 4.3 kb. Each of the fragments of 1.8 kb
and 2.5 kb was subcloned to a pBlueScriptII SK (-) (manufactured by
Stratagene). The cDNA fragment of 4.3 kb was subjected to a
self-ligation.
[0434] In order to determine the base sequence of cDNA of human
amino acid transporter LAT1 contained in each of the plasmids
having the three cDNA fragments, eight kinds of primers were
synthesized (SEQ ID NO:18 to SEQ ID NO:25). The base sequence of
cDNA was determined by a diterminator cycle sequencing method (by
Applied Biosystems) using the eight kinds of synthetic primers and
M13 forward primer and M13R reverse primer which were the
commercially available universal primers (manufactured by
Stratagene).
[0435] The resulting sequence of full-length cDNA coding for the
human amino acid transporter LAT1 and the corresponding amino acid
sequence were mentioned in SEQ ID NO:1 and SEQ ID NO:2,
respectively.
[0436] Further, from the resulting plasmid containing the cDNA of
human 4F2hc coding for the human amino acid transporter LAT1, cRNA
(SEQ ID NO:26; an RNA complementary to cDNA) was prepared using a
T3 RNA polymerase (manufactured by Stratagene).
[0437] When a homology in the amino acid sequences for a rat amino
acid transporter LAT1 and for a human amino acid transporter LAT1
was analyzed, the human LAT1 had an amino acid homology of about
91% to the rat LAT1. The result is shown in FIG. 1.
[0438] When an amino acid sequence of the human amino acid
transporter LAT1 was analyzed by a hydrophobic plot analysis
(Kyte-Doolittle hydropathy analysis), it was estimated that the
human LAT1 was a cell membrane surface molecule having 12
transmembrane domains (membrane-spanning domains). The result is
shown in FIG. 2.
Example 3
Analysis of Expression of mRNA of Human Amino Acid Transporter LAT1
in Various Tissues of Human Being
[0439] The cDNA coding for the human amino acid transporter LAT1
(cDNA fragment corresponding to 649th to 1128th bases of SEQ ID
NO:1) was excised by a restriction enzyme SmaI and labeled with
.sup.32P-dCTP to prepare a hybridization probe. A northern blotting
to various tissues of human being was carried out using the probe
as follows.
[0440] A Nylon membrane where human poly(A).sup.+RNA was blotted
(trade name: MTN Blot; manufactured by Clontech) was subjected to
hybridization and washing using the .sup.32P-dCTP-labeled human
LAT1 probe according to the protocol attached to the kit. The
result is shown in FIG. 3.
[0441] As a result, expression of mRNA of human LAT1 having a size
of about 4.8 kb was noted in placenta, brain, testis, bone marrow
and fetal liver. A weak expression of mRNA was noted in peripheral
leukocytes as well.
Example 4
Analysis of Biological Activity of Human Amino Acid Transporter
LAT1
[0442] (1) Analysis of Ability of Mediating the Transport of Amino
Acid into the Cell.
[0443] From the studies up to now concerning the proliferation of
tumor cells, it has been predicted that the known heavy chain
(4F2hc) of a cell membrane surface antigen which is a heterodimer
of heavy chain classified under a glycoprotein of type II and light
chain and named 4F2 (CD98) may play an important role in activation
of an amino acid transporter which has not been identified yet (J.
Immunol., Vol. 126, p. 1409-1414, 1981; J. Immunol., Vol. 129, p.
623-628, 1982; Proc. Natl. Acad. Sci. USA, Vol. 84, p. 6526-6530,
1987; Cancer Res., Vol. 46, p. 1478-1484, 1986; J. Biol. Chem.,
Vol. 267, p. 15285-18288, 1992; Proc. Natl. Acad. Sci. USA, Vol.
89, p. 5606-5610, 1992; Biochem. J, Vol. 324, p. 535-541, 1997; and
J. Expt. Biol., Vol. 196, p. 123-137, 1994).
[0444] In view of the above, the fact whether the amino acid
transporter LAT1 of the present invention carries the transport of
the amino acid into the cells was analyzed by such a method that
the cells in which only human LAT1 was expressed and other cells in
which both human LAT1 and human 4F2hc were expressed together were
used and the incorporated amounts of leucine (neutral amino acid)
into each cells were measured.
[0445] Incidentally, such a test method is based upon a method
where oocytes of Xenopus laevis which are commonly used in the
incorporation test of various substances into cells are used
(Special Issue of Jikken Igaku, "Method of Experiments of
Biosignals", Vol. 11, No. 3, p. 30-38, 1993).
[0446] A sole cRNA (25 ng) coding for the human LAT1 prepared in
the above Example, a sole cRNA (25 ng) coding for the human 4F2hc
prepared in the above Example, or the cRNA (17.5 ng) coding for the
human LAT1 together with the cRNA (7.5 ng) coding for the human
4F2hc was injected into oocytes of Xenopus laevis and incubated for
2 or 5 days whereupon oocytes expressing the human LAT1 only,
oocytes expressing the human 4F2hc only and oocytes co-expressing
the human LAT1 and the human 4F2hc were prepared, respectively.
[0447] A radiolabeled leucine which was radiolabeled with .sup.14C
was used as a substrate and incorporation of the labeled leucine
for each oocytes was carried out as follows according to a method
by Kanai, et al. (Kanai and Hediger, Nature, Vol. 360, p. 467-471,
1992).
[0448] Thus, to be specific, each oocytes were incubated for 30
minutes in a choline chloride uptake solution (consisting of 100 mM
of choline chloride, 2 mM of potassium chloride, 1.8 mM of calcium
chloride, 1 mM of magnesium chloride and 5 mM of HEPES; pH 7.4)
containing .sup.14C-labeled leucine (50 .mu.M) whereby the amount
of the .sup.14C-labeled leucine incorporated into the oocytes was
determined by measuring the radioactivity of the oocytes by means
of a scintillation counter. Incidentally, as a control, the same
experiment was carried out using the oocytes where any of the above
RNA was not injected but only water was infused. The result is
shown in FIG. 4.
[0449] The result was that, in the oocytes where only human LAT1
was expressed, incorporation of leucine was rarely noted like in
the case of oocytes into which only water was injected as a control
while, in the case of oocytes where both human LAT1 and human 4F2hc
were expressed, a large incorporation of leucine was confirmed. The
result was believed to be due to the fact that human 4F2hc is
necessary in order that the human amino acid transporter LAT1
achieves the function of mediating the incorporation of amino
acid.
[0450] (2) Analysis of Salt-Dependency of the Transport of Amino
Acid into the Cells.
[0451] The fact whether there is a salt-dependency of the human
amino acid transporter LAT1 in the ability of mediating the
transport of amino acid into the cells was analyzed as follows. To
be specific, the analysis was carried out by observing the changes
in the incorporated amount of leucine into the cells by changing
the type of the uptake solution which incubated the oocytes in the
above-mentioned Example 4(1).
[0452] The oocytes of Xenopus laevis co-expressing the human LAT1
and the human 4F2hc prepared in Example 4(1) were incubated for 30
minutes in the above-mentioned choline chloride uptake solution
containing .sup.14C-labeled leucine (50 .mu.M), a sodium uptake
solution containing .sup.14C-labeled leucine (50 .mu.M) (100 mM of
choline chloride in the above choline uptake solution were changed
to 100 mM of sodium chloride) or a gluconic acid uptake solution
containing .sup.14C-labeled leucine (50 .mu.M) (100 mM of sodium
chloride in the above sodium uptake solution were changed to 100 mM
of sodium gluconate).
[0453] Amount of the .sup.14C-labeled leucine incorporated into the
oocytes was determined by measuring the radioactivity of the
oocytes by means of a scintillation counter. The result is shown in
FIG. 5.
[0454] The result shows that, even when choline outside the oocytes
was changed to sodium or even when chlorine ion outside the oocytes
was changed to gluconic acid ion, that did not affect the
incorporation of leucine into the oocytes at all. Therefore, it was
noted that the human amino acid transporter LAT1 was a transporter
molecule which acted independently upon sodium ion and chlorine
ion.
[0455] (3) Affinity of the Human Amino Acid Transporter LAT1 to the
Substrate.
[0456] In order to analyze the affinity of the human amino acid
transporter LAT1 to the substrate, a Michaelis-Menten kinetic test
(Dictionary of Biochemistry, second edition, p. 1307-1308, 4th
printing, 1992) was carried out.
[0457] This kinetic test was carried out by checking the changes in
the incorporated rate of leucine depending upon the difference in
the concentration of leucine as a substrate.
[0458] The incorporation experiment of leucine was carried out
according to the method mentioned in the above Example 4(1) using
oocytes of Xenopus laevis where the human LAT1 and the human 4F2hc
were co-expressed. The result is shown in FIG. 6.
[0459] As a result, the Michaelis constant (Km) was about 21
.mu.M.
[0460] (4) Analysis of Substrate Specificity of the Human Amino
Acid Transporter LAT1 (No. 1)
[0461] The substrate specificity of the human amino acid
transporter LAT1 (type of the substrate incorporated into the cells
mediated by LAT1) was analyzed by a competitive antagonism
test.
[0462] To be specific, oocytes of Xenopus laevis which co-expressed
the human LAT1 and the human 4F2hc were analyzed by measuring the
changes in the incorporated amount of .sup.14C-labeled leucine as a
substrate into the oocytes when incubated in the presence of a test
substance (various amino acid, pharmaceuticals, physiologically
active substances or other low-molecular synthetic compounds). When
the incorporated amount of the .sup.14C-labeled leucine decreased
as compared with the control where no test substance was added, it
was noted that the test substance was incorporated into the oocytes
mediated by the human amino acid transporter LAT1.
[0463] Oocytes of Xenopus laevis co-expressing the human LAT1 and
the human 4F2hc prepared in Example 4(1) were incubated for 30
minutes in a choline chloride uptake solution containing
.sup.14C-labeled leucine (20 .mu.M) and any of the following test
substances (2 mM).
[0464] Incidentally, as a control, incubation was similarly carried
out in a choline uptake solution containing .sup.14C-labeled
leucine but containing none of the test substance.
[0465] [Test Substances]
[0466] Glycine, alanine, serine, threonine, cysteine, leucine,
isoleucine, phenylalanine, methionine, tyrosine, histidine,
tryptophan, valine, asparagine, glutamine, aspartic acid, glutamic
acid, lysine, arginine, proline and BCH
(2-amino-2-norbornane-carboxylic acid).
[0467] Amount of the .sup.14C-labeled leucine incorporated into the
oocytes was determined by measuring the radioactivity of the
oocytes by means of a scintillation counter. The result is shown in
FIG. 7.
[0468] Further, incorporation of the following test substances into
oocytes was also tested according to the above-mentioned method
using .sup.14C-labeled phenylalanine instead of .sup.14C-labeled
leucine. As a control, incubation in a choline uptake solution
containing .sup.14C-labeled phenylalanine but containing none of
the test substance was carried out similarly.
[0469] [Test Substances]
[0470] L-DOPA (a therapeutic agent for Parkinson's disease) and
triiodothyronine (a thyroid hormone).
[0471] The result is shown in FIG. 8 and FIG. 9.
[0472] As a result, in various amino acids, pharmaceuticals and
physiologically active substances, a cis-inhibiting action for
incorporation of .sup.14C-labeled leucine or .sup.14C-labeled
phenylalanine into the cells (oocytes) was observed. Particularly,
leucine, isoleucine, phenylalanine, methionine, tyrosine,
histidine, tryptophan and valine strongly inhibited the
incorporation of .sup.14C-labeled leucine mediated by the human
LAT1 and, therefore, it was strongly suggested that any of the
amino acids was transported into the oocytes mediated by the human
LAT1. 2-Amino-2-norbornane-carboxylic acid (BCH) which was known as
an inhibitor for incorporation of neutral amino acids also
inhibited the incorporation of .sup.14C-labeled leucine. Further,
incorporation of .sup.14C-labeled phenylalanine into oocytes was
strongly inhibited by the pharmaceutical agents such as L-DOPA (a
therapeutic agent for Parkinson's disease) and the physiologically
active substances such as triiodothyronine (thyroid hormone). On
the contrary, when acidic amino acids (such as glutamic acid and
aspartic acid) or basic amino acids (such as lysine and arginine)
were used as the test substances, incorporation of .sup.14C-labeled
leucine mediated by the human LAT1 was not affected at all.
[0473] The result strongly suggests that the human amino acid
transporter LAT1 mediates the transport of various amino acids
(particularly neutral or nearly neutral amino acids), various
pharmaceuticals, various physiologically active substances and
other low-molecular synthetic compounds into cells.
[0474] (5) Analysis of the Substrate Specificity of the Human Amino
Acid Transporter LAT1 (No. 2).
[0475] Based upon the result of Example 4(4), an analysis was
carried out whether leucine, isoleucine, phenylalanine, methionine,
tyrosine, histidine, tryptophan and valine were incorporated into
oocytes mediated by the human LAT1.
[0476] The test was carried out in the same manner as in Example
2(1) using each of the following .sup.14C-labeled amino acids
prepared by labeling each of the above-mentioned amino acids with
.sup.14C instead of .sup.14C-labeled leucine as a substrate.
[0477] [.sup.14C-Labeled Amino Acids]
[0478] .sup.14C-Labeled leucine, .sup.14C-labeled isoleucine,
.sup.14C-labeled phenylalanine, .sup.14C-labeled methionine,
.sup.14C-labeled tyrosine, .sup.14C-labeled histidine,
.sup.14C-labeled tryptophan and .sup.14C-labeled valine.
[0479] For the sake of comparison, the same test was carried out
using .sup.14C-labeled glycine, .sup.14C-labeled serine,
.sup.14C-labeled D-leucine and .sup.14C-labeled D-phenylalanine.
The result is shown in FIG. 10.
[0480] As a result, it was confirmed that leucine, isoleucine,
phenylalanine, methionine, tyrosine, histidine, tryptophan and
valine were significantly incorporated into oocytes. In addition,
D-leucine and D-phenylalanine were also shown to be incorporated
into the oocytes.
Example 5
Analysis of Expression of mRNA of the Human Amino Acid Transporter
LAT1 in Various Tumor Cells Derived from Human Being
[0481] Total RNA was collected from various tumor cells derived
from human being by a conventional method using Isogen (trade name;
manufactured by Nippon Gene) and the RNA was subjected to an
agarose electrophoresis by a conventional method and blotted to a
nitrocellulose membrane.
[0482] The cDNA fragment coding for the human amino acid
transporter LAT1 prepared in Example 3 was subjected to a northern
blotting using a hybridization probe prepared by labeling with
.sup.32P-dCTP. The northern blotting was carried out according to a
protocol attached to a commercially available Nylon membrane for
northern blotting (such as MTN Blot [trade name] manufactured by
Clontech) where various poly(A).sup.+RNA was blotted.
[0483] As a result of the northern blotting, expression of mRNA
coding for the human LAT1 in various tumor cells derived from human
being was able to be confirmed.
Example 6
Cloning of a Rat Neutral Amino Acid Transporter
[0484] (1) Isolation of cDNA of Rat 4F2hc and Preparation of
cRNA.
[0485] A cDNA library was prepared from poly(A).sup.+RNA purified
from rat liver using a kit for the synthesis of cDNA (trade name:
Superscript Choice System; manufactured by Gibco) and integrated
into the excised site of the restriction enzyme EcoRI of a phage
vector .lamda.ZipLox (manufactured by Gibco). A segment
corresponding to from 135th to 580th bases of a rat 4F2hc gene
(Broer, et al., Biochem. J., Vol. 312, p. 863, 1995) was amplified
by a PCR and labeled with .sup.32P-dCTP and the resulting probe was
used for the screening of a rat liver cDNA library. Hybridization
was carried out for one night in a solution for hybridization of
37.degree. C. and the filter membrane was washed with
0.1.times.SSC/0.1% SDS at 37.degree. C. With regard to the solution
for the hybridization, a buffer of pH 6.5 containing 5.times.SSC,
3.times.Denhard's solution, 0.2% of SDS, 10% of dextran sulfate,
50% of formamide, 0.01% of Antifoam B (an antifoaming agent
manufactured by Sigma), 0.2 mg/ml of salmon sperm-modified DNA, 2.5
mM of sodium pyrophosphate and 25 mM of MES was used. The cDNA
moiety of the .lamda.ZipLox phage into which cDNA was incorporated
was incorporated into a plasmid pZL1 and then further subcloned to
a plasmid pBluescript II SK- (manufactured by Stratagene).
[0486] With regard to the resulting clone, i.e. a clone containing
cDNA of rat 4F2hc, a base sequence of cDNA was determined by a
dideoxy method using a synthetic primer for the determination of
base sequence and a kit for the determination of base sequence
(trade name: Sequenase ver. 2.0; manufactured by Amersham). As
such, it was confirmed that the cloned cDNA was that of a rat 4F2hc
gene. The base sequence of the resulting 4F2hc was shown in SEQ ID
NO:2 in the Sequence Listing which will be given later.
[0487] From the above-prepared plasmid containing the cDNA of the
rat 4F2hc, cRNA (an RNA complementary to cDNA) was prepared using a
T7 RNA polymerase.
[0488] (2) Cloning of a Rat Neutral Amino Acid Transporter
LAT1.
[0489] This was carried out as follows by means of an expression
cloning method according to a method by Kanai, et al. (Kanai and
Hediger, Nature, Vol. 360, p. 467-471, 1992).
[0490] A rat C6 glioma cell poly(A).sup.+RNA (400 .mu.g) was
fractionated by a gel electrophoresis.
[0491] Each of the fractions obtained by the fractionation was
injected into oocytes together with the cRNA of rat 4F2hc obtained
in the above (1) followed by incubating for two days.
[0492] For the oocytes into which RNA was injected, an experiment
of incorporation of a substrate was carried out using leucine as a
substrate as follows according to a method by Kanai, et al. (Kanai
and Hediger, Nature, Vol. 360, p. 467-471, 1992). Thus, the oocytes
were incubated for 30 minutes in a choline chloride uptake solution
containing 50 .mu.M of .sup.14C-leucine as a substrate (100 mM of
choline chloride, 2 mM of potassium chloride, 1.8 mM of calcium
chloride, 1 mM of magnesium chloride and 5 mM of HEPES; pH 7.4) and
the incorporated rate of the substrate was measured by counting the
radioactivity which was incorporated into the oocytes.
Incidentally, in this system, it was confirmed that a synergistic
enhancement in the incorporation was noted in the oocytes into
which both rat C6 glioma cell poly(A).sup.+RNA (mRNA) and cRNA of
rat 4F2hc were injected as compared with the oocytes into which
each of them was solely infused (FIG. 11).
[0493] Among the RNA fractions prepared by the fractionation, the
oocytes into which RNA was infused selected a fraction showing the
highest incorporation rate of leucine. A cDNA library was prepared
for the poly(A).sup.+RNA (2.8-4.0 kb) of this fraction using a kit
for the synthesis of cDNA and a plasmid cloning (trade name:
Superscript Plasmid System; manufactured by Gibco). Those DNA's
were integrated into the sites recognizing the restriction enzymes
SalI and NotI of the plasmid pSPORT1 (manufactured by Gibco) and
the resulting recombined plasmid DNA was introduced into a
competent cell of Escherichia coli DH10B strain (trade name:
Electro Max DH10B Competent Cell; manufactured by Gibco). The
resulting transformant was incubated on a nitrocellulose membrane
to give about 500 colonies per plate. A plasmid DNA was prepared
from those colonies followed by excising with a restriction enzyme
NotI. The resulting DNA was subjected to an in vitro transcription
to synthesize a capped cRNA.
[0494] The resulting cRNA (about 45 ng) was infused into oocytes
together with the rat 4F2hc cRNA (5 ng) obtained hereinabove (1).
With regard to those oocytes, a screening for positive clone was
carried out by conducting a leucine incorporation experiment
according to the same way as mentioned above. In conducting the
screening, the group where DNA extracted from plural clones was
pooled was checked and, when incorporation of leucine was confirmed
in some groups, they were further subdivided into plural groups and
a screening was further carried out.
[0495] With regard to the resulting clone, i.e. the clone
containing cDNA of the rat neutral amino acid transporter LAT1, the
base sequence thereof was determined by a dideoxy method using a
synthetic primer for the determination of group sequence and a kit
for the determination of base sequence, (trade name: Sequenase ver.
2.0; manufactured by Amersham).
[0496] As a result, a base sequence of the rat neutral amino acid
transporter LAT1 gene was obtained. In addition, the base sequence
of cDNA was analyzed by a conventional method and the translation
region of cDNA and the amino acid sequence of LAT1 encoded there
were determined. The translation region was 64th to 1599th
bases.
[0497] Those sequences were shown in SEQ ID NO:4 (amino acid
sequence) and NO:3 (base sequence) in the Sequence Listing which
will be given later.
[0498] As a result of analysis of the amino acid sequence of LAT1
by means of a Kyte-Doolittle hydropathy analysis (hydrophobic
plot), 12 transmembrane regions (membrane-spanning domains) were
predicted as shown in FIG. 12. Further, in the second hydrophilic
loop, there was a tyrosine phosphorylated site and, in the fourth
and eighth hydrophilic loops, there were two sites supposed to be
proteinkinase-C-dependent phosphorylated sites.
[0499] (3) Expression of LAT1 Gene in Various Tissues of Rat and in
an Cultured Rat Cell Line (Analysis by Northern Blotting).
[0500] A cDNA fragment corresponding to 202nd to 1534th bases of
the rat LAT1 gene was labeled with .sup.32P-dCTP and, using it as a
probe, a northern blotting was carried out as follows for the RNA
extracted from various tissues of rat and from cultured tumor cell
line derived from rat. Thus, 3 .mu.g of poly(A).sup.+RNA were
subjected to an electrophoresis using 1% agarose/formaldehyde gell
and transferred to a nitrocellulose filter. The filter was
subjected to a hybridization for one night in a hybridization
solution containing the LAT1 cDNA fragment labeled with
.sup.32P-dCTP at 42.degree. C. The filter was washed with
0.1.times.SSC containing 0.1% of SDS at 65.degree. C.
[0501] As a result of the northern blotting (FIG. 13), bands were
detected at about 3.8 kb in C6 glioma cell, placenta, brain,
spleen, large intestine and testis and, in placenta, another band
was detected at about 2.6 kb in addition to the above whereupon
expression was noted. Although the expression was very weak in
normal liver, a strong band was detected at about 3.8 kb in rat
hepatoma cell line and rat hepatocarcinoma cell line whereupon an
expression was noted (FIG. 14).
[0502] Further, upon long exposure, a faint band was noted at about
3.8 kb even in other tissues.
[0503] (4) Expression of LAT1 Gene in a Human Tumor Cell Line
(Analysis by a Northern Blotting).
[0504] A cDNA fragment corresponding to 202nd to 1534th bases of
the rat LAT1 gene was labeled with .sup.32P-dCTP and, using this as
a probe, RNA extracted from an cultured tumor cell line derived
from human being was subjected to a northern blotting as follows.
Poly(A).sup.+RNA (3 .mu.g) was subjected to an electrophoresis by
1% agarose/formaldehyde gel and transferred to a nitrocellulose
filter. The filter was subjected to a hybridization for one night
in a hybridization solution containing the rat LAT1 cDNA fragment
labeled with .sup.32P-dCTP at 37.degree. C. The filter was washed
with 0.1.times.SSC containing 0.1% of SDS at 37.degree. C.
[0505] As a result of the northern blotting (FIG. 15), strong bands
were detected at about 4.0 kb in stomach signet ring cell carcinoma
cell line, lung small-cell carcinoma cell line and melanoma cell
line while a weak band was detected at 4.0 kb in neuroblastoma cell
line whereupon an expression was noted.
Example 7
Characterization of the Neutral Amino Acid Transporter LAT1
[0506] (1) Role of 4F2hc in the Transporting Activity of LAT1.
[0507] Activities in the incorporation of leucine in case the rat
LAT1 gene cRNA was solely expressed in oocytes and in case the rat
LAT1 gene cRNA and the 4F2hc gene cRNA were simultaneously
expressed in oocytes were compared.
[0508] Rat LAT1 gene cRNA (25 ng), rat 4F2hc gene cRNA (25 ng) or
rat LAT1 gene cRNA (12.5 g)/rat 4F2hc gene cRNA (12.5 ng) was
expressed by injecting into the oocytes and incubated for 2 days or
5 days.
[0509] An experiment of the incorporation of leucine was carried
out as follows in accordance with a method mentioned in the above
Example 6(2). Thus, the oocytes into which rat LAT1 gene cRNA, rat
4F2hc gene cRNA or rat LAT1 gene cRNA/rat 4F2hc gene cRNA was
injected were incubated for 30 minutes in an uptake solution
containing .sup.14C-leucine (50 .mu.M) and incorporation of
radioactivity into the oocytes was measured.
[0510] The result (FIG. 16) was that, in the oocytes into which
only LAT1 was expressed, incorporation of leucine was in the same
level as in the oocytes into which water was injected as a control
but, in the oocytes into which both LAT1 and 4F2hc were expressed,
a big incorporation of leucine was noted whereupon 4F2hc was
believed to be necessary for LAT1 for achieving its function.
[0511] (2) Salt-Dependency of the Transport Activity of LAT1.
[0512] Influence of a salt added to the medium was tested in a test
of incorporation of leucine into the oocytes when both rat LAT1
gene cRNA and 4F2hc gene cRNA were used.
[0513] An experiment of the incorporation of leucine was carried
out according to a method mentioned in the above Example 6(2) using
the oocytes into which both rat LAT1 gene cRNA and rat 4F2hc gene
cRNA were injected. With regard to an uptake solution however, a
sodium uptake solution (100 mM choline chloride was changed to 100
mM sodium chloride) was used instead of a choline chloride uptake
solution when an influence of sodium ion was checked. When an
influence of chlorine ion was checked, a gluconic acid uptake
solution (100 mM sodium chloride was changed to 100 mM sodium
gluconate) was used instead of a sodium uptake solution.
[0514] The result (FIG. 17) was that, even when choline outside the
oocytes was changed to sodium and even when chlorine ion outside
the oocytes was changed to gluconic acid ion, there was no
affection in the incorporation of leucine at all. From the result,
it was shown that LAT1 was a transporter which acted independently
of sodium ion and chlorine ion.
[0515] (3) Michaelis-Menten Kinetic Test of LAT1.
[0516] A Michaelis-Menten kinetic test was carried out for a
neutral amino acid transporter. By checking the changes in the
incorporating rate of leucine with the difference in the
concentrations of the substrate leucine, a Michaelis-Menten kinetic
test of the neutral amino acid transporter was carried out.
[0517] An experiment of the incorporation of leucine was carried
out according to a method mentioned in the above Example 6(2) using
the oocytes into which both rat LAT1 gene cRNA and rat 4F2hc gene
cRNA were injected. As a result (FIG. 18), the Km value was about
24 .mu.M.
[0518] (4) Substrate-Specificity of LAT1 (an Inhibiting Experiment
by Addition of Amino Acid and a Similar Substance Thereto).
[0519] In an experiment of the incorporation of leucine by the
oocytes into which both rat LAT1 gene cRNA and rat 4F2hc gene cRNA
were injected, an influence of addition of various amino acids and
similar substances thereto to the system was tested.
[0520] An experiment of the incorporation of leucine was carried
out according to a method mentioned in the above Example 6(2) using
the oocytes into which both rat LAT1 gene cRNA and rat 4F2hc gene
cRNA were injected. In this case however, a choline uptake solution
was used and the incorporation of .sup.14C-leucine (20 .mu.M) was
measured in the presence or absence of 2 mM of various compound
(unlabeled).
[0521] The result (FIG. 19) was that a cis-inhibiting effect was
observed in various kinds of neutral amino acids. Especially,
leucine, isoleucine, phenylalanine, methionine, tyrosine,
histidine, tryptophan and valine strongly inhibited the
incorporation of .sup.14C-leucine mediated by LAT1. In addition, in
the substances other than the standard amino acids, the
incorporation of .sup.14C-leucine mediated by LAT1 was also
inhibited by pharmaceutical agents and physiologically active
substances such as L-DOPA (a therapeutic agent for Parkinson's
disease), melphalan (antitumor agent), triiodothyronine (thyroid
hormone), thyroxin (thyroid hormone). Further,
2-amino-2-norbornane-carboxylic acid which was known as an
inhibitor for the incorporation of neutral amino acids inhibited
the incorporation of .sup.14C-leucine as well. Acidic amino acids
and basic amino acids did not affect the incorporation of
.sup.14C-leucine mediated by LAT1.
[0522] (5) Substrate-Selectivity of LAT1 (a Test on the
Incorporation Using Various Kinds of Amino Acids and Similar
Substances Thereto as Substrates).
[0523] Incorporation by LAT1 was tested using various kinds of
amino acids and similar substances thereto as substrate.
[0524] A test on the incorporation using various kinds of amino
acids and similar substances thereto was carried out according to
the method mentioned in the above Example 6(2) using the oocytes
into which both rat LAT1 gene cRNA and rat 5F2hc gene cRNA were
injected. As a substrate however, various radiolabeled compounds
were used in place of .sup.14C-leucine.
[0525] The result was that incorporation into the oocytes was noted
when leucine (a .sup.14C compound), isoleucine (a .sup.14C
compound), phenylalanine (a .sup.14C compound), methionine (a
.sup.14C compound), tyrosine (a .sup.14C compound), histidine (a
.sup.14C compound), tryptophan (a .sup.14C compound) and valine (a
.sup.14C compound) were used as substrates.
Example 8
Control of Cell Proliferation by Suppression of the Neutral Amino
Acid Transporter LAT1
[0526] (1) Inhibition of Suppressing the Cell Proliferation by an
LAT1 Suppression.
[0527] A suppressing effect to the cell proliferation of a LAT1
suppression by an LAT1 suppressive agent was tested.
[0528] A rat liver cell line where LAT1 was highly expressed was
incubated on a William's medium, 20 mM of D-leucine or BCH which
suppressed the incorporation mediated by LAT1 were added to the
medium and, by means of an incubation for 48 hours, cell numbers
were investigated using a Cell Counting Kit-8 (manufactured by
Dojindo Laboratories). The cell numbers were measured as an
absorption at 450 nm (O.D. 450).
[0529] The result (FIG. 20) was that, in a group where D-leucine or
BCH was added, a reduction in the cell numbers was noted as
compared with a control group where neither D-leucine nor BCH was
added whereupon it was believed that cell proliferation was
suppressed by a neutral amino acid incorporation suppression by
LAT1 suppression.
Example 9
Expression of LAT1 Gene and 4F2hc Gene in Various Tumor Cell Lines
of Human Being (an Analysis by a Northern Blotting)
[0530] A cDNA fragment corresponding to 649th to 1128th bases of
the hLAT1 gene was excised by a restriction enzyme SmaI, a probe
was prepared by labeling with .sup.32P-dCTP and a northern blotting
to human tumor cell line was carried out as follows. From various
human tumor cell lines was extracted poly(A).sup.+RNA and then
hybridization and washing using .sup.32P-dCTP labeled LAT1 probe
were carried out.
[0531] The cDNA fragment corresponding to 106th to 645th bases of
the h4F2hc gene was excised by a restriction enzyme PstI, a probe
was prepared by labeling with .sup.32P-dCTP and a northern blotting
to human tumor cell line was carried out in the same manner.
[0532] As a result of the northern blotting, in all tumor cell
lines investigated in FIG. 21 and FIG. 22, expression of LAT1 was
noted near 4.8 kb. With regard to the 4F2hc, expression was noted
in most of the tumor cell lines near 2.2 kb. However, strength of
the expression varied depending upon the cells and, particularly in
the case of leukemia cell lines Daudi, CCRF-SB and P30/OHK, no
signal by a northern blotting was detected (FIG. 22).
Example 10
Significance of T24 Cells Derived from Human Bladder Cancer as an
Evaluating System for LAT1 Inhibitors
[0533] T24 cells derived from human bladder cancer were incubated
and maintained in an Eagle's minimal essential medium containing
10% of fetal bovine serum. A test for the incorporation of amino
acids into T24 cells was carried out by incubating the T24 cells on
a 24-well plate and finished when the state became confluent. The
amino acid incorporation test was started by removing the
incubating solution and adding a Dulbecco's PBS (manufactured by
Gibco) containing .sup.14C-amino acid and finished by removing it,
cooling with ice and washing with a Dulbecco's PBS. After washing,
the above was dissolved in 0.1N NaOH and the radioactivity was
measured by a liquid scintillation counter.
[0534] (1) Na.sup.+-Dependency of T24 Cells for the Incorporation
of Leucine.
[0535] Influence of sodium ion in the medium on the leucine
incorporation experiment by T24 cells was investigated.
[0536] With regard to the solution for the incorporation, a choline
uptake solution (where sodium chloride was substituted with choline
chloride) was used in place of a Dulbecco's PBS when influence of
sodium ion in the medium on the incorporation of leucine was
checked.
[0537] As a result (FIG. 23), there was no affection at all for the
incorporation of leucine even when choline outside the cells was
changed to sodium. Therefore, it was noted that the incorporation
of leucine by T24 cells was carried on a transport system which was
not dependent upon sodium ion.
[0538] (2) Michaelis-Menten Kinetic Test for the Incorporation of
Leucine by T24 Cells.
[0539] A Michaelis-Menten kinetic test was carried out for the
incorporation of leucine by T24 cells. The Michaelis-Menten kinetic
test was conducted by investigating the changes in the incorporated
rate of leucine by the difference in the concentration of the
substrate leucine.
[0540] As a result (FIG. 24), Km value was 100.3 .mu.M and Vmax
value was 23,870 pmol/mg protein/minute.
[0541] (3) Experiment on the Inhibition of Incorporation of Leucine
by T24 Cells by Addition of Amino Acid and Similar Substance
Thereto.
[0542] In an experiment of the incorporation of leucine by T24
cells, influence of addition of various amino acids and similar
substances thereto was investigated.
[0543] In an experiment of the incorporation of leucine, the
incorporation of .sup.14C-leucine (20 .mu.M) in the presence and
absence of 2 mM of various compounds (unlabeled) was measured.
[0544] As a result (FIG. 25), a strong cis-inhibiting effect was
observed by methionine, leucine, isoleucine, valine, phenylalanine,
tyrosine, tryptophan, histidine and cysteine. BCH which was an
amino acid transport system L-specific inhibitor strongly inhibited
the incorporation of leucine. The result of this inhibiting
experiment was identical with the result when LAT1 was expressed in
the oocytes of Xenopus.
[0545] (4) Inhibiting Mode of the Leucine Incorporation by T24
Cells by BCH, an Incorporation Inhibitor.
[0546] Dependency of the .sup.14C-leucine incorporation by T24
cells on the concentration was measured in the absence of BCH, in
the presence of 50 .mu.M of BCH and in the presence of 100 .mu.M of
BCH and the inhibiting mode was investigated by means of double
reciprocal plots.
[0547] As a result (FIG. 26), it was clarified that the inhibition
by BCH was a competitive inhibition and its Ki value was 156
.mu.M.
Example 11
Effect of BCH, an Amino Acid Incorporation Inhibitor, on the
Proliferation of Human Tumor Cell Line
[0548] T24 cells derived from human bladder cancer were incubated
and maintained in an Eagle's minimal essential medium containing
10% of fetal bovine serum. Human Daudi cells were incubated and
maintained in an RPMI medium containing 20% of fetal bovine serum.
T24 cells or Daudil cells were incubated in a 24-well plate (800
cells/well) for 5 days in a medium with or without 20 mM of BCH and
the cell numbers were counted.
[0549] As a result (FIG. 27), it was clarified that the cell
proliferation was rapid in the case of T24 cells as compared with
in the case of Daudi cells and that, although BCH highly suppressed
the proliferation of T24, it rarely showed a suppressing effect for
the proliferation of Daudi cells.
[0550] T24 cells were strongly expressed together with LAT1 and
4F2hc (FIG. 21) and, as shown in Example 10, LAT1 showed a strong
function activity in T24 cells. On the contrary, in Daudi cells,
although LAT1 was strongly expressed, no expression of 4F2hc
necessary for achieving the function of LAT1 was detected (FIG. 22)
and, therefore, it is believed that, in Daudi cells, LAT1 does not
function. The fact that the proliferation of T24 cells having a
strong function activity of LAT1 was rapid, that BCH showed a high
suppression for cell proliferation, that the proliferation of Daudi
cells where LAT1 was believed not to function was slow and that BCH
showed no effect of suppression of the proliferation supports the
hypothesis that the incorporation of essential amino acids mediated
by LAT1 forms one of the rate-determining steps for the cell
proliferation and that such a inhibition shows the suppression of
cell proliferation.
[0551] In CCRF-SB cells and P30/OHK cells (FIG. 22) where
expression of 4F2hc was not detected like Daudi cells, it was
confirmed that, like Daudi cells, the proliferation was slow and
the effect of BCH was weak and that, like T24 cells, the
proliferation was quick in the cells where both LAT1 and 4F2hc were
strongly expressed and BCH showed a strong suppressing effect.
Example 13
Survival Effect of BCH, an Amino Acid Transporter Suppressor, in
Tumor-Inoculated Mouse
[0552] Mouse sarcoma 180 cells were intraperitoneally transplanted
(1.times.10.sup.6) to male ICR mouse and, from the next day of the
transplantation, BCH which was a inhibitor for the amino acid
transporter, D-Leu having a inhibiting effect on amino acid
transporter and D-Ala having no inhibiting action thereon were
administered at the dose of 300 mg/kg for ten days. After the
transplantation, it was confirmed every day whether the mouse was
dead or alive.
[0553] As a result of the observation for 19 days, all cases were
alive in the untreated control while, in the group inoculated with
sarcoma 180 cells, the group inoculated with sarcoma 180 cells and
the group administered with a vehicle after inoculation of sarcoma
180 cells, the living periods were significantly shortened as
compared with the control (FIG. 28). On the contrary, in the group
where BCH was administered or D-Leu was administered after the
inoculation of sarcoma 180 cells, a significant survival effect by
treatment with such an agent was noted (FIG. 28). No survival
effect was noted in D-Ala (FIG. 28).
INDUSTRIAL APPLICABILITY
[0554] The amino acid transporter molecule of the present invention
has an important biological function of mediating the incorporation
of various amino acids which are essential nutrients for the
manufacture and the proliferation of cells and, in addition, it
shows an expression in a broad range of tumor cells as compared
with the expression in normal cells whereby the molecule is quite
hopeful as a target in the development of, for example, antitumor
agents (anticancer agents).
[0555] Thus, when a pharmaceutical agent having the biological
activity on the molecule or the activity for suppressing the
expression of the molecule (such as antisense DNA pharmaceutical
agent, antisense RNA pharmaceutical agent, antibody pharmaceutical
agent, antibody fragment pharmaceutical agent, peptide antagonist
pharmaceutical agent and non-peptide antagonist pharmaceutical
agent such as low-molecular compounds) is used and suppresses the
incorporation of the nutrients (various amino acids and
physiologically active substances) mediated by the molecule into
the tumor cells, it is now possible to make the tumor cells in a
state of amino acid starvation and to inhibit the existence and the
proliferation of tumor cells.
[0556] Accordingly, the protein of the present invention or a part
thereof, DNA coding for the protein or a part thereof, RNA coding
for the protein or a part thereof, DNA which hybridizes to the DNA,
expression vector containing the DNA, transformed cell which is
transformed by the DNA or by the vector, cell into which the RNA is
introduced, antibody or a part thereof having a reactivity with the
protein or a part thereof, cell which produces the antibody,
labeled DNA where the a part of the DNA is radiolabeled, labeled
RNA where a part of the RNA is radiolabeled, labeled antibody where
the antibody or a part of the antibody is labeled, a kit comprising
the labeled DNA, a kit comprising the labeled RNA and a kit
comprising the labeled antibody are able to be provided as
pharmaceutical agents having such an antitumor effect and/or
reagents in the development of such pharmaceutical agents.
[0557] In addition, when various substances such as DNA, RNA or
transformed cells of the present invention are used, it is now
possible to conduct a drug design, a screening (such as a reporter
gene assay) and an identification of pharmaceutical agents which
control (activate, suppress or inhibit) the biological activity of
the protein of the present invention, pharmaceutical agents which
inhibit the transcription of the protein of the present invention
to mRNA, pharmaceutical agents which inhibit the translation of the
protein of the present invention from the mRNA, pharmaceutical
agents which inhibit the interaction of the protein with other
molecules, etc.
[0558] Further, a part of DNA and RNA of the present invention is
able to be provided as a probe in the identification of DNA or RNA
which hybridizes therewith using a colony hybridization method or a
plaque hybridization method. Furthermore, a part of DNA of the
present invention is able to be provided as a primer for the
amplification of the gene coding for DNA of the present invention
or transporter molecule of the present invention by a PCR.
[0559] Still further, a part of DNA of the present invention, DNA
complementary to the DNA or a part of RNA of the present invention
is able to be provided not only as the above-mentioned reagent but
also as the so-called antisense DNA pharmaceutical agent or
antisense RNA pharmaceutical agent.
[0560] As mentioned above, the protein of the present invention is
able to identify the pharmaceutical agent which controls the
biological activity of the protein of the present invention or the
expression of the protein when the state where the protein molecule
is expressed on the cell surface is utilized. It is also possible
that, based upon the amino acid sequence of the protein, a peptide
antagonist having an ability of inhibiting the biological activity
of the protein is designed. The peptide antagonist which is
designed as such competitively inhibits the bond of the amino acid
transporter which is the protein of the present invention with
various substrates or the bond of the protein of the present
invention with other molecule whereby it is able to be provided as
a pharmaceutical agent which does not make the biological function
of the protein of the present invention achieved.
[0561] The protein of the present invention or a part thereof and
cells such as a transformed cell expressing the protein are able to
be provided as immune sensitizing antigens in the preparation of
antibody (antiserum, monoclonal antibody) to the protein of the
present invention.
[0562] Antiserum (polyclonal antibody) and monoclonal antibody
having a reactivity with the amino acid transporter molecule which
is the protein of the present invention are able to be provided as
an antibody pharmaceutical agent where achievement of the
biological activity of the molecule is inhibited (neutralized) when
bonded to the molecule.
[0563] Further, when the antibody is labeled with various
substances which are able to give a detectable signal, it is able
to be provided as a reagent in the analysis (immunohistological
staining, western blotting, ELISA, etc.) of expressed state of the
protein of the present invention in various biological materials
(such as cells, tissues, organs and body fluid).
[0564] As same as such a labeled antibody, the labeled DNA labeled
with various substances being able to give a signal by which DNA of
the present invention or a part thereof is detectable can be
provided as a reagent in the test (such as a southern blotting and
an FISH) in the identification of the gene coding for the protein
of the present invention.
[0565] Further and similarly, a radiolabeled RNA where the RNA of
the present invention or a part thereof is labeled with a
radioisotope is able to be provided as a reagent in the analysis
(such as a northern blotting) of the expressed state of mRNA coding
for the protein of the present invention in cells, tissue or
organs.
Sequence CWU 1
1
2714539DNAHomo
sapiens5'UTR(1)..(65)CDS(66)..(1589)3'UTR(1590)..(4474) 1cggcgcgcac
actgctcgct gggccgcggc tcccgggtgt cccaggcccg gccggtgcgc 60agagc atg
gcg ggt gcg ggc ccg aag cgg cgc gcg cta gcg gcg ccg gcg 110 Met Ala
Gly Ala Gly Pro Lys Arg Arg Ala Leu Ala Ala Pro Ala 1 5 10 15gcc
gag gag aag gaa gag gcg cgg gag aag atg ctg gcc gcc aag agc 158Ala
Glu Glu Lys Glu Glu Ala Arg Glu Lys Met Leu Ala Ala Lys Ser 20 25
30gcg gac ggc tcg gcg ccg gca ggc gag ggc gag ggc gtg acc ctg cag
206Ala Asp Gly Ser Ala Pro Ala Gly Glu Gly Glu Gly Val Thr Leu Gln
35 40 45cgg aac atc acg ctg ctc aac ggc gtg gcc atc atc gtg ggg acc
att 254Arg Asn Ile Thr Leu Leu Asn Gly Val Ala Ile Ile Val Gly Thr
Ile 50 55 60atc ggc tcg ggc atc ttc gtg acg ccc acg ggc gtg ctc aag
gag gca 302Ile Gly Ser Gly Ile Phe Val Thr Pro Thr Gly Val Leu Lys
Glu Ala 65 70 75ggc tcg ccg ggg ctg gcg ctg gtg gtg tgg gcc gcg tgc
ggc gtc ttc 350Gly Ser Pro Gly Leu Ala Leu Val Val Trp Ala Ala Cys
Gly Val Phe 80 85 90 95tcc atc gtg ggc gcg ctc tgc tac gcg gag ctc
ggc acc acc atc tcc 398Ser Ile Val Gly Ala Leu Cys Tyr Ala Glu Leu
Gly Thr Thr Ile Ser 100 105 110aaa tcg ggc ggc gac tac gcc tac atg
ctg gag gtc tac ggc tcg ctg 446Lys Ser Gly Gly Asp Tyr Ala Tyr Met
Leu Glu Val Tyr Gly Ser Leu 115 120 125ccc gcc ttc ctc aag ctc tgg
atc gag ctg ctc atc atc cgg cct tca 494Pro Ala Phe Leu Lys Leu Trp
Ile Glu Leu Leu Ile Ile Arg Pro Ser 130 135 140tcg cag tac atc gtg
gcc ctg gtc ttc gcc acc tac ctg ctc aag ccg 542Ser Gln Tyr Ile Val
Ala Leu Val Phe Ala Thr Tyr Leu Leu Lys Pro 145 150 155ctc ttc ccc
acc tgc ccg gtg ccc gag gag gca gcc aag ctc gtg gcc 590Leu Phe Pro
Thr Cys Pro Val Pro Glu Glu Ala Ala Lys Leu Val Ala160 165 170
175tgc ctc tgc gtg ctg ctg ctc acg gcc gtg aac tgc tac agc gtg aag
638Cys Leu Cys Val Leu Leu Leu Thr Ala Val Asn Cys Tyr Ser Val Lys
180 185 190gcc gcc acc cgg gtc cag gat gcc ttt gcc gcc gcc aag ctc
ctg gcc 686Ala Ala Thr Arg Val Gln Asp Ala Phe Ala Ala Ala Lys Leu
Leu Ala 195 200 205ctg gcc ctg atc atc ctg ctg ggc ttc gtc cag atc
ggg aag ggt gat 734Leu Ala Leu Ile Ile Leu Leu Gly Phe Val Gln Ile
Gly Lys Gly Asp 210 215 220gtg tcc aat cta gat ccc aac ttc tca ttt
gaa ggc acc aaa ctg gat 782Val Ser Asn Leu Asp Pro Asn Phe Ser Phe
Glu Gly Thr Lys Leu Asp 225 230 235gtg ggg aac att gtg ctg gca tta
tac agc ggc ctc ttt gcc tat gga 830Val Gly Asn Ile Val Leu Ala Leu
Tyr Ser Gly Leu Phe Ala Tyr Gly240 245 250 255gga tgg aat tac ttg
aat ttc gtc aca gag gaa atg atc aac ccc tac 878Gly Trp Asn Tyr Leu
Asn Phe Val Thr Glu Glu Met Ile Asn Pro Tyr 260 265 270aga aac ctg
ccc ctg gcc atc atc atc tcc ctg ccc atc gtg acg ctg 926Arg Asn Leu
Pro Leu Ala Ile Ile Ile Ser Leu Pro Ile Val Thr Leu 275 280 285gtg
tac gtg ctg acc aac ctg gcc tac ttc acc acc ctg tcc acc gag 974Val
Tyr Val Leu Thr Asn Leu Ala Tyr Phe Thr Thr Leu Ser Thr Glu 290 295
300cag atg ctg tcg tcc gag gcc gtg gcc gtg gac ttc ggg aac tat cac
1022Gln Met Leu Ser Ser Glu Ala Val Ala Val Asp Phe Gly Asn Tyr His
305 310 315ctg ggc gtc atg tcc tgg atc atc ccc gtc ttc gtg ggc ctg
tcc tgc 1070Leu Gly Val Met Ser Trp Ile Ile Pro Val Phe Val Gly Leu
Ser Cys320 325 330 335ttc ggc tcc gtc aat ggg tcc ctg ttc aca tcc
tcc agg ctc ttc ttc 1118Phe Gly Ser Val Asn Gly Ser Leu Phe Thr Ser
Ser Arg Leu Phe Phe 340 345 350gtg ggg tcc cgg gaa ggc cac ctg ccc
tcc atc ctc tcc atg atc cac 1166Val Gly Ser Arg Glu Gly His Leu Pro
Ser Ile Leu Ser Met Ile His 355 360 365cca cag ctc ctc acc ccc gtg
ccg tcc ctc gtg ttc acg tgt gtg atg 1214Pro Gln Leu Leu Thr Pro Val
Pro Ser Leu Val Phe Thr Cys Val Met 370 375 380acg ctg ctc tac gcc
ttc tcc aag gac atc ttc tcc gtc atc aac ttc 1262Thr Leu Leu Tyr Ala
Phe Ser Lys Asp Ile Phe Ser Val Ile Asn Phe 385 390 395ttc agc ttc
ttc aac tgg ctc tgc gtg gcc ctg gcc atc atc ggc atg 1310Phe Ser Phe
Phe Asn Trp Leu Cys Val Ala Leu Ala Ile Ile Gly Met400 405 410
415atc tgg ctg cgc cac aga aag cct gag ctt gag cgg ccc atc aag gtg
1358Ile Trp Leu Arg His Arg Lys Pro Glu Leu Glu Arg Pro Ile Lys Val
420 425 430aac ctg gcc ctg cct gtg ttc ttc atc ctg gcc tgc ctc ttc
ctg atc 1406Asn Leu Ala Leu Pro Val Phe Phe Ile Leu Ala Cys Leu Phe
Leu Ile 435 440 445gcc gtc tcc ttc tgg aag aca ccc gtg gag tgt ggc
atc ggc ttc acc 1454Ala Val Ser Phe Trp Lys Thr Pro Val Glu Cys Gly
Ile Gly Phe Thr 450 455 460atc atc ctc agc ggg ctg ccc gtc tac ttc
ttc ggg gtc tgg tgg aaa 1502Ile Ile Leu Ser Gly Leu Pro Val Tyr Phe
Phe Gly Val Trp Trp Lys 465 470 475aac aag ccc aag tgg ctc ctc cag
ggc atc ttc tcc acg acc gtc ctg 1550Asn Lys Pro Lys Trp Leu Leu Gln
Gly Ile Phe Ser Thr Thr Val Leu480 485 490 495tgt cag aag ctc atg
cag gtg gtc ccc cag gag aca tag ccaggaggcc 1599Cys Gln Lys Leu Met
Gln Val Val Pro Gln Glu Thr 500 505gagtggctgc cggaggagca tgcgcagagg
ccagttaaag tagatcacct cctcgaaccc 1659actccggttc cccgcaaccc
acagctcagc tgcccatccc agtccctcgc cgtccctccc 1719aggtcgggca
gtggaggctg ctgtgaaaac tctggtacga atctcatccc tcaactgagg
1779gccagggacc caggtgtgcc tgtgctcctg cccaggagca gcttttggtc
tccttgggcc 1839ctttttccct tccctccttt gtttacttat atatatattt
tttttaaact taaattttgg 1899gtcaacttga caccactaag atgatttttt
aaggagctgg gggaaggcag gagccttcct 1959ttctcctgcc ccaagggccc
agaccctggg caaacagagc tactgagact tggaacctca 2019ttgctacgac
agacttgcac tgaagccgga cagctgccca gacacatggg cttgtgacat
2079tcgtgaaaac caaccctgtg ggcttatgtc tctgccttag ggtttgcaga
gtggaaactc 2139agccgtaggg tggcactggg agggggtggg ggatctgggc
aaggtgggtg attcctccca 2199ggaggtgctt gaggccccga tggactcctg
accataatcc tagccccgag acaccatcct 2259gagccaggga acagccccag
ggttgggggg tgccggcatc tcccctagct caccaggcct 2319ggcctctggg
cagtgtggcc tcttggctat ttctgttcca gttttggagg ctgagttctg
2379gttcatgcag acaaagccct gtccttcagt cttctagaaa cagagacaag
aaaggcagac 2439acaccgcggc caggcaccca tgtgggcgcc caccctgggc
tccacacagc agtgtcccct 2499gccccagagg tcgcagctac cctcagcctc
caatgcattg gcctctgtac cgcccggcag 2559ccccttctgg ccggtgctgg
gttcccactc ccggcctagg cacctccccg ctctccctgt 2619cacgctcatg
tcctgtcctg gtcctgatgc ccgttgtcta ggagacagag ccaagcactg
2679ctcacgtctc tgccgcctgc gtttggaggc ccctgggctc tcacccagtc
cccacccgcc 2739tgcagagagg gaactagggc accccttgtt tctgttgttc
ccgtgaattt ttttcgctat 2799gggaggcagc cgaggcctgg ccaatgcggc
ccactttcct gagctgtcgc tgcctccatg 2859gcagcagcca aggaccccca
gaacaagaag acccccccgc aggatccctc ctgagctcgg 2919ggggctctgc
cttctcaggc cccgggcttc ccttctcccc agccagaggt ggagccaagt
2979ggtccagcgt cactccagtg ctcagctgtg gctggaggag ctggcctgtg
gcacagccct 3039gagtgtccca agccgggagc caacgaagcc ggacacggct
tcactgacca gcggctgctc 3099aagccgcaag ctctcagcaa gtgcccagtg
gagcctgccg cccccacctg ggcaccggga 3159ccccctcacc atccagtggg
cccggagaaa cctgatgaac agtttgggga ctcaggacca 3219gatgtccgtc
tctcttgctt gaggaatgaa gacctttatt cacccctgcc ccgttgcttc
3279ccgctgcaca tggacagact tcacagcgtc tgctcatagg acctgcatcc
ttcctgggga 3339cgaattccac tcgtccaagg gacagcccac ggtctggagg
ccgaggacca ccagcaggca 3399ggtggactga ctgtgttggg caagacctct
tccctctggg cctgttctct tggctgcaaa 3459taaggacagc agctggtgcc
ccacctgcct ggtgcattgc tgtgtgaatc caggaggcag 3519tggacatcgt
aggcagccac ggccccgggt ccaggagaag tgctccctgg aggcacgcac
3579cactgcttcc cactggggcc ggcggggccc acgcacgacg tcagcctctt
accttcccgc 3639ctcggctagg ggtcctcggg atgccgttct gttccaacct
cctgctctgg gaggtggaca 3699tgcctcaagg atacagggag ccggcggcct
ctcgacggca cgcacttgcc tgttggctgc 3759tgcggctgtg ggcgagcatg
ggggctgcca gcgtctgttg tggaaagtag ctgctagtga 3819aatggctggg
gccgctgggg tccgtcttca cactgcgcag gtctcttctg ggcgtctgag
3879ctggggtggg agctcctccg cagaaggttg gtggggggtc cagtctgtga
tccttggtgc 3939tgtgtgcccc actccagcct ggggacccca cttcagaagg
taggggccgt gtcccgcggt 3999gctgactgag gcctgcttcc ccctccccct
cctgctgtgc tggaattcca cagggaccag 4059ggccaccgca ggggactgtc
tcagaagact tgatttttcc gtcccttttt ctccacactc 4119cactgacaaa
cgtccccagc ggtttccact tgtgggcttc aggtgttttc aagcacaacc
4179caccacaaca agcaagtgca ttttcagtcg ttgtgctttt ttgttttgtg
ctaacgtctt 4239actaatttaa agatgctgtc ggcaccatgt ttatttattt
ccagtggtca tgctcagcct 4299tgctgctctg cgtggcgcag gtgccatgcc
tgctccctgt ctgtgtccca gccacgcagg 4359gccatccact gtgacgtcgg
ccgaccaggc tggacaccct ctgccgagta atgacgtgtg 4419tggctgggac
cttctttatt ctgtgttaat ggctaacctg ttacactggg ctgggttggg
4479tagggtgttc tggctttttt gtggggtttt tatttttaaa gaaacactca
atcatcctag 45392507PRTHomo sapiens 2Met Ala Gly Ala Gly Pro Lys Arg
Arg Ala Leu Ala Ala Pro Ala Ala 1 5 10 15Glu Glu Lys Glu Glu Ala
Arg Glu Lys Met Leu Ala Ala Lys Ser Ala 20 25 30Asp Gly Ser Ala Pro
Ala Gly Glu Gly Glu Gly Val Thr Leu Gln Arg 35 40 45Asn Ile Thr Leu
Leu Asn Gly Val Ala Ile Ile Val Gly Thr Ile Ile 50 55 60Gly Ser Gly
Ile Phe Val Thr Pro Thr Gly Val Leu Lys Glu Ala Gly 65 70 75 80Ser
Pro Gly Leu Ala Leu Val Val Trp Ala Ala Cys Gly Val Phe Ser 85 90
95Ile Val Gly Ala Leu Cys Tyr Ala Glu Leu Gly Thr Thr Ile Ser Lys
100 105 110Ser Gly Gly Asp Tyr Ala Tyr Met Leu Glu Val Tyr Gly Ser
Leu Pro 115 120 125Ala Phe Leu Lys Leu Trp Ile Glu Leu Leu Ile Ile
Arg Pro Ser Ser 130 135 140Gln Tyr Ile Val Ala Leu Val Phe Ala Thr
Tyr Leu Leu Lys Pro Leu145 150 155 160Phe Pro Thr Cys Pro Val Pro
Glu Glu Ala Ala Lys Leu Val Ala Cys 165 170 175Leu Cys Val Leu Leu
Leu Thr Ala Val Asn Cys Tyr Ser Val Lys Ala 180 185 190Ala Thr Arg
Val Gln Asp Ala Phe Ala Ala Ala Lys Leu Leu Ala Leu 195 200 205Ala
Leu Ile Ile Leu Leu Gly Phe Val Gln Ile Gly Lys Gly Asp Val 210 215
220Ser Asn Leu Asp Pro Asn Phe Ser Phe Glu Gly Thr Lys Leu Asp
Val225 230 235 240Gly Asn Ile Val Leu Ala Leu Tyr Ser Gly Leu Phe
Ala Tyr Gly Gly 245 250 255Trp Asn Tyr Leu Asn Phe Val Thr Glu Glu
Met Ile Asn Pro Tyr Arg 260 265 270Asn Leu Pro Leu Ala Ile Ile Ile
Ser Leu Pro Ile Val Thr Leu Val 275 280 285Tyr Val Leu Thr Asn Leu
Ala Tyr Phe Thr Thr Leu Ser Thr Glu Gln 290 295 300Met Leu Ser Ser
Glu Ala Val Ala Val Asp Phe Gly Asn Tyr His Leu305 310 315 320Gly
Val Met Ser Trp Ile Ile Pro Val Phe Val Gly Leu Ser Cys Phe 325 330
335Gly Ser Val Asn Gly Ser Leu Phe Thr Ser Ser Arg Leu Phe Phe Val
340 345 350Gly Ser Arg Glu Gly His Leu Pro Ser Ile Leu Ser Met Ile
His Pro 355 360 365Gln Leu Leu Thr Pro Val Pro Ser Leu Val Phe Thr
Cys Val Met Thr 370 375 380Leu Leu Tyr Ala Phe Ser Lys Asp Ile Phe
Ser Val Ile Asn Phe Phe385 390 395 400Ser Phe Phe Asn Trp Leu Cys
Val Ala Leu Ala Ile Ile Gly Met Ile 405 410 415Trp Leu Arg His Arg
Lys Pro Glu Leu Glu Arg Pro Ile Lys Val Asn 420 425 430Leu Ala Leu
Pro Val Phe Phe Ile Leu Ala Cys Leu Phe Leu Ile Ala 435 440 445Val
Ser Phe Trp Lys Thr Pro Val Glu Cys Gly Ile Gly Phe Thr Ile 450 455
460Ile Leu Ser Gly Leu Pro Val Tyr Phe Phe Gly Val Trp Trp Lys
Asn465 470 475 480Lys Pro Lys Trp Leu Leu Gln Gly Ile Phe Ser Thr
Thr Val Leu Cys 485 490 495Gln Lys Leu Met Gln Val Val Pro Gln Glu
Thr 500
50533455DNARat5'UTR(1)..(63)CDS(64)..(1602)3'UTR(1603)..(3455)
3cgcggagagc ggctcggccg cgcgcacgcc gggtatccag gccgagccgg gaacgtcgag
60agc atg gcg gtc gcg ggc gca aag cgg cgc gcg gtt gcg gcc ccc gcg
108 Met Ala Val Ala Gly Ala Lys Arg Arg Ala Val Ala Ala Pro Ala 1 5
10 15acg acg gcg gcg gag gag gag cgg cag gcg cgg gag aag atg ctg
gag 156Thr Thr Ala Ala Glu Glu Glu Arg Gln Ala Arg Glu Lys Met Leu
Glu 20 25 30gcg cgg cgc ggg gac ggc gcg gac ccc gag ggc gaa ggc gtg
acc ctg 204Ala Arg Arg Gly Asp Gly Ala Asp Pro Glu Gly Glu Gly Val
Thr Leu 35 40 45cag cgc aat atc aca ctg atc aat ggt gtg gcc atc ata
gtg ggc acc 252Gln Arg Asn Ile Thr Leu Ile Asn Gly Val Ala Ile Ile
Val Gly Thr 50 55 60atc atc ggt tcg ggc atc ttc gtg acg ccc acc ggc
gtg ctc aag gaa 300Ile Ile Gly Ser Gly Ile Phe Val Thr Pro Thr Gly
Val Leu Lys Glu 65 70 75gcc ggc tcg ccc gga ctg tcg ctt gtg gtg tgg
gct gtg tgc ggc gtc 348Ala Gly Ser Pro Gly Leu Ser Leu Val Val Trp
Ala Val Cys Gly Val 80 85 90 95ttc tcc atc gtg ggc gca ctg tgc tac
gcg gag ctg ggc act acc atc 396Phe Ser Ile Val Gly Ala Leu Cys Tyr
Ala Glu Leu Gly Thr Thr Ile 100 105 110tca aag tca ggc ggc gac tat
gcc tac atg cta gag gtc tac ggc tcg 444Ser Lys Ser Gly Gly Asp Tyr
Ala Tyr Met Leu Glu Val Tyr Gly Ser 115 120 125ctg ccc gcc ttc ctc
aag ctc tgg atc gag ctg ctc atc att cgg ccc 492Leu Pro Ala Phe Leu
Lys Leu Trp Ile Glu Leu Leu Ile Ile Arg Pro 130 135 140tcc tca cag
tac atc gtg gcg ctg gtc ttc gcc aca tac ctg ctc aag 540Ser Ser Gln
Tyr Ile Val Ala Leu Val Phe Ala Thr Tyr Leu Leu Lys 145 150 155ccg
gtc ttc ccc act tgt ccc gtg ccc gag gag gct gcc aag ctc gtg 588Pro
Val Phe Pro Thr Cys Pro Val Pro Glu Glu Ala Ala Lys Leu Val160 165
170 175gcc tgc ctc tgc gtg cta cta ctc acg gct gtg aac tgc tac agt
gtg 636Ala Cys Leu Cys Val Leu Leu Leu Thr Ala Val Asn Cys Tyr Ser
Val 180 185 190aag gct gct acc cgt gtg cag gat gcc ttt gcg gct gcc
aaa ctg ctg 684Lys Ala Ala Thr Arg Val Gln Asp Ala Phe Ala Ala Ala
Lys Leu Leu 195 200 205gcc ctg gcc ctc atc atc ctg ctc ggc ttc atc
cag atg gga aag gac 732Ala Leu Ala Leu Ile Ile Leu Leu Gly Phe Ile
Gln Met Gly Lys Asp 210 215 220ata gga caa ggg gat gca tcc aac ctg
cac cag aag ttg tcc ttt gaa 780Ile Gly Gln Gly Asp Ala Ser Asn Leu
His Gln Lys Leu Ser Phe Glu 225 230 235ggc acc aat ctg gac gtg ggg
aac att gtg ttg gca ttg tac agt ggc 828Gly Thr Asn Leu Asp Val Gly
Asn Ile Val Leu Ala Leu Tyr Ser Gly240 245 250 255ctc ttc gcc tac
gga gga tgg aac tat ctg aat ttt gtc acg gag gag 876Leu Phe Ala Tyr
Gly Gly Trp Asn Tyr Leu Asn Phe Val Thr Glu Glu 260 265 270atg atc
aac ccc tac agg aac ctc ccc ctg gcc atc atc atc tcc ttg 924Met Ile
Asn Pro Tyr Arg Asn Leu Pro Leu Ala Ile Ile Ile Ser Leu 275 280
285ccc att gtc acc ctg gtc tat gtg ctg acg aac ctg gcc tac ttc act
972Pro Ile Val Thr Leu Val Tyr Val Leu Thr Asn Leu Ala Tyr Phe Thr
290 295 300acc ctg tct acc aac cag atg ctg aca tct gaa gcc gtg gct
gtg gat 1020Thr Leu Ser Thr Asn Gln Met Leu Thr Ser Glu Ala Val Ala
Val Asp 305 310 315ttt ggg aac tac cac ctg gga gtc atg tcc tgg atc
att cct gtc ttc 1068Phe Gly Asn Tyr His Leu Gly Val Met Ser Trp Ile
Ile Pro Val Phe320 325 330 335gtg ggc ttg tcc tgc ttc ggc tct gtc
aat ggg tct ctg ttc acg tcc 1116Val Gly Leu Ser Cys Phe Gly Ser Val
Asn Gly Ser Leu Phe Thr Ser 340 345 350tca aga ctg ttc ttc gtg gga
tcc agg gag ggc cac ctg cct tcc atc 1164Ser Arg Leu Phe Phe Val Gly
Ser Arg Glu Gly His Leu Pro Ser Ile 355 360 365ctc tcc atg atc cac
cca cag ctt ctg aca ccg gtg cca tca ctg gtg 1212Leu Ser Met Ile His
Pro Gln Leu Leu Thr Pro Val Pro Ser Leu Val 370 375 380ttc acg tgt
gtc atg acc ctg
atg tac gcc ttc tcc aga gac atc ttc 1260Phe Thr Cys Val Met Thr Leu
Met Tyr Ala Phe Ser Arg Asp Ile Phe 385 390 395tcc atc atc aac ttc
ttc agc ttc ttc aac tgg ctg tgt gtg gcc ctg 1308Ser Ile Ile Asn Phe
Phe Ser Phe Phe Asn Trp Leu Cys Val Ala Leu400 405 410 415gcc atc
atc ggc atg atg tgg ctc cgc ttt aag aag cct gag ctg gag 1356Ala Ile
Ile Gly Met Met Trp Leu Arg Phe Lys Lys Pro Glu Leu Glu 420 425
430cgt ccc atc aag gtg aat ctg gcc ctc cca gtg ttc ttt atc ctg gcc
1404Arg Pro Ile Lys Val Asn Leu Ala Leu Pro Val Phe Phe Ile Leu Ala
435 440 445tgc ctc ttc ctc atc gcc gtg tcc ttc tgg aag aca ccc ctg
gag tgc 1452Cys Leu Phe Leu Ile Ala Val Ser Phe Trp Lys Thr Pro Leu
Glu Cys 450 455 460ggc att ggc ttc gcc atc atc ctc agc ggg ctg cct
gtc tac ttc ttt 1500Gly Ile Gly Phe Ala Ile Ile Leu Ser Gly Leu Pro
Val Tyr Phe Phe 465 470 475ggt gtg tgg tgg aaa aac aag ccc aaa tgg
atc ctg cag gtc atc ttc 1548Gly Val Trp Trp Lys Asn Lys Pro Lys Trp
Ile Leu Gln Val Ile Phe480 485 490 495tcc gtg acc gtg ctc tgc cag
aag ctg atg cag gtg gtt cct cag gag 1596Ser Val Thr Val Leu Cys Gln
Lys Leu Met Gln Val Val Pro Gln Glu 500 505 510act tag ccacgtgtcc
tgggtgccgc gggagagtgc actgtgactg cttccagaca 1652Thractcaccttt
ggaaaagcag cgtccaggcc cgtcatcccc acagctccag tgagcaccac
1712taactatctt aacaccatcc gctgtccctc aaaggtcagg tgtccacagt
ggccgtgaaa 1772gaaacctggt acgaatttgg tcccagatgg tgaccatcca
tgcatacata gcagccactg 1832tgaggtgtgc tgtggcctga ggcctggtct
ttctgacttt ggggactgcc acatctgggc 1892tttctcctct atgatttttt
gttttgtttt tgtagcgttc atttgggtca agtttacact 1952accgagatga
ttattttttg acaaaacagg gtagcaaaga gcaggagatg gtgtggccgg
2012acagtccggc tctgagtggg aactgcaggc cacagctctt ctccgactgt
tgttcgttca 2072gtagcacatt gtggctggag gggaccacat cactgtcacc
aagtcagaac tactgagact 2132caaacatcac cttttccact gtggacttgc
actgacaaac ggacgatgaa tgtgctagct 2192tgggtttgag ttttctgggt
ctgtcctaga gatgaaaccc caacctgacc cacgaggcag 2252agctctactg
tgggtcattt gttccattgt aaatgcagag ctccggtctg accactctga
2312agtcctggtg attccccttc ccctggctcc aaatgaaaga cctctgcagc
cataacccta 2372gtggcacctg gccaccaact gtcaactgcg gggccatgtg
ctcctgtgca cacaagctgg 2432ctctacacat tcaaggggca ctgctctggg
tcttactccc tgtcccaccc cagctctcct 2492agaaccagac cggcaccatg
gggctccacc acacacctct gtccacctcc ataattcctg 2552agactgctag
cagctctctg tcaagtcacc accgtccccc ctcagccccc cgggccactg
2612ttcaaaagaa taggcaccaa ctacccttct gctctctgcc acctgtgtga
cgtgaccact 2672ccagctccct gagcgtgaaa actgctggct acgtgctgct
gtccctcctg tgtgggacca 2732gtctgttccg gggagacggt tgagtccagc
agcacatcca ctgaagcagc tgatctgact 2792gaaggacttg agggcatgag
aatcccccgc tggcccttcc attgcctcag agctggcctc 2852cctgaggggg
tgtcaactgg agtgtctact gtgaagctct tacatagtgg caccctgata
2912tctcctgggg ttcccttgtg ttggggtgag gaggcagagg tcaaggtcag
agtgccccta 2972gaaggctctc cagagatgtg aactcaggtc cccagacaca
agcctgggtt caaagggcag 3032ggcaagtctt ggtccacgtt catggtgctg
acccaggccc tctgagaagg ccctgtcatt 3092cctattctga tgtcctgagg
acgcccatct gtaggttttt ggttttaaat caagccacag 3152ccacagtcat
ttggcccaat gctttgcatt gtgttgtcct aacacatcac tgccctgtgg
3212aacccccctg cctggccctt ttcagtggtc agtgtccagt gctgggtacg
gtgtgttccc 3272accacactgg gtccacctgc tgtgccactg gacttagtgc
tgtggttgta atgtctttta 3332ctattgtatt aatgactagt ctgttacatt
agactggggg tggggtgcaa gggtctgctg 3392gtttgtgagg ctttttgatt
gggggggtgg tttgtttttt ttttttaaag ctattggagt 3452tct 34554512PRTRat
4Met Ala Val Ala Gly Ala Lys Arg Arg Ala Val Ala Ala Pro Ala Thr 1
5 10 15Thr Ala Ala Glu Glu Glu Arg Gln Ala Arg Glu Lys Met Leu Glu
Ala 20 25 30Arg Arg Gly Asp Gly Ala Asp Pro Glu Gly Glu Gly Val Thr
Leu Gln 35 40 45Arg Asn Ile Thr Leu Ile Asn Gly Val Ala Ile Ile Val
Gly Thr Ile 50 55 60Ile Gly Ser Gly Ile Phe Val Thr Pro Thr Gly Val
Leu Lys Glu Ala 65 70 75 80Gly Ser Pro Gly Leu Ser Leu Val Val Trp
Ala Val Cys Gly Val Phe 85 90 95Ser Ile Val Gly Ala Leu Cys Tyr Ala
Glu Leu Gly Thr Thr Ile Ser 100 105 110Lys Ser Gly Gly Asp Tyr Ala
Tyr Met Leu Glu Val Tyr Gly Ser Leu 115 120 125Pro Ala Phe Leu Lys
Leu Trp Ile Glu Leu Leu Ile Ile Arg Pro Ser 130 135 140Ser Gln Tyr
Ile Val Ala Leu Val Phe Ala Thr Tyr Leu Leu Lys Pro145 150 155
160Val Phe Pro Thr Cys Pro Val Pro Glu Glu Ala Ala Lys Leu Val Ala
165 170 175Cys Leu Cys Val Leu Leu Leu Thr Ala Val Asn Cys Tyr Ser
Val Lys 180 185 190Ala Ala Thr Arg Val Gln Asp Ala Phe Ala Ala Ala
Lys Leu Leu Ala 195 200 205Leu Ala Leu Ile Ile Leu Leu Gly Phe Ile
Gln Met Gly Lys Asp Ile 210 215 220Gly Gln Gly Asp Ala Ser Asn Leu
His Gln Lys Leu Ser Phe Glu Gly225 230 235 240Thr Asn Leu Asp Val
Gly Asn Ile Val Leu Ala Leu Tyr Ser Gly Leu 245 250 255Phe Ala Tyr
Gly Gly Trp Asn Tyr Leu Asn Phe Val Thr Glu Glu Met 260 265 270Ile
Asn Pro Tyr Arg Asn Leu Pro Leu Ala Ile Ile Ile Ser Leu Pro 275 280
285Ile Val Thr Leu Val Tyr Val Leu Thr Asn Leu Ala Tyr Phe Thr Thr
290 295 300Leu Ser Thr Asn Gln Met Leu Thr Ser Glu Ala Val Ala Val
Asp Phe305 310 315 320Gly Asn Tyr His Leu Gly Val Met Ser Trp Ile
Ile Pro Val Phe Val 325 330 335Gly Leu Ser Cys Phe Gly Ser Val Asn
Gly Ser Leu Phe Thr Ser Ser 340 345 350Arg Leu Phe Phe Val Gly Ser
Arg Glu Gly His Leu Pro Ser Ile Leu 355 360 365Ser Met Ile His Pro
Gln Leu Leu Thr Pro Val Pro Ser Leu Val Phe 370 375 380Thr Cys Val
Met Thr Leu Met Tyr Ala Phe Ser Arg Asp Ile Phe Ser385 390 395
400Ile Ile Asn Phe Phe Ser Phe Phe Asn Trp Leu Cys Val Ala Leu Ala
405 410 415Ile Ile Gly Met Met Trp Leu Arg Phe Lys Lys Pro Glu Leu
Glu Arg 420 425 430Pro Ile Lys Val Asn Leu Ala Leu Pro Val Phe Phe
Ile Leu Ala Cys 435 440 445Leu Phe Leu Ile Ala Val Ser Phe Trp Lys
Thr Pro Leu Glu Cys Gly 450 455 460Ile Gly Phe Ala Ile Ile Leu Ser
Gly Leu Pro Val Tyr Phe Phe Gly465 470 475 480Val Trp Trp Lys Asn
Lys Pro Lys Trp Ile Leu Gln Val Ile Phe Ser 485 490 495Val Thr Val
Leu Cys Gln Lys Leu Met Gln Val Val Pro Gln Glu Thr 500 505
51051863DNAHomo
sapiens5'UTR(1)..(109)CDS(110)..(1699)3'UTR(1700)..(1863)
5gcgcggagcc acagaggccg gggagagcgt tctgggtccg agggtccagg taggggttga
60gccaccatct gaccgcaagc tgcgtcgtgt cgccggttct gcaggcacc atg agc cag
118 Met Ser Gln 1gac acc gag gtg gat atg aag gag gtg gag ctg aat
gag tta gag ccc 166Asp Thr Glu Val Asp Met Lys Glu Val Glu Leu Asn
Glu Leu Glu Pro 5 10 15gag aag cag ccg atg aac gcg gcg tct ggg gcg
gcc atg tcc ctg gcg 214Glu Lys Gln Pro Met Asn Ala Ala Ser Gly Ala
Ala Met Ser Leu Ala 20 25 30 35gga gcc gag aag aat ggt ctg gtg aag
atc aag gtg gcg gaa gac gag 262Gly Ala Glu Lys Asn Gly Leu Val Lys
Ile Lys Val Ala Glu Asp Glu 40 45 50gcg gag gcg gca gcc gcg gct aag
ttc acg ggc ctg tcc aag gag gag 310Ala Glu Ala Ala Ala Ala Ala Lys
Phe Thr Gly Leu Ser Lys Glu Glu 55 60 65ctg ctg aag gtg gca ggc agc
ccc ggc tgg gta cgc acc cgc tgg gca 358Leu Leu Lys Val Ala Gly Ser
Pro Gly Trp Val Arg Thr Arg Trp Ala 70 75 80ctg ctg ctg ctc ttc tgg
ctc ggc tgg ctc ggc atg ctt gct ggt gcc 406Leu Leu Leu Leu Phe Trp
Leu Gly Trp Leu Gly Met Leu Ala Gly Ala 85 90 95gtg gtc ata atc gtg
cga gcg ccg cgt tgt cgc gag cta ccg gcg cag 454Val Val Ile Ile Val
Arg Ala Pro Arg Cys Arg Glu Leu Pro Ala Gln100 105 110 115aag tgg
tgg cac acg ggc gcc ctc tac cgc atc ggc gac ctt cag gcc 502Lys Trp
Trp His Thr Gly Ala Leu Tyr Arg Ile Gly Asp Leu Gln Ala 120 125
130ttc cag ggc cac ggc gcg ggc aac ctg gcg ggt ctg aag ggg cgt ctc
550Phe Gln Gly His Gly Ala Gly Asn Leu Ala Gly Leu Lys Gly Arg Leu
135 140 145gat tac ctg agc tct ctg aag gtg aag ggc ctt gtg ctg ggt
cca att 598Asp Tyr Leu Ser Ser Leu Lys Val Lys Gly Leu Val Leu Gly
Pro Ile 150 155 160cac aag aac cag aag gat gat gtc gct cag act gac
ttg ctg cag atc 646His Lys Asn Gln Lys Asp Asp Val Ala Gln Thr Asp
Leu Leu Gln Ile 165 170 175gac ccc aat ttt ggc tcc aag gaa gat ttt
gac agt ctc ttg caa tcg 694Asp Pro Asn Phe Gly Ser Lys Glu Asp Phe
Asp Ser Leu Leu Gln Ser180 185 190 195gct aaa aaa aag agc atc cgt
gtc att ctg gac ctt act ccc aac tac 742Ala Lys Lys Lys Ser Ile Arg
Val Ile Leu Asp Leu Thr Pro Asn Tyr 200 205 210cgg ggt gag aac tcg
tgg ttc tcc act cag gtt gac act gtg gcc acc 790Arg Gly Glu Asn Ser
Trp Phe Ser Thr Gln Val Asp Thr Val Ala Thr 215 220 225aag gtg aag
gat gct ctg gag ttt tgg ctg caa gct ggc gtg gat ggg 838Lys Val Lys
Asp Ala Leu Glu Phe Trp Leu Gln Ala Gly Val Asp Gly 230 235 240ttc
cag gtt cgg gac ata gag aat ctg aag gat gca tcc tca ttc ttg 886Phe
Gln Val Arg Asp Ile Glu Asn Leu Lys Asp Ala Ser Ser Phe Leu 245 250
255gct gag tgg caa aat atc acc aag ggc ttc agt gaa gac agg ctc ttg
934Ala Glu Trp Gln Asn Ile Thr Lys Gly Phe Ser Glu Asp Arg Leu
Leu260 265 270 275att gcg ggg act aac tcc tcc gac ctt cag cag atc
ctg agc cta ctc 982Ile Ala Gly Thr Asn Ser Ser Asp Leu Gln Gln Ile
Leu Ser Leu Leu 280 285 290gaa tcc aac aaa gac ttg ctg ttg act agc
tca tac ctg tct gat tct 1030Glu Ser Asn Lys Asp Leu Leu Leu Thr Ser
Ser Tyr Leu Ser Asp Ser 295 300 305ggt tct act ggg gag cat aca aaa
tcc cta gtc aca cag tat ttg aat 1078Gly Ser Thr Gly Glu His Thr Lys
Ser Leu Val Thr Gln Tyr Leu Asn 310 315 320gcc act ggc aat cgc tgg
tgc agc tgg agt ttg tct cag gca agg ctc 1126Ala Thr Gly Asn Arg Trp
Cys Ser Trp Ser Leu Ser Gln Ala Arg Leu 325 330 335ctg act tcc ttc
ttg ccg gct caa ctt ctc cga ctc tac cag ctg atg 1174Leu Thr Ser Phe
Leu Pro Ala Gln Leu Leu Arg Leu Tyr Gln Leu Met340 345 350 355ctc
ttc acc ctg cca ggg acc cct gtt ttc agc tac ggg gat gag att 1222Leu
Phe Thr Leu Pro Gly Thr Pro Val Phe Ser Tyr Gly Asp Glu Ile 360 365
370ggc ctg gat gca gct gcc ctt cct gga cag cct atg gag gct cca gtc
1270Gly Leu Asp Ala Ala Ala Leu Pro Gly Gln Pro Met Glu Ala Pro Val
375 380 385atg ctg tgg gat gag tcc agc ttc cct gac atc cca ggg gct
gta agt 1318Met Leu Trp Asp Glu Ser Ser Phe Pro Asp Ile Pro Gly Ala
Val Ser 390 395 400gcc aac atg act gtg aag ggc cag agt gaa gac cct
ggc tcc ctc ctt 1366Ala Asn Met Thr Val Lys Gly Gln Ser Glu Asp Pro
Gly Ser Leu Leu 405 410 415tcc ttg ttc cgg cgg ctg agt gac cag cgg
agt aag gag cgc tcc cta 1414Ser Leu Phe Arg Arg Leu Ser Asp Gln Arg
Ser Lys Glu Arg Ser Leu420 425 430 435ctg cat ggg gac ttc cac gcg
ttc tcc gct ggg cct gga ctc ttc tcc 1462Leu His Gly Asp Phe His Ala
Phe Ser Ala Gly Pro Gly Leu Phe Ser 440 445 450tat atc cgc cac tgg
gac cag aat gag cgt ttt ctg gta gtg ctt aac 1510Tyr Ile Arg His Trp
Asp Gln Asn Glu Arg Phe Leu Val Val Leu Asn 455 460 465ttt ggg gat
gtg ggc ctc tcg gct gga ctg cag gcc tcc gac ctg cct 1558Phe Gly Asp
Val Gly Leu Ser Ala Gly Leu Gln Ala Ser Asp Leu Pro 470 475 480gcc
agc gcc agc ctc cca gcc aag gct gac ctc ctg ctc agc acc cag 1606Ala
Ser Ala Ser Leu Pro Ala Lys Ala Asp Leu Leu Leu Ser Thr Gln 485 490
495cca ggc cgt gag gag ggc tcc cct ctt gag ctg gaa cgc ctg aaa ctg
1654Pro Gly Arg Glu Glu Gly Ser Pro Leu Glu Leu Glu Arg Leu Lys
Leu500 505 510 515gag cct cac gaa ggg ctg ctg ctc cgc ttc ccc tac
gcg gcc tga 1699Glu Pro His Glu Gly Leu Leu Leu Arg Phe Pro Tyr Ala
Ala 520 525 530cttcagcctg acatggaccc actacccttc tcctttcctt
cccaggccct ttggttctga 1759tttttctctt ttttaaaaac aaacaaacaa
actgttgcag attatgagtg aacccccaaa 1819tagggtgttt tctgccttca
aataaaagtc acccctgcat ggtg 18636529PRTHomo sapiens 6Met Ser Gln Asp
Thr Glu Val Asp Met Lys Glu Val Glu Leu Asn Glu 1 5 10 15Leu Glu
Pro Glu Lys Gln Pro Met Asn Ala Ala Ser Gly Ala Ala Met 20 25 30Ser
Leu Ala Gly Ala Glu Lys Asn Gly Leu Val Lys Ile Lys Val Ala 35 40
45Glu Asp Glu Ala Glu Ala Ala Ala Ala Ala Lys Phe Thr Gly Leu Ser
50 55 60Lys Glu Glu Leu Leu Lys Val Ala Gly Ser Pro Gly Trp Val Arg
Thr 65 70 75 80Arg Trp Ala Leu Leu Leu Leu Phe Trp Leu Gly Trp Leu
Gly Met Leu 85 90 95Ala Gly Ala Val Val Ile Ile Val Arg Ala Pro Arg
Cys Arg Glu Leu 100 105 110Pro Ala Gln Lys Trp Trp His Thr Gly Ala
Leu Tyr Arg Ile Gly Asp 115 120 125Leu Gln Ala Phe Gln Gly His Gly
Ala Gly Asn Leu Ala Gly Leu Lys 130 135 140Gly Arg Leu Asp Tyr Leu
Ser Ser Leu Lys Val Lys Gly Leu Val Leu145 150 155 160Gly Pro Ile
His Lys Asn Gln Lys Asp Asp Val Ala Gln Thr Asp Leu 165 170 175Leu
Gln Ile Asp Pro Asn Phe Gly Ser Lys Glu Asp Phe Asp Ser Leu 180 185
190Leu Gln Ser Ala Lys Lys Lys Ser Ile Arg Val Ile Leu Asp Leu Thr
195 200 205Pro Asn Tyr Arg Gly Glu Asn Ser Trp Phe Ser Thr Gln Val
Asp Thr 210 215 220Val Ala Thr Lys Val Lys Asp Ala Leu Glu Phe Trp
Leu Gln Ala Gly225 230 235 240Val Asp Gly Phe Gln Val Arg Asp Ile
Glu Asn Leu Lys Asp Ala Ser 245 250 255Ser Phe Leu Ala Glu Trp Gln
Asn Ile Thr Lys Gly Phe Ser Glu Asp 260 265 270Arg Leu Leu Ile Ala
Gly Thr Asn Ser Ser Asp Leu Gln Gln Ile Leu 275 280 285Ser Leu Leu
Glu Ser Asn Lys Asp Leu Leu Leu Thr Ser Ser Tyr Leu 290 295 300Ser
Asp Ser Gly Ser Thr Gly Glu His Thr Lys Ser Leu Val Thr Gln305 310
315 320Tyr Leu Asn Ala Thr Gly Asn Arg Trp Cys Ser Trp Ser Leu Ser
Gln 325 330 335Ala Arg Leu Leu Thr Ser Phe Leu Pro Ala Gln Leu Leu
Arg Leu Tyr 340 345 350Gln Leu Met Leu Phe Thr Leu Pro Gly Thr Pro
Val Phe Ser Tyr Gly 355 360 365Asp Glu Ile Gly Leu Asp Ala Ala Ala
Leu Pro Gly Gln Pro Met Glu 370 375 380Ala Pro Val Met Leu Trp Asp
Glu Ser Ser Phe Pro Asp Ile Pro Gly385 390 395 400Ala Val Ser Ala
Asn Met Thr Val Lys Gly Gln Ser Glu Asp Pro Gly 405 410 415Ser Leu
Leu Ser Leu Phe Arg Arg Leu Ser Asp Gln Arg Ser Lys Glu 420 425
430Arg Ser Leu Leu His Gly Asp Phe His Ala Phe Ser Ala Gly Pro Gly
435 440 445Leu Phe Ser Tyr Ile Arg His Trp Asp Gln Asn Glu Arg Phe
Leu Val 450 455 460Val Leu Asn Phe Gly Asp Val Gly Leu Ser Ala Gly
Leu Gln Ala Ser465 470 475 480Asp Leu Pro Ala Ser Ala Ser Leu Pro
Ala Lys Ala Asp Leu Leu Leu 485 490 495Ser Thr Gln Pro Gly Arg Glu
Glu Gly Ser Pro Leu Glu Leu Glu Arg 500 505 510Leu Lys Leu Glu Pro
His
Glu Gly Leu Leu Leu Arg Phe Pro Tyr Ala 515 520
525Ala71797DNARat5'UTR(1)..(19)CDS(20)..(1603)3'UTR(1604)..(1797)
7cgttgctgtc gcaggtacc atg agc cag gac acc gaa gtg gac atg aaa gat
52 Met Ser Gln Asp Thr Glu Val Asp Met Lys Asp 1 5 10gtg gag ctg
aac gag ctg gaa ccg gag aag cag cct atg aat gca gcg 100Val Glu Leu
Asn Glu Leu Glu Pro Glu Lys Gln Pro Met Asn Ala Ala 15 20 25gac ggg
gcg gca gcc ggg gag aag aac ggt ctg gtg aag att aag gtg 148Asp Gly
Ala Ala Ala Gly Glu Lys Asn Gly Leu Val Lys Ile Lys Val 30 35 40gcc
gaa gac gag gcg gaa gcc ggg gtc aag ttc aca ggc tta tcc aag 196Ala
Glu Asp Glu Ala Glu Ala Gly Val Lys Phe Thr Gly Leu Ser Lys 45 50
55gag gag cta ttg aag gta gct ggc agc ccg ggc tgg gtg cgc acc cgc
244Glu Glu Leu Leu Lys Val Ala Gly Ser Pro Gly Trp Val Arg Thr Arg
60 65 70 75tgg gcg ctg ctg ctg ctc ttc tgg ctc ggt tgg ctg ggt atg
ctg gcg 292Trp Ala Leu Leu Leu Leu Phe Trp Leu Gly Trp Leu Gly Met
Leu Ala 80 85 90ggc gcc gtg gtt atc atc gtt cgg gcg cca cgc tgc cgt
gag ctg ccg 340Gly Ala Val Val Ile Ile Val Arg Ala Pro Arg Cys Arg
Glu Leu Pro 95 100 105gta cag aga tgg tgg cac aag ggc gcc ctc tac
cgc atc ggc gac ctt 388Val Gln Arg Trp Trp His Lys Gly Ala Leu Tyr
Arg Ile Gly Asp Leu 110 115 120cag gcc ttc gta ggc ccg gaa gcg aga
ggc ata gct ggt ctg aag aac 436Gln Ala Phe Val Gly Pro Glu Ala Arg
Gly Ile Ala Gly Leu Lys Asn 125 130 135cat ctg gag tac ttg agc acc
ctg aag gtg aag ggc cta gtt ttg ggc 484His Leu Glu Tyr Leu Ser Thr
Leu Lys Val Lys Gly Leu Val Leu Gly140 145 150 155cca att cac aag
aac cag aag gat gaa gtc aat gaa acc gac ttg aaa 532Pro Ile His Lys
Asn Gln Lys Asp Glu Val Asn Glu Thr Asp Leu Lys 160 165 170cag att
gat ccc gat tta ggc tcc cag gaa gat ttt aaa gac ctt cta 580Gln Ile
Asp Pro Asp Leu Gly Ser Gln Glu Asp Phe Lys Asp Leu Leu 175 180
185caa agt gcc aag aaa aag agc att cac atc att ttg gac ctc act ccc
628Gln Ser Ala Lys Lys Lys Ser Ile His Ile Ile Leu Asp Leu Thr Pro
190 195 200aac tat aag ggc cag aat gca tgg ttc ctc cct cct cag gct
gac att 676Asn Tyr Lys Gly Gln Asn Ala Trp Phe Leu Pro Pro Gln Ala
Asp Ile 205 210 215gta gcc acc aaa atg aag gag gct ctg agt tct tgg
ttg cag gac ggt 724Val Ala Thr Lys Met Lys Glu Ala Leu Ser Ser Trp
Leu Gln Asp Gly220 225 230 235gtg gat ggg ttc caa gtt cgg gat gtg
gga aag ctg gcg aat gca tcc 772Val Asp Gly Phe Gln Val Arg Asp Val
Gly Lys Leu Ala Asn Ala Ser 240 245 250ttg tac ttg gct gag tgg cag
aat atc acc aag aac ttc agt gag gac 820Leu Tyr Leu Ala Glu Trp Gln
Asn Ile Thr Lys Asn Phe Ser Glu Asp 255 260 265agg ctt ttg att gca
ggg acc gcg tcc tct gac ctg caa caa att gtc 868Arg Leu Leu Ile Ala
Gly Thr Ala Ser Ser Asp Leu Gln Gln Ile Val 270 275 280aac ata ctt
gaa tcc acc agc gat ctg ctg ctg acc agc tca tac ctg 916Asn Ile Leu
Glu Ser Thr Ser Asp Leu Leu Leu Thr Ser Ser Tyr Leu 285 290 295tca
cag ccc gtt ttc act ggg gag cat gca gaa ctc cta gtg att aag 964Ser
Gln Pro Val Phe Thr Gly Glu His Ala Glu Leu Leu Val Ile Lys300 305
310 315tat ttg aat gcc act ggc agc cgc tgg tgc agc tgg agt gtg tcg
cag 1012Tyr Leu Asn Ala Thr Gly Ser Arg Trp Cys Ser Trp Ser Val Ser
Gln 320 325 330gca gga ctc ctg aca tcc ttt ata ccg gct cag ttt ctc
cga ctc tac 1060Ala Gly Leu Leu Thr Ser Phe Ile Pro Ala Gln Phe Leu
Arg Leu Tyr 335 340 345cag ctg ctg ctc ttc act ctg cca gga act cct
gtt ttc agc tat ggg 1108Gln Leu Leu Leu Phe Thr Leu Pro Gly Thr Pro
Val Phe Ser Tyr Gly 350 355 360gat gag ctt ggc ctt cag gca gtt gcc
ctt cct gga cag cct atg gag 1156Asp Glu Leu Gly Leu Gln Ala Val Ala
Leu Pro Gly Gln Pro Met Glu 365 370 375gct cca ttc atg ctg tgg aat
gag tct agc aac tcc caa acc tca agt 1204Ala Pro Phe Met Leu Trp Asn
Glu Ser Ser Asn Ser Gln Thr Ser Ser380 385 390 395cct gta agc ctc
aac atg aca gtg aag ggc caa aat gaa gac ccc ggc 1252Pro Val Ser Leu
Asn Met Thr Val Lys Gly Gln Asn Glu Asp Pro Gly 400 405 410tcc ctc
ctc acc cag ttc cgg cga ctg agt gac ctc cgt ggt aag gag 1300Ser Leu
Leu Thr Gln Phe Arg Arg Leu Ser Asp Leu Arg Gly Lys Glu 415 420
425cgc tct ctg tta cac ggt gac ttt gat gca ctg tct tcc tca tct ggg
1348Arg Ser Leu Leu His Gly Asp Phe Asp Ala Leu Ser Ser Ser Ser Gly
430 435 440ctc ttc tcc tac gtc cgc cac tgg gac cag aat gag cgt tac
ctg gtg 1396Leu Phe Ser Tyr Val Arg His Trp Asp Gln Asn Glu Arg Tyr
Leu Val 445 450 455gtg ctc aac ttc cag gat gtg ggc ctg tca gcc agg
gta gga gcc tcc 1444Val Leu Asn Phe Gln Asp Val Gly Leu Ser Ala Arg
Val Gly Ala Ser460 465 470 475aac ctc cct gct ggc ata agc ctg cca
gcc agt gct aac ctt ttg ctt 1492Asn Leu Pro Ala Gly Ile Ser Leu Pro
Ala Ser Ala Asn Leu Leu Leu 480 485 490agt act gac agc acc cgg cta
agc cgt gag gag ggc acc tcc ctg agc 1540Ser Thr Asp Ser Thr Arg Leu
Ser Arg Glu Glu Gly Thr Ser Leu Ser 495 500 505ctg gaa aac ctg agc
ctg aat cct tat gag ggc ttg ttg tta cag ttc 1588Leu Glu Asn Leu Ser
Leu Asn Pro Tyr Glu Gly Leu Leu Leu Gln Phe 510 515 520cct ttt gtg
gcc tga tccctctaca cagaacctgc cacccttctt tcctctctca 1643Pro Phe Val
Ala 525ggcctttgga attctggtct ttctctcctt attttgtttt tgtttttaaa
cttttgcaga 1703ttacatatga attcttacac tgggggtttt tgttttcaaa
ataaaaaaaa tcacccctaa 1763aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaa
17978527PRTRat 8Met Ser Gln Asp Thr Glu Val Asp Met Lys Asp Val Glu
Leu Asn Glu 1 5 10 15Leu Glu Pro Glu Lys Gln Pro Met Asn Ala Ala
Asp Gly Ala Ala Ala 20 25 30Gly Glu Lys Asn Gly Leu Val Lys Ile Lys
Val Ala Glu Asp Glu Ala 35 40 45Glu Ala Gly Val Lys Phe Thr Gly Leu
Ser Lys Glu Glu Leu Leu Lys 50 55 60Val Ala Gly Ser Pro Gly Trp Val
Arg Thr Arg Trp Ala Leu Leu Leu 65 70 75 80Leu Phe Trp Leu Gly Trp
Leu Gly Met Leu Ala Gly Ala Val Val Ile 85 90 95Ile Val Arg Ala Pro
Arg Cys Arg Glu Leu Pro Val Gln Arg Trp Trp 100 105 110His Lys Gly
Ala Leu Tyr Arg Ile Gly Asp Leu Gln Ala Phe Val Gly 115 120 125Pro
Glu Ala Arg Gly Ile Ala Gly Leu Lys Asn His Leu Glu Tyr Leu 130 135
140Ser Thr Leu Lys Val Lys Gly Leu Val Leu Gly Pro Ile His Lys
Asn145 150 155 160Gln Lys Asp Glu Val Asn Glu Thr Asp Leu Lys Gln
Ile Asp Pro Asp 165 170 175Leu Gly Ser Gln Glu Asp Phe Lys Asp Leu
Leu Gln Ser Ala Lys Lys 180 185 190Lys Ser Ile His Ile Ile Leu Asp
Leu Thr Pro Asn Tyr Lys Gly Gln 195 200 205Asn Ala Trp Phe Leu Pro
Pro Gln Ala Asp Ile Val Ala Thr Lys Met 210 215 220Lys Glu Ala Leu
Ser Ser Trp Leu Gln Asp Gly Val Asp Gly Phe Gln225 230 235 240Val
Arg Asp Val Gly Lys Leu Ala Asn Ala Ser Leu Tyr Leu Ala Glu 245 250
255Trp Gln Asn Ile Thr Lys Asn Phe Ser Glu Asp Arg Leu Leu Ile Ala
260 265 270Gly Thr Ala Ser Ser Asp Leu Gln Gln Ile Val Asn Ile Leu
Glu Ser 275 280 285Thr Ser Asp Leu Leu Leu Thr Ser Ser Tyr Leu Ser
Gln Pro Val Phe 290 295 300Thr Gly Glu His Ala Glu Leu Leu Val Ile
Lys Tyr Leu Asn Ala Thr305 310 315 320Gly Ser Arg Trp Cys Ser Trp
Ser Val Ser Gln Ala Gly Leu Leu Thr 325 330 335Ser Phe Ile Pro Ala
Gln Phe Leu Arg Leu Tyr Gln Leu Leu Leu Phe 340 345 350Thr Leu Pro
Gly Thr Pro Val Phe Ser Tyr Gly Asp Glu Leu Gly Leu 355 360 365Gln
Ala Val Ala Leu Pro Gly Gln Pro Met Glu Ala Pro Phe Met Leu 370 375
380Trp Asn Glu Ser Ser Asn Ser Gln Thr Ser Ser Pro Val Ser Leu
Asn385 390 395 400Met Thr Val Lys Gly Gln Asn Glu Asp Pro Gly Ser
Leu Leu Thr Gln 405 410 415Phe Arg Arg Leu Ser Asp Leu Arg Gly Lys
Glu Arg Ser Leu Leu His 420 425 430Gly Asp Phe Asp Ala Leu Ser Ser
Ser Ser Gly Leu Phe Ser Tyr Val 435 440 445Arg His Trp Asp Gln Asn
Glu Arg Tyr Leu Val Val Leu Asn Phe Gln 450 455 460Asp Val Gly Leu
Ser Ala Arg Val Gly Ala Ser Asn Leu Pro Ala Gly465 470 475 480Ile
Ser Leu Pro Ala Ser Ala Asn Leu Leu Leu Ser Thr Asp Ser Thr 485 490
495Arg Leu Ser Arg Glu Glu Gly Thr Ser Leu Ser Leu Glu Asn Leu Ser
500 505 510Leu Asn Pro Tyr Glu Gly Leu Leu Leu Gln Phe Pro Phe Val
Ala 515 520 525922DNAArtificial SequenceDescription of Artificial
Sequence Artificially synthesized primer sequence 9cgaagtggac
atgaaagatg tg 221022DNAArtificial SequenceDescription of Artificial
Sequence Artificially synthesized primer sequence 10aaactaggcc
cttcaccttc ag 221124DNAArtificial SequenceDescription of Artificial
Sequence Artificially synthesized primer sequence 11actgctgctg
ctcttctggc tcgg 241224DNAArtificial SequenceDescription of
Artificial Sequence Artificially synthesized primer sequence
12gtggatgggt tccaggttcg ggac 241324DNAArtificial
SequenceDescription of Artificial Sequence Artificially synthesized
primer sequence 13tgctgtggga tgagtccagc ttcc 241424DNAArtificial
SequenceDescription of Artificial Sequence Artificially synthesized
primer sequence 14gcaggaggtc agccttggct ggca 241524DNAArtificial
SequenceDescription of Artificial Sequence Artificially synthesized
primer sequence 15cttgcctgag acaaactcca gctg 241624DNAArtificial
SequenceDescription of Artificial Sequence Artificially synthesized
primer sequence 16actgtcaaaa tcttccttgg agcc 241724DNAArtificial
SequenceDescription of Artificial Sequence Artificially synthesized
primer sequence 17ttctcgggct ctaactcatt cagc 241823DNAArtificial
SequenceDescription of Artificial Sequence Artificially synthesized
primer sequence 18tgctgctgct cacggccgtg aac 231917DNAArtificial
SequenceDescription of Artificial Sequence Artificially synthesized
primer sequence 19tggcggcctt cacgctg 172025DNAArtificial
SequenceDescription of Artificial Sequence Artificially synthesized
primer sequence 20atctagattg gacacatcac ccttc 252122DNAArtificial
SequenceDescription of Artificial Sequence Artificially synthesized
primer sequence 21gtggtgaagt aggccaggtt gg 222221DNAArtificial
SequenceDescription of Artificial Sequence Artificially synthesized
primer sequence 22gtggggtccc gggaaggcca c 212322DNAArtificial
SequenceDescription of Artificial Sequence Artificially synthesized
primer sequence 23cttgtttttc caccagaccc cg 222422DNAArtificial
SequenceDescription of Artificial Sequence Artificially synthesized
primer sequence 24tgagggatga gattcgtacc ag 222523DNAArtificial
SequenceDescription of Artificial Sequence Artificially synthesized
primer sequence 25cctgggagga atcacccacc ttg 23261524RNAHomo
sapiensCDS(1)..(1524) 26aug gcg ggu gcg ggc ccg aag cgg cgc gcg cua
gcg gcg ccg gcg gcc 48Met Ala Gly Ala Gly Pro Lys Arg Arg Ala Leu
Ala Ala Pro Ala Ala 1 5 10 15gag gag aag gaa gag gcg cgg gag aag
aug cug gcc gcc aag agc gcg 96Glu Glu Lys Glu Glu Ala Arg Glu Lys
Met Leu Ala Ala Lys Ser Ala 20 25 30gac ggc ucg gcg ccg gca ggc gag
ggc gag ggc gug acc cug cag cgg 144Asp Gly Ser Ala Pro Ala Gly Glu
Gly Glu Gly Val Thr Leu Gln Arg 35 40 45aac auc acg cug cuc aac ggc
gug gcc auc auc gug ggg acc auu auc 192Asn Ile Thr Leu Leu Asn Gly
Val Ala Ile Ile Val Gly Thr Ile Ile 50 55 60ggc ucg ggc auc uuc gug
acg ccc acg ggc gug cuc aag gag gca ggc 240Gly Ser Gly Ile Phe Val
Thr Pro Thr Gly Val Leu Lys Glu Ala Gly 65 70 75 80ucg ccg ggg cug
gcg cug gug gug ugg gcc gcg ugc ggc guc uuc ucc 288Ser Pro Gly Leu
Ala Leu Val Val Trp Ala Ala Cys Gly Val Phe Ser 85 90 95auc gug ggc
gcg cuc ugc uac gcg gag cuc ggc acc acc auc ucc aaa 336Ile Val Gly
Ala Leu Cys Tyr Ala Glu Leu Gly Thr Thr Ile Ser Lys 100 105 110ucg
ggc ggc gac uac gcc uac aug cug gag guc uac ggc ucg cug ccc 384Ser
Gly Gly Asp Tyr Ala Tyr Met Leu Glu Val Tyr Gly Ser Leu Pro 115 120
125gcc uuc cuc aag cuc ugg auc gag cug cuc auc auc cgg ccu uca ucg
432Ala Phe Leu Lys Leu Trp Ile Glu Leu Leu Ile Ile Arg Pro Ser Ser
130 135 140cag uac auc gug gcc cug guc uuc gcc acc uac cug cuc aag
ccg cuc 480Gln Tyr Ile Val Ala Leu Val Phe Ala Thr Tyr Leu Leu Lys
Pro Leu145 150 155 160uuc ccc acc ugc ccg gug ccc gag gag gca gcc
aag cuc gug gcc ugc 528Phe Pro Thr Cys Pro Val Pro Glu Glu Ala Ala
Lys Leu Val Ala Cys 165 170 175cuc ugc gug cug cug cuc acg gcc gug
aac ugc uac agc gug aag gcc 576Leu Cys Val Leu Leu Leu Thr Ala Val
Asn Cys Tyr Ser Val Lys Ala 180 185 190gcc acc cgg guc cag gau gcc
uuu gcc gcc gcc aag cuc cug gcc cug 624Ala Thr Arg Val Gln Xaa Ala
Phe Ala Ala Ala Lys Leu Leu Ala Leu 195 200 205gcc cug auc auc cug
cug ggc uuc guc cag auc ggg aag ggu gau gug 672Ala Leu Ile Ile Leu
Leu Gly Phe Val Gln Ile Gly Lys Gly Xaa Val 210 215 220ucc aau cua
gau ccc aac uuc uca uuu gaa ggc acc aaa cug gau gug 720Ser Asn Leu
Xaa Pro Asn Phe Ser Phe Glu Gly Thr Lys Leu Xaa Val225 230 235
240ggg aac auu gug cug gca uua uac agc ggc cuc uuu gcc uau gga gga
768Gly Asn Ile Val Leu Ala Leu Tyr Ser Gly Leu Phe Ala Tyr Gly Gly
245 250 255ugg aau uac uug aau uuc guc aca gag gaa aug auc aac ccc
uac aga 816Trp Asn Tyr Leu Asn Phe Val Thr Glu Glu Met Ile Asn Pro
Tyr Arg 260 265 270aac cug ccc cug gcc auc auc auc ucc cug ccc auc
gug acg cug gug 864Asn Leu Pro Leu Ala Ile Ile Ile Ser Leu Pro Ile
Val Thr Leu Val 275 280 285uac gug cug acc aac cug gcc uac uuc acc
acc cug ucc acc gag cag 912Tyr Val Leu Thr Asn Leu Ala Tyr Phe Thr
Thr Leu Ser Thr Glu Gln 290 295 300aug cug ucg ucc gag gcc gug gcc
gug gac uuc ggg aac uau cac cug 960Met Leu Ser Ser Glu Ala Val Ala
Val Asp Phe Gly Asn Tyr His Leu305 310 315 320ggc guc aug ucc ugg
auc auc ccc guc uuc gug ggc cug ucc ugc uuc 1008Gly Val Met Ser Trp
Ile Ile Pro Val Phe Val Gly Leu Ser Cys Phe 325 330 335ggc ucc guc
aau ggg ucc cug uuc aca ucc ucc agg cuc uuc uuc gug 1056Gly Ser Val
Asn Gly Ser Leu Phe Thr Ser Ser Arg Leu Phe Phe Val 340 345 350ggg
ucc cgg gaa ggc cac cug ccc ucc auc cuc ucc aug auc cac cca
1104Gly Ser Arg Glu Gly His Leu Pro Ser Ile Leu Ser Met Ile His Pro
355 360 365cag cuc cuc acc ccc gug ccg ucc cuc gug uuc acg ugu gug
aug acg 1152Gln Leu Leu Thr Pro Val Pro Ser Leu Val Phe Thr Cys Val
Met Thr 370 375 380cug cuc uac gcc uuc ucc aag gac auc uuc ucc guc
auc aac uuc uuc 1200Leu Leu Tyr Ala Phe Ser Lys Asp Ile Phe Ser Val
Ile Asn Phe Phe385 390 395 400agc uuc uuc aac ugg cuc ugc gug gcc
cug gcc auc auc ggc aug auc 1248Ser Phe Phe Asn Trp Leu Cys Val Ala
Leu Ala Ile Ile Gly Met Ile 405 410 415ugg cug cgc cac aga aag ccu
gag cuu gag cgg ccc auc aag gug aac 1296Trp Leu Arg His Arg Lys Pro
Glu Leu Glu Arg Pro Ile Lys Val Asn 420 425 430cug gcc cug ccu gug
uuc uuc auc cug gcc ugc cuc uuc cug auc gcc 1344Leu Ala Leu Pro Val
Phe Phe Ile Leu Ala Cys Leu Phe Leu Ile Ala 435 440 445guc ucc uuc
ugg aag aca ccc gug gag ugu ggc auc ggc uuc acc auc 1392Val Ser Phe
Trp Lys Thr Pro Val Glu Cys Gly Ile Gly Phe Thr Ile 450 455 460auc
cuc agc ggg cug ccc guc uac uuc uuc ggg guc ugg ugg aaa aac 1440Ile
Leu Ser Gly Leu Pro Val Tyr Phe Phe Gly Val Trp Trp Lys Asn465 470
475 480aag ccc aag ugg cuc cuc cag ggc auc uuc ucc acg acc guc cug
ugu 1488Lys Pro Lys Trp Leu Leu Gln Gly Ile Phe Ser Thr Thr Val Leu
Cys 485 490 495cag aag cuc aug cag gug guc ccc cag gag aca uag
1524Gln Lys Leu Met Gln Val Val Pro Gln Glu Thr 500
505271590RNAHomo sapiensCDS(1)..(1590) 27aug agc cag gac acc gag
gug gau aug aag gag gug gag cug aau gag 48Met Ser Gln Asp Thr Glu
Val Xaa Met Lys Glu Val Glu Leu Asn Glu 1 5 10 15uua gag ccc gag
aag cag ccg aug aac gcg gcg ucu ggg gcg gcc aug 96Leu Glu Pro Glu
Lys Gln Pro Met Asn Ala Ala Ser Gly Ala Ala Met 20 25 30ucc cug gcg
gga gcc gag aag aau ggu cug gug aag auc aag gug gcg 144Ser Leu Ala
Gly Ala Glu Lys Asn Gly Leu Val Lys Ile Lys Val Ala 35 40 45gaa gac
gag gcg gag gcg gca gcc gcg gcu aag uuc acg ggc cug ucc 192Glu Asp
Glu Ala Glu Ala Ala Ala Ala Ala Lys Phe Thr Gly Leu Ser 50 55 60aag
gag gag cug cug aag gug gca ggc agc ccc ggc ugg gua cgc acc 240Lys
Glu Glu Leu Leu Lys Val Ala Gly Ser Pro Gly Trp Val Arg Thr 65 70
75 80cgc ugg gca cug cug cug cuc uuc ugg cuc ggc ugg cuc ggc aug
cuu 288Arg Trp Ala Leu Leu Leu Leu Phe Trp Leu Gly Trp Leu Gly Met
Leu 85 90 95gcu ggu gcc gug guc aua auc gug cga gcg ccg cgu ugu cgc
gag cua 336Ala Gly Ala Val Val Ile Ile Val Arg Ala Pro Arg Cys Arg
Glu Leu 100 105 110ccg gcg cag aag ugg ugg cac acg ggc gcc cuc uac
cgc auc ggc gac 384Pro Ala Gln Lys Trp Trp His Thr Gly Ala Leu Tyr
Arg Ile Gly Asp 115 120 125cuu cag gcc uuc cag ggc cac ggc gcg ggc
aac cug gcg ggu cug aag 432Leu Gln Ala Phe Gln Gly His Gly Ala Gly
Asn Leu Ala Gly Leu Lys 130 135 140ggg cgu cuc gau uac cug agc ucu
cug aag gug aag ggc cuu gug cug 480Gly Arg Leu Xaa Tyr Leu Ser Ser
Leu Lys Val Lys Gly Leu Val Leu145 150 155 160ggu cca auu cac aag
aac cag aag gau gau guc gcu cag acu gac uug 528Gly Pro Ile His Lys
Asn Gln Lys Xaa Xaa Val Ala Gln Xaa Asp Leu 165 170 175cug cag auc
gac ccc aau uuu ggc ucc aag gaa gau uuu gac agu cuc 576Leu Gln Ile
Asp Pro Asn Phe Gly Ser Lys Glu Xaa Phe Asp Ser Leu 180 185 190uug
caa ucg gcu aaa aaa aag agc auc cgu guc auu cug gac cuu acu 624Leu
Gln Ser Ala Lys Lys Lys Ser Ile Arg Val Ile Leu Asp Leu Xaa 195 200
205ccc aac uac cgg ggu gag aac ucg ugg uuc ucc acu cag guu gac acu
672Pro Asn Tyr Arg Gly Glu Asn Ser Trp Phe Ser Xaa Gln Val Asp Xaa
210 215 220gug gcc acc aag gug aag gau gcu cug gag uuu ugg cug caa
gcu ggc 720Val Ala Thr Lys Val Lys Xaa Ala Leu Glu Phe Trp Leu Gln
Ala Gly225 230 235 240gug gau ggg uuc cag guu cgg gac aua gag aau
cug aag gau gca ucc 768Val Xaa Gly Phe Gln Val Arg Asp Ile Glu Asn
Leu Lys Xaa Ala Ser 245 250 255uca uuc uug gcu gag ugg caa aau auc
acc aag ggc uuc agu gaa gac 816Ser Phe Leu Ala Glu Trp Gln Asn Ile
Thr Lys Gly Phe Ser Glu Asp 260 265 270agg cuc uug auu gcg ggg acu
aac ucc ucc gac cuu cag cag auc cug 864Arg Leu Leu Ile Ala Gly Xaa
Asn Ser Ser Asp Leu Gln Gln Ile Leu 275 280 285agc cua cuc gaa ucc
aac aaa gac uug cug uug acu agc uca uac cug 912Ser Leu Leu Glu Ser
Asn Lys Asp Leu Leu Leu Xaa Ser Ser Tyr Leu 290 295 300ucu gau ucu
ggu ucu acu ggg gag cau aca aaa ucc cua guc aca cag 960Ser Xaa Ser
Gly Ser Xaa Gly Glu His Thr Lys Ser Leu Val Thr Gln305 310 315
320uau uug aau gcc acu ggc aau cgc ugg ugc agc ugg agu uug ucu cag
1008Tyr Leu Asn Ala Xaa Gly Asn Arg Trp Cys Ser Trp Ser Leu Ser Gln
325 330 335gca agg cuc cug acu ucc uuc uug ccg gcu caa cuu cuc cga
cuc uac 1056Ala Arg Leu Leu Xaa Ser Phe Leu Pro Ala Gln Leu Leu Arg
Leu Tyr 340 345 350cag cug aug cuc uuc acc cug cca ggg acc ccu guu
uuc agc uac ggg 1104Gln Leu Met Leu Phe Thr Leu Pro Gly Thr Pro Val
Phe Ser Tyr Gly 355 360 365gau gag auu ggc cug gau gca gcu gcc cuu
ccu gga cag ccu aug gag 1152Xaa Glu Ile Gly Leu Xaa Ala Ala Ala Leu
Pro Gly Gln Pro Met Glu 370 375 380gcu cca guc aug cug ugg gau gag
ucc agc uuc ccu gac auc cca ggg 1200Ala Pro Val Met Leu Trp Xaa Glu
Ser Ser Phe Pro Asp Ile Pro Gly385 390 395 400gcu gua agu gcc aac
aug acu gug aag ggc cag agu gaa gac ccu ggc 1248Ala Val Ser Ala Asn
Met Xaa Val Lys Gly Gln Ser Glu Asp Pro Gly 405 410 415ucc cuc cuu
ucc uug uuc cgg cgg cug agu gac cag cgg agu aag gag 1296Ser Leu Leu
Ser Leu Phe Arg Arg Leu Ser Asp Gln Arg Ser Lys Glu 420 425 430cgc
ucc cua cug cau ggg gac uuc cac gcg uuc ucc gcu ggg ccu gga 1344Arg
Ser Leu Leu His Gly Asp Phe His Ala Phe Ser Ala Gly Pro Gly 435 440
445cuc uuc ucc uau auc cgc cac ugg gac cag aau gag cgu uuu cug gua
1392Leu Phe Ser Tyr Ile Arg His Trp Asp Gln Asn Glu Arg Phe Leu Val
450 455 460gug cuu aac uuu ggg gau gug ggc cuc ucg gcu gga cug cag
gcc ucc 1440Val Leu Asn Phe Gly Xaa Val Gly Leu Ser Ala Gly Leu Gln
Ala Ser465 470 475 480gac cug ccu gcc agc gcc agc cuc cca gcc aag
gcu gac cuc cug cuc 1488Asp Leu Pro Ala Ser Ala Ser Leu Pro Ala Lys
Ala Asp Leu Leu Leu 485 490 495agc acc cag cca ggc cgu gag gag ggc
ucc ccu cuu gag cug gaa cgc 1536Ser Thr Gln Pro Gly Arg Glu Glu Gly
Ser Pro Leu Glu Leu Glu Arg 500 505 510cug aaa cug gag ccu cac gaa
ggg cug cug cuc cgc uuc ccc uac gcg 1584Leu Lys Leu Glu Pro His Glu
Gly Leu Leu Leu Arg Phe Pro Tyr Ala 515 520 525gcc uga 1590Ala
* * * * *